KR101622809B1 - Organic compounds and organic electro luminescence device comprising the same - Google Patents

Organic compounds and organic electro luminescence device comprising the same Download PDF

Info

Publication number
KR101622809B1
KR101622809B1 KR1020130144909A KR20130144909A KR101622809B1 KR 101622809 B1 KR101622809 B1 KR 101622809B1 KR 1020130144909 A KR1020130144909 A KR 1020130144909A KR 20130144909 A KR20130144909 A KR 20130144909A KR 101622809 B1 KR101622809 B1 KR 101622809B1
Authority
KR
South Korea
Prior art keywords
group
compound
mmol
synthesis
mol
Prior art date
Application number
KR1020130144909A
Other languages
Korean (ko)
Other versions
KR20150061177A (en
Inventor
박성진
조현종
김회문
이인혁
김은진
김영배
김태형
백영미
Original Assignee
주식회사 두산
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 두산 filed Critical 주식회사 두산
Priority to KR1020130144909A priority Critical patent/KR101622809B1/en
Publication of KR20150061177A publication Critical patent/KR20150061177A/en
Application granted granted Critical
Publication of KR101622809B1 publication Critical patent/KR101622809B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1029Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
    • C09K2211/1033Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom with oxygen
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1029Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
    • C09K2211/1037Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom with sulfur

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Electroluminescent Light Sources (AREA)

Abstract

본 발명은 신규 유기 화합물 및 이를 포함하는 유기 전계 발광 소자에 관한 것으로서, 본 발명의 화합물은 유기 전계 발광 소자용 재료, 바람직하게는 발광층의 호스트 재료로 도입됨으로써, 유기 전계 발광 소자의 발광효율, 구동 전압 및 수명 등의 전반적인 특성이 향상될 수 있다.
The present invention relates to a novel organic compound and an organic electroluminescent device including the same, wherein the compound of the present invention is introduced into a material for an organic electroluminescent device, preferably a host material of the luminescent layer, The overall characteristics such as voltage and lifetime can be improved.

Description

유기 화합물 및 이를 포함하는 유기 전계 발광 소자{ORGANIC COMPOUNDS AND ORGANIC ELECTRO LUMINESCENCE DEVICE COMPRISING THE SAME}TECHNICAL FIELD [0001] The present invention relates to an organic compound and an organic electroluminescent device including the organic compound.

본 발명은 유기 전계 발광 소자의 재료로 사용될 수 있는 신규 유기 화합물 및 이를 포함하여 소자의 발광효율, 구동전압, 수명 등이 향상되는 유기 전계 발광 소자에 관한 것이다.The present invention relates to a novel organic compound that can be used as a material of an organic electroluminescent device, and an organic electroluminescent device including the same and having improved luminous efficiency, driving voltage, and life span of the device.

1950년대 Bernanose의 유기 박막 발광 관측을 시점으로 하여, 1965년 안트라센 단결정을 이용한 청색 전기발광으로 유기 전계 발광(electroluminescent, EL) 소자(이하, 간단히 '유기 EL 소자'로 칭함)에 대한 연구가 이어져 왔다. 1987년 탕(Tang)에 의하여 정공층과 발광층의 기능층으로 나눈 적층구조의 유기 EL 소자가 제시되었다. 이후, 고효율, 고수명의 유기 EL 소자를 만들기 위하여, 소자 내 각각의 특징적인 유기물 층을 도입하는 형태로 발전하여 왔으며, 이에 사용되는 특화된 물질의 개발로 이어졌다. Studies on organic electroluminescent (EL) devices (hereinafter, simply referred to as 'organic EL devices') by blue electroluminescence using anthracene single crystals in 1965 have been carried out with reference to the observation of organic thin film luminosity of Bernanose in the 1950s . In 1987, a layered organic EL device was proposed by Tang divided into a hole layer and a functional layer of a light emitting layer. Thereafter, in order to make a high efficiency and high number of organic EL devices, each organic EL device has been developed in a manner of introducing each characteristic organic material layer in the device, leading to the development of specialized materials used therefor.

유기 전계 발광 소자에서는 두 전극 사이에 전압을 걸어 주면 양극에서는 정공이 유기물층으로 주입되고, 음극에서는 전자가 유기물층으로 주입된다. 주입된 정공과 전자가 만났을 때 엑시톤(exciton)이 형성되며, 이 엑시톤이 바닥상태로 떨어질 때 빛이 나게 된다. 이때, 유기물층으로 사용되는 물질은 그 기능에 따라, 발광 물질, 정공 주입 물질, 정공 수송 물질, 전자 수송 물질, 전자 주입 물질 등으로 분류될 수 있다. In the organic electroluminescent device, when a voltage is applied between two electrodes, holes are injected into the organic layer in the anode, and electrons are injected into the organic layer in the cathode. When the injected holes and electrons meet, an exciton is formed. When the exciton falls to the ground state, light is emitted. At this time, the material used as the organic material layer can be classified into a light emitting material, a hole injecting material, a hole transporting material, an electron transporting material, an electron injecting material and the like depending on its function.

발광 물질은 발광색에 따라 청색, 녹색, 적색 발광 물질과, 보다 나은 천연색을 구현하기 위해 필요한 노란색 및 주황색 발광 물질로 구분될 수 있다. 또한, 색순도의 증가와 에너지 전이를 통한 발광 효율을 증가시키기 위하여, 발광 물질로서 호스트/도판트 계를 사용할 수 있다. The luminescent material can be classified into blue, green and red luminescent materials according to luminescent colors and yellow and orange luminescent materials necessary for realizing better natural colors. Further, in order to increase the color purity and to increase the luminous efficiency through energy transfer, a host / dopant system can be used as a luminescent material.

도판트 물질은 유기 물질을 사용하는 형광 도판트와 Ir, Pt 등의 중원자(heavy atoms)가 포함된 금속 착체 화합물을 사용하는 인광 도판트로 나눌 수 있다. 이때, 인광 재료는 이론적으로 형광 재료에 비해 최대 4배의 발광 효율을 향상시킬 수 있기 때문에, 인광 도판트 뿐만 아니라 인광 호스트 재료들에 대한 연구가 많이 진행되고 있다. The dopant material can be divided into a fluorescent dopant using an organic material and a phosphorescent dopant using a metal complex compound containing heavy atoms such as Ir and Pt. Since the phosphorescent material can theoretically improve the luminous efficiency up to 4 times as much as that of the fluorescent material, studies on phosphorescent host materials as well as phosphorescent dopants have been conducted.

현재까지 정공 주입층, 정공 수송층. 정공 차단층, 전자 수송층으로는 NPB, BCP, Alq3 등이 널리 알려져 있으며, 발광 재료로는 안트라센 유도체들이 형광 도판트/호스트 재료로서 보고되고 있다. 특히, 발광 재료 중 효율 향상 측면에서 큰 장점을 가지고 있는 인광 재료들은 청색(blue), 녹색(green), 적색(red) 도판트 재료로서 Firpic, Ir(ppy)3, (acac)Ir(btp)2 등의 Ir을 포함하는 금속 착체 화합물이 사용되고 있다. 현재까지는 4,4-dicarbazolybiphenyl(CBP)가 인광 호스트 재료로서 우수한 특성을 나타내고 있다.Up to now, hole injecting layer, hole transporting layer. NPB, BCP, and Alq 3 are widely known as the hole blocking layer and the electron transporting layer, and anthracene derivatives as a luminescent material have been reported as fluorescent dopant / host material. Particularly, phosphorescent materials which have a great advantage in terms of efficiency improvement of light emitting materials include Firpic, Ir (ppy) 3 , (acac) Ir (btp) as a blue, green, 2 or the like is used. Up to now, 4,4-dicarbazolybiphenyl (CBP) has shown excellent properties as a phosphorescent host material.

그러나, 기존의 재료들은 유리전이온도가 낮아 열적 안정성이 떨어지기 때문에, OLED 소자에서의 수명 측면에서 만족할 만한 수준이 되지 못하고, 발광 특성 측면에서도 개선이 필요한 실정이다. 따라서, 보다 성능이 뛰어난 재료의 개발이 요구되고 있다.However, since the conventional materials have low glass transition temperature and thermal stability deteriorates, they are not satisfactory in terms of lifetime in the OLED device, and improvements in the light emitting properties are needed. Therefore, development of materials with higher performance is required.

본 발명은 높은 유리 전이온도로 인해 열적 안정성이 우수하면서, 정공과 전자의 결합력을 향상시켜 발광 특성을 향상시킬 수 있는 신규 유기 화합물을 제공하는 것을 목적으로 한다.It is an object of the present invention to provide a novel organic compound which is excellent in thermal stability due to a high glass transition temperature and can improve the bonding strength between holes and electrons to improve luminescent properties.

또, 본 발명은 상기 신규 유기 화합물을 포함하여 구동전압, 발광효율 등이 향상된 유기 전계 발광 소자를 제공하는 것을 목적으로 한다.It is another object of the present invention to provide an organic electroluminescent device including the novel organic compound and having improved driving voltage, luminous efficiency, and the like.

본 발명은 하기 화학식 1로 표시되는 화합물을 제공한다:The present invention provides a compound represented by the following formula (1): < EMI ID =

Figure 112013108009545-pat00001
Figure 112013108009545-pat00001

상기 화학식 1에서,In Formula 1,

Y1과 Y2, Y2와 Y3, 및 Y3와 Y4 중 하나는 모두 C(R1)이되, 각각의 C(R1)은 R1이 서로 축합하여 하기 화학식 2로 표시되는 축합 고리를 형성하고, Wherein one of Y 1 and Y 2 , Y 2 and Y 3 , and one of Y 3 and Y 4 is C (R 1 ), and each C (R 1 ) is a condensation product of R 1 and R 1 , Forming a ring,

Y1 내지 Y4 중에서 하기 화학식 2의 축합 고리를 형성하지 않은 나머지는 각각 독립적으로 N 또는 C(R1)이며, Y 1 to Y 4 are independently N or C (R 1 ), and the remainder not forming the condensed ring of the formula (2)

이때 R1이 복수인 경우, 이들은 서로 동일하거나 상이하며;Wherein when R < 1 > is plural, they are the same or different from each other;

Figure 112013108009545-pat00002
Figure 112013108009545-pat00002

상기 화학식 2에서,In Formula 2,

점선은 화학식 1에 축합되는 부위를 의미하고;The dotted line means a moiety condensed in formula (1);

Y5와 Y6, Y6과 Y7 및 Y7과 Y8 중 하나는 모두 C(R2)이되, 각각의 C(R2)은 R2가 서로 축합하여 하기 화학식 3으로 표시되는 축합 고리를 형성하고,Wherein one of Y 5 and Y 6 , Y 6 and Y 7, and Y 7 and Y 8 is both C (R 2 ), and each of C (R 2 ) and R 2 is condensed with each other to form a condensed ring Lt; / RTI >

Y5 내지 Y8 중에서 하기 화학식 3의 축합 고리를 형성하지 않은 나머지는 각각 독립적으로 N 또는 C(R2)이며, To from Y 5 to Y 8 rest does not form a condensed ring of the general formula (3) are each independently N or C (R 2),

이때, R2가 복수인 경우, 이들은 서로 동일하거나 상이하고;When a plurality of R < 2 > s are the same or different from each other;

Figure 112013108009545-pat00003
Figure 112013108009545-pat00003

상기 화학식 3에서,In Formula 3,

점선은 화학식 2에 축합되는 부위를 의미하고;The dotted line means a moiety condensed in formula (2);

Y9 내지 Y12는 각각 독립적으로 N 또는 C(R3)이고, Y 9 to Y 12 are each independently N or C (R 3 )

이때 R3이 복수인 경우, 이들은 서로 동일하거나 상이하며;Wherein when R < 3 > is plural, they are the same or different from each other;

X1, X4 및 X5는 각각 독립적으로 O, S, Se, N(Ar1), C(Ar2)(Ar3) 및 Si(Ar4)(Ar5)로 이루어진 군에서 선택되고, 이때 X1, X4 및 X5 중에서 적어도 하나는 N(Ar1)이며;X 1, X 4 and X 5 is selected from the group consisting of each independently O, S, Se, N ( Ar 1), C (Ar 2) (Ar 3) and Si (Ar 4) (Ar 5 ), In this case, X 1 , X 4 And X < 5 > is N (Ar < 1 >);

X2 및 X3는 각각 독립적으로 N 또는 C(R4)이고, 이때 복수의 R4가 복수인 경우, 이들은 서로 동일하거나 상이하며;X 2 and X 3 are each independently N or C (R 4 ), provided that when plural R 4 are plural, they are the same as or different from each other;

R1 내지 R4 및 Ar1 내지 Ar5는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), 할로겐, 시아노기, 아미노기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, C1~C40의 알킬보론기, C6~C40의 아릴보론기, C1~C40의 포스핀기, C1~C40의 포스핀옥사이드기 및 C6~C40의 아릴실릴기로 이루어진 군에서 선택되거나, 또는 인접하는 기와 결합하여 축합 고리를 형성할 수 있으며,R 1 to R 4 and Ar 1 to Ar 5 are the same or different and each independently represents hydrogen, deuterium (D), halogen, cyano group, amino group, C 1 to C 40 alkyl group, C 2 to C 40 alkene A C 2 to C 40 alkynyl group, a C 6 to C 40 aryl group, a heteroaryl group having 5 to 40 nuclear atoms, a C 6 to C 40 aryloxy group, a C 1 to C 40 alkyloxy group , A C 6 to C 40 arylamine group, a C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C 1 to C 40 alkylsilyl group, a C 1 to C 40 alkylboron group , C group 6 to arylboronic of C 40, C 1 ~ C 40 of the phosphine group, C 1 ~ C 40 of the phosphine oxide group, and a C 6 to C 40 selected from an aryl silyl group the group consisting of or of, or adjacent groups of To form a condensed ring,

R1 내지 R4 및 Ar1 내지 Ar5의 C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, C1~C40의 알킬보론기, C6~C40의 아릴보론기, C1~C40의 포스핀기, C1~C40의 포스핀옥사이드기 및 C6~C40의 아릴실릴기는 각각 독립적으로 중수소(D), 할로겐, 시아노기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, C1~C40의 알킬보론기, C6~C40의 아릴보론기, C1~C40의 포스핀기, C1~C40의 포스핀옥사이드기 및 C6~C40의 아릴실릴기로 이루어진 군으로부터 선택되는 1종 이상의 치환기로 치환되거나 비치환될 수 있으며, 이때 상기 치환기가 복수인 경우, 이들은 서로 동일하거나 또는 상이할 수 있다.R 1 to R 4 and Ar 1 to Ar 5 of C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ C 40 of the alkynyl group, C 6 ~ C 40 aryl group, nuclear atoms of 5 to 40 heteroaryl group, C 6 ~ C 40 of the aryloxy group, C 1 ~ C 40 alkyloxy group of, C 6 ~ C 40 aryl amine group, C 3 ~ C 40 cycloalkyl group, a nuclear atoms of 3 to 40 heterocycloalkyl group, C 1 ~ C 40 alkylsilyl group, C 1 ~ C 40 group of an alkyl boron, C 6 ~ C 40 aryl boron group, C 1 ~ C 40 of the phosphine group, C 1 ~ C 40 of the phosphine oxide group, and a C 6 ~ C 40 aryl silyl groups are each independently a heavy hydrogen (D), a halogen, a cyano group, an alkenyl group of C 1 ~ C 40 alkyl group, C 2 ~ C 40 of, C 2 ~ C 40 alkynyl group, C 6 ~ C 40 aryl group, an aryloxy group of nuclear atoms aryl of from 5 to 40 heteroaryl group, a C 6 ~ C 40, alkyloxy group of C 1 ~ C 40 of, C 6 ~ C 40 of the arylamine group, C 3 ~ C 40 cycloalkyl group, a 3 to 40 nuclear atoms of a heterocycloalkyl group, C 1 ~ C 40 alkyl yarn Group, C 1 ~ C 40 group of an alkyl boron, C 6 ~ C 40 aryl boron group, C 1 ~ C 40 of the phosphine group, C 1 ~ C 40 phosphine oxide group, and a C 6 ~ C 40 aryl silyl And when the substituent is plural, they may be the same or different from each other.

또한, 본 발명은 양극, 음극 및 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하며, 상기 1층 이상의 유기물층 중에서 적어도 하나는 상기 화학식 1의 화합물을 포함하는 것이 특징인 유기 전계 발광 소자를 제공한다.The organic electroluminescent device according to the present invention includes a cathode, an anode, and at least one organic layer interposed between the anode and the cathode, wherein at least one of the organic layers includes one or more organic compounds A light emitting device is provided.

여기서, 상기 화학식 1의 화합물을 포함하는 1층 이상의 유기물층 중 적어도 하나는 정공 주입층, 정공 수송층, 전자수송층, 전자주입층 및 발광층으로 구성된 군으로부터 선택될 수 있으며, 바람직하게는 발광층으로서, 이때 상기 화학식 1로 표시되는 화합물은 청색, 녹색 또는 적색의 인광 호스트 재료이다. At least one of the organic layers including the compound of Formula 1 may be selected from the group consisting of a hole injection layer, a hole transport layer, an electron transport layer, an electron injection layer, and a light emitting layer. Preferably, The compound represented by the formula (1) is a blue, green or red phosphorescent host material.

본 발명에 따른 화학식 1 로 표시되는 화합물은 열적 안정성 및 인광 특성이 우수하기 때문에, 유기 전계 발광 소자의 유기물층 재료로 사용될 수 있다.The compound represented by the formula (1) according to the present invention is excellent in thermal stability and phosphorescence property and can be used as an organic material layer material of an organic electroluminescent device.

특히, 본 발명은 화학식 1로 표시되는 화합물을 발광층의 인광 호스트 재료로 사용할 경우, 종래 호스트 재료에 비해 우수한 발광 성능, 낮은 구동전압, 높은 효율 및 장수명을 갖는 유기 전계 발광 소자를 제조할 수 있고, 나아가 성능, 수명이 크게 향상된 풀 칼라 디스플레이 패널도 제조할 수 있다.In particular, when the compound represented by the general formula (1) is used as a phosphorescent host material in the light emitting layer, an organic electroluminescent device having excellent light emitting performance, low driving voltage, high efficiency, Further, a full color display panel having greatly improved performance and lifetime can be manufactured.

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

<신규 화합물><Novel compound>

본 발명에 따른 신규 화합물은 N, O, S 등의 헤테로원자를 1개 이상 함유하는 3개의 인덴 모이어티가 순차적으로 축합(fused)되어 기본 골격을 이루며, 이러한 기본 골격에 다양한 치환체가 결합된 구조로서, 상기 화학식 1로 표시되는 것을 특징으로 한다.The novel compound according to the present invention has a structure in which three inden moieties containing one or more heteroatoms such as N, O, S are sequentially fused to form a basic skeleton and various substituents are bonded to the basic skeleton Which is characterized by being represented by the above formula (1).

상기 화학식 1로 표시되는 화합물은 N, O, S 등의 헤테로원자를 1개 이상 함유하는 3개의 인덴 모이어티가 축합된 기본 골결을 포함함으로써, 넓은 밴드갭 (sky blue ~ red)과 높은 삼중항 에너지를 가질 수 있다. 뿐만 아니라, 상기 화합물은 상기 3개의 인덴 모이어티가 축합된 기본 골격을 포함하면서, 이러한 기본 골격에 방향족 환 치환체가 도입됨에 따라, 분자 전체가 바이폴라(bipolar) 특성을 가질 수 있어, 정공과 전자의 결합력을 높일 수 있다. 따라서, 유기 EL 소자에 상기 화학식 1의 화합물을 적용할 경우, 상기 화합물이 종래 CBP에 비해 발광층의 호스트 재료로서 우수한 특성을 나타낼 수 있기 때문에, 소자의 인광특성이 개선됨과 동시에 정공 주입 능력 및/또는 수송 능력, 발광효율, 구동전압, 수명 특성 등이 개선될 수 있다. 그리고, 상기 화합물은 상기 치환체들에 의해서 에너지 레벨이 조절될 수 있어, 넓은 밴드갭 (sky blue ~ red)을 갖게 되고, 따라서 발광층뿐만 아니라, 정공 수송층, 정공 주입층 등으로도 응용될 수 있다.The compound represented by the general formula (1) includes a basic framework in which three inden moieties containing one or more hetero atoms such as N, O, S and the like are condensed to form a compound having a broad band gap (sky blue to red) You can have energy. In addition, since the compound contains a basic skeleton in which the three indene moieties are condensed, and the aromatic ring substituent is introduced into such a skeleton, the whole molecule can have a bipolar characteristic, The bonding force can be increased. Therefore, when the compound of Formula 1 is applied to the organic EL device, since the compound can exhibit superior characteristics as a host material of the light emitting layer compared to the conventional CBP, the phosphorescence characteristics of the device are improved and the hole injection ability and / Transporting ability, luminous efficiency, driving voltage, lifetime characteristics and the like can be improved. The compound has a wide band gap (sky blue to red) because the energy level can be controlled by the above-mentioned substituents, and thus it can be applied not only to a light emitting layer but also to a hole transporting layer, a hole injecting layer and the like.

또한, 상기 화학식 1의 화합물은 상기 기본 골격에 도입된 다양한 방향족 환(aromatic ring) 치환체로 인해 화합물의 분자량이 유의적으로 증대됨으로써, 유리전이온도가 향상될 수 있고, 이로 인해 종래 CBP(4,4-dicarbazolybiphenyl)보다 높은 열적 안정성을 가질 수 있다. 또한, 본 발명의 화합물이 발광층 등의 유기물층에 포함될 경우, 상기 다양한 방향족 환 치환체로 인해서 유기물층의 결정화 억제에도 효과적이기 때문에, 상기 화합물을 포함하는 유기 EL 소자는 내구성 및 수명 특성이 크게 향상될 수 있다.In addition, since the compound of formula (1) has an aromatic ring substituent introduced into the basic skeleton, the molecular weight of the compound is significantly increased, so that the glass transition temperature can be improved. As a result, 4-dicarbazolybiphenyl). &Lt; / RTI &gt; In addition, when the compound of the present invention is contained in an organic material layer such as a light emitting layer, since the various aromatic ring substituents are effective in inhibiting the crystallization of the organic material layer, the durability and lifetime characteristics of the organic EL device containing the compound can be greatly improved .

아울러, 본 발명의 화합물은 유기 EL 소자의 정공 주입/수송층의 재료로, 혹은 청색, 녹색 및/또는 적색의 인광 호스트 재료(바람직하게는 인광 호스트 재료)로 사용될 수 있으며, 특히 인광 호스트 재료로 채택될 경우, 종래 CBP 대비 소자의 효율(예컨대, 전류 효율, 발광 효율) 및 수명 측면에서 월등히 우수한 효과를 발휘할 수 있다. 또한, 상기 화합물은 도입된 치환기에 따라 발광 보조층 등 다양한 유기물층에 사용될 수 있다. 따라서, 본 발명에 따른 화합물은 유기 EL 소자의 성능 개선 및 수명 향상에 크게 기여할 수 있으며, 특히 이러한 유기 EL 소자의 수명 향상은 풀 칼라 유기 발광 패널에서의 성능 극대화에도 큰 효과가 있다.
In addition, the compound of the present invention can be used as a material of a hole injection / transport layer of an organic EL device, or as a blue, green and / or red phosphorescent host material (preferably a phosphorescent host material) It is possible to exert an excellent effect in terms of the efficiency (for example, current efficiency, luminous efficiency) and life span of the device compared to the conventional CBP. In addition, the compound may be used in various organic layers such as a light-emitting auxiliary layer according to the introduced substituent. Therefore, the compound according to the present invention can greatly contribute to the improvement of the performance and the life of the organic EL device, and in particular, the lifetime of the organic EL device is greatly improved in maximizing the performance of the full-color organic EL panel.

상기 화학식 1로 표시되는 화합물에서, Y1과 Y2, Y2와 Y3, 및 Y3와 Y4 중 하나는 모두 C(R1)이되, 각각의 C(R1)은 R1이 서로 축합하여 상기 화학식 2로 표시되는 축합 고리를 형성한다. 예를 들어, Y1 내지 Y4 중에서 Y1과 Y2가 모두 C(R1)인 경우, 각각의 C(R1)은 R1이 서로 축합하여 상기 화학식 2의 축합 고리를 형성하고, 따라서 본 발명의 화합물은 하기 화학식 4 또는 7로 표시된다.In the compounds of the formula (1), the Y 1 and Y 2, Y 2 and Y 3, and Y 3 and Y 4 either both C (R 1), provided each of the C (R 1) is R 1 each And condensed to form a condensed ring represented by the general formula (2). For example, Y 1 to Y 4 when in the Y 1 and Y 2 are both C (R 1), and each C (R 1) is R 1 are condensed with each other to form a condensed ring of the general formula (2), and thus The compound of the present invention is represented by the following formula (4) or (7).

또, Y1 내지 Y4 중에서 상기 화학식 2의 축합 고리를 형성하지 않는 나머지는 각각 독립적으로 N 또는 C(R1)이고, 바람직하게는 모두 C(R1)일 수 있다. 이때, R1이 복수인 경우, 이들은 서로 동일하거나 상이하다.The remaining of Y 1 to Y 4 which do not form the condensed ring of formula (2) may be independently N or C (R 1 ), preferably all C (R 1 ). Here, when a plurality of R &lt; 1 &gt; s are the same or different from each other.

상기 화학식 2에서, Y5와 Y6, Y6과 Y7 및 Y7과 Y8 중 하나는 모두 C(R2)이되, 각각의 C(R2)은 R2가 서로 축합하여 상기 화학식 3으로 표시되는 축합 고리를 형성한다.In Formula 2, Y 5 and Y 6 , Y 6 and Y 7, and Y 7 and Y 8 are all C (R 2 ), and each of C (R 2 ) and R 2 is condensed with each other, To form a condensed ring represented by the following formula.

또, Y5 내지 Y8 중에서 상기 화학식 3의 축합 고리를 형성하지 않는 나머지는 각각 독립적으로 N 또는 C(R2)이고, 바람직하게는 모두 C(R2)일 수 있다. 이때, R2가 복수인 경우, 이들은 서로 동일하거나 상이하다. The remaining of Y 5 to Y 8 not forming the condensed ring of formula (3) may be independently N or C (R 2 ), preferably all C (R 2 ). At this time, when a plurality of R &lt; 2 &gt; are present, they are the same as or different from each other.

상기 화학식 3에서, Y9 내지 Y12는 각각 독립적으로 N 또는 C(R3)이고, 바람직하게는 모두 C(R3)일 수 있다. 이때, R3이 복수인 경우, 이들은 서로 동일하거나 상이하다.In Formula 3, Y 9 to Y 12 are each independently N or C (R 3 ), preferably all C (R 3 ). Here, when a plurality of R &lt; 3 &gt; is plural, they are the same or different from each other.

또, 상기 화학식에서, X1, X4 및 X5는 각각 독립적으로, O, S, Se, N(Ar1), C(Ar2)(Ar3) 및 Si(Ar4)(Ar5)로 이루어진 군에서 선택되고, 이때 X1, X4 및 X5 중에서 적어도 하나는 N(Ar1)이며, 바람직하게는 X4 및 X5가 모두 N(Ar1)일 수 있다. Further, in the formula, X 1, X 4 and X 5 are, each independently, O, S, Se, N (Ar 1), C (Ar 2) (Ar 3) and Si (Ar 4) (Ar 5 ) , Wherein at least one of X 1 , X 4 and X 5 is N (Ar 1 ), preferably X 4 And X &lt; 5 &gt; may all be N (Ar &lt; 1 &gt;).

또, X2 및 X3는 각각 독립적으로 N 또는 C(R4)이고, 이때 R4가 복수인 경우, 이들은 동일하거나 상이하다.X 2 and X 3 are each independently N or C (R 4 ), and when R 4 is plural, they are the same or different.

R1 내지 R4, 및 Ar1 내지 Ar5는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), 할로겐, 시아노기, 아미노기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, C1~C40의 알킬보론기, C6~C40의 아릴보론기, C6~C40의 아릴포스핀기, C6~C40의 아릴포스핀옥사이드기 및 C6~C40의 아릴실릴기로 이루어진 군에서 선택되거나, 또는 인접하는 기와 결합하여 축합 고리를 형성할 수 있다. R 1 to R 4 and Ar 1 to Ar 5 are the same or different and each independently represents hydrogen, deuterium (D), halogen, cyano group, amino group, C 1 to C 40 alkyl group, C 2 to C 40 alkenyl group, C 2 ~ C 40 of the alkynyl group, C 6 ~ C 40 aryl group, nuclear atoms aryl of from 5 to 40 heteroaryl group, a C 6 ~ C 40 aryloxy group, C 1 ~ C 40 of alkyloxy An arylamine group of C 6 to C 40 , a cycloalkyl group of C 3 to C 40 , a heterocycloalkyl group of 3 to 40 nucleus atoms, a C 1 to C 40 alkylsilyl group, a C 1 to C 40 alkyl boron group, C group 6 to arylboronic of C 40, C 6 to C 40 aryl phosphine group, C 6 to C 40 aryl phosphine oxide group, and a C 6 to C 40 aryl silyl group selected from the group consisting of, or in, or May be bonded to adjacent groups to form a condensed ring.

바람직하게, R1 내지 R4 및 Ar1 내지 Ar5는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기 및 C6~C40의 아릴아민기로 이루어진 군에서 선택될 수 있다.Preferably, R 1 to R 4 and Ar 1 to Ar 5 are the same or different and each independently represents hydrogen, deuterium (D), a C 6 to C 40 aryl group, a heteroaryl group having 5 to 40 nuclear atoms And an arylamine group having from 6 to 40 carbon atoms.

예를 들어, R1 내지 R4 및 Ar1 내지 Ar5는 서로 동일하거나 상이하며, 각각 독립적으로 수소 또는 중수소(D)이거나, 또는 하기 치환체 S1 내지 S211로 이루어진 군에서 선택될 수 있으나, 이에 한정되는 것은 아니다.For example, R 1 to R 4 and Ar 1 to Ar 5 may be the same or different and each independently hydrogen or deuterium (D), or may be selected from the group consisting of the following substituents S1 to S211, It is not.

Figure 112013108009545-pat00004
Figure 112013108009545-pat00004

Figure 112013108009545-pat00005
Figure 112013108009545-pat00005

Figure 112013108009545-pat00006
Figure 112013108009545-pat00006

Figure 112013108009545-pat00007
Figure 112013108009545-pat00007

Figure 112013108009545-pat00008
Figure 112013108009545-pat00008

Figure 112013108009545-pat00009
Figure 112013108009545-pat00009

Figure 112013108009545-pat00010
Figure 112013108009545-pat00010

Figure 112013108009545-pat00011
Figure 112013108009545-pat00011

Figure 112013108009545-pat00012
Figure 112013108009545-pat00012

Figure 112013108009545-pat00013

Figure 112013108009545-pat00013

또, R1 내지 R4 및 Ar1 내지 Ar5는 서로 동일하거나 상이하며, 각각 독립적으로 하기 화학식 D-1 내지 D-15로 표시되는 치환체 중에서 선택될 수 있으나, 이에 한정되는 것은 아니다.In addition, R 1 to R 4 and Ar 1 to Ar 5 may be the same or different and each independently selected from substituents represented by the following formulas (D-1) to (D-15), but are not limited thereto.

Figure 112013108009545-pat00014
Figure 112013108009545-pat00014

상기 화학식 D-1 내지 D-15에서,In the above formulas D-1 to D-15,

L은 단일결합이거나, 혹은 C6~C18의 아릴렌기, 및 핵원자수 5 내지 18의 헤테로아릴렌기로 이루어진 군에서 선택되며,L is a single bond or a group selected from the group consisting of a C 6 to C 18 arylene group and a heteroarylene group having 5 to 18 nuclear atoms,

R11이 복수개인 경우, 이들은 서로 동일하거나 상이하고, When there are a plurality of R &lt; 11 & gt ;, they are the same as or different from each other,

R21이 복수개인 경우, 이들은 서로 동일하거나 상이하며, When there are a plurality of R &lt; 21 &gt; s, they are the same or different from each other,

R11 및 R21은 서로 동일하거나 상이하고, 각각 독립적으로 수소, 중수소, 할로겐기, 시아노기, 니트로기, 아미노기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C1~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C1~C60의 포스핀기, C1~C60의 포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택되거나, 또는 인접한 기와 결합하여 축합 고리를 형성할 수 있으며,R 11 and R 21 are each other the same or different, each independently represent hydrogen, deuterium, a halogen group, a cyano group, a nitro group, an amino group, an alkenyl group of C 1 ~ C 40 alkyl group, C 2 ~ C 40 of, C 2 ~ alkynyl group of C 40, C 3 ~ C 40 cycloalkyl group, the number of nuclear atoms of 3 to 40 of the heterocycloalkyl of the alkyl group, C 6 ~ C 60 aryl group, the number of nuclear atoms of 5 to 60 heteroaryl group, C 1 ~ C 40 alkyloxy, C 6 ~ C 60 aryloxy group, C 1 ~ C 40 alkyl silyl group, the group C 6 ~ C 60 aryl silyl, C 1 ~ group alkylboronic of C 40, C 6 ~ C group of 60 arylboronic, C 1 ~ C 60 of the phosphine group, C 1 ~ C 60 phosphine oxide group, and a C 6 ~, or selected from the group consisting of an aryl amine of the C 60 of, or the adjacent groups combine to form a condensed ring In addition,

n은 0 내지 4의 정수이다.
n is an integer of 0 to 4;

본 발명에 따른 화학식 1로 표시되는 화합물은 하기 화학식 4 내지 9 중 어느 하나로 표시될 수 있다.The compound represented by the formula (1) according to the present invention can be represented by any one of the following formulas (4) to (9).

Figure 112013108009545-pat00015
Figure 112013108009545-pat00015

Figure 112013108009545-pat00016
Figure 112013108009545-pat00016

Figure 112013108009545-pat00017
Figure 112013108009545-pat00017

Figure 112013108009545-pat00018
Figure 112013108009545-pat00018

Figure 112013108009545-pat00019
Figure 112013108009545-pat00019

Figure 112013108009545-pat00020
Figure 112013108009545-pat00020

상기 화학식 4 내지 9에서,In the above formulas 4 to 9,

상기 Y1 내지 Y8, 및 X1 내지 X4는 각각 화학식 1에서 정의한 바와 같다.Y 1 to Y 8 , and X 1 to X 4 are each as defined in formula (1).

또, 상기 화학식 1의 화합물은 하기 화학식 C-1 내지 C-36 중 어느 하나로 표시될 수 있다.The compound of formula (1) may be represented by any of the following formulas (C-1) to (C-36).

Figure 112013108009545-pat00021
Figure 112013108009545-pat00021

Figure 112013108009545-pat00022
Figure 112013108009545-pat00022

Figure 112013108009545-pat00023
Figure 112013108009545-pat00023

Figure 112013108009545-pat00024
Figure 112013108009545-pat00024

Figure 112013108009545-pat00025
Figure 112013108009545-pat00025

Figure 112013108009545-pat00026
Figure 112013108009545-pat00026

상기 화학식 C-1 내지 화학식 C-36 에서, In the above formulas C-1 to C-36,

X1 내지 X5, 및 Y1 내지 Y12는 각각 화학식 1에서 정의한 바와 같다.
X 1 to X 5 , and Y 1 to Y 12 are each as defined in formula (1).

또, 본 발명에 따른 화학식 1로 표시되는 화합물은 하기 화학식 10 내지 15 중 어느 하나로 표시된다.The compound represented by the formula (1) according to the present invention is represented by any one of the following formulas (10) to (15).

Figure 112013108009545-pat00027
Figure 112013108009545-pat00027

Figure 112013108009545-pat00028
Figure 112013108009545-pat00028

Figure 112013108009545-pat00029
Figure 112013108009545-pat00029

Figure 112013108009545-pat00030
Figure 112013108009545-pat00030

Figure 112013108009545-pat00031
Figure 112013108009545-pat00031

Figure 112013108009545-pat00032
Figure 112013108009545-pat00032

상기 화학식 10 내지 15에서,In the above formulas 10 to 15,

X2 및 X3, Y1 내지 Y4, 및 Ar1 내지 Ar5는 각각 화학식 1에서 정의한 바와 같다.
X 2 and X 3 , Y 1 to Y 4 , and Ar 1 to Ar 5 are as defined in formula (1), respectively.

본 발명에 따른 화학식 1의 화합물은 하기 화학식 A-1 내지 화학식 A-24 중 어느 하나로 표시될 수 있으나, 이에 한정되는 것은 아니다. 이 중에서 화합물의 물리적, 화학적 특성을 고려하여, 본 발명의 화합물은 하기 화학식 A-1 내지 화학식 A-6 중 어느 하나로 표시되는 것이 바람직하다.The compound of formula (I) according to the present invention may be represented by any one of the following formulas A-1 to A-24, but is not limited thereto. Among them, the compound of the present invention is preferably represented by any one of the following formulas (A-1) to (A-6) in consideration of the physical and chemical properties of the compound.

Figure 112013108009545-pat00033
Figure 112013108009545-pat00033

상기 화학식 A-1 내지 A-24에서,In the above Formulas A-1 to A-24,

R4, Y1 내지 Y4 및 Ar1 내지 Ar5은 각각 화학식 1에서 정의한 바와 같다.
R 4 , Y 1 to Y 4, and Ar 1 to Ar 5 are each as defined in formula (1).

본 발명에 따른 화학식 1의 화합물의 구체적인 예로는 하기 화합물 Inv-1 내지 화합물 Inv-750 등이 있는데, 이에 한정되는 것은 아니다. Specific examples of the compound of formula (1) according to the present invention include, but are not limited to, the following compounds Inv-1 to Inv-750.

Figure 112013108009545-pat00034
Figure 112013108009545-pat00034

Figure 112013108009545-pat00035
Figure 112013108009545-pat00035

Figure 112013108009545-pat00036
Figure 112013108009545-pat00036

Figure 112013108009545-pat00037
Figure 112013108009545-pat00037

Figure 112013108009545-pat00038
Figure 112013108009545-pat00038

Figure 112013108009545-pat00039
Figure 112013108009545-pat00039

Figure 112013108009545-pat00040
Figure 112013108009545-pat00040

Figure 112013108009545-pat00041
Figure 112013108009545-pat00041

Figure 112013108009545-pat00042
Figure 112013108009545-pat00042

Figure 112013108009545-pat00043
Figure 112013108009545-pat00043

Figure 112013108009545-pat00044
Figure 112013108009545-pat00044

Figure 112013108009545-pat00045
Figure 112013108009545-pat00045

Figure 112013108009545-pat00046
Figure 112013108009545-pat00046

Figure 112013108009545-pat00047
Figure 112013108009545-pat00047

Figure 112013108009545-pat00048
Figure 112013108009545-pat00048

Figure 112013108009545-pat00049
Figure 112013108009545-pat00049

Figure 112013108009545-pat00050
Figure 112013108009545-pat00050

Figure 112013108009545-pat00051
Figure 112013108009545-pat00051

Figure 112013108009545-pat00052
Figure 112013108009545-pat00052

Figure 112013108009545-pat00053
Figure 112013108009545-pat00053

Figure 112013108009545-pat00054
Figure 112013108009545-pat00054

Figure 112013108009545-pat00055
Figure 112013108009545-pat00055

Figure 112013108009545-pat00056
Figure 112013108009545-pat00056

Figure 112013108009545-pat00057
Figure 112013108009545-pat00057

Figure 112013108009545-pat00058
Figure 112013108009545-pat00058

Figure 112013108009545-pat00059
Figure 112013108009545-pat00059

Figure 112013108009545-pat00060
Figure 112013108009545-pat00060

Figure 112013108009545-pat00061
Figure 112013108009545-pat00061

Figure 112013108009545-pat00062
Figure 112013108009545-pat00062

Figure 112013108009545-pat00063
Figure 112013108009545-pat00063

Figure 112013108009545-pat00064
Figure 112013108009545-pat00064

Figure 112013108009545-pat00065
Figure 112013108009545-pat00065

Figure 112013108009545-pat00066
Figure 112013108009545-pat00066

Figure 112013108009545-pat00067
Figure 112013108009545-pat00067

Figure 112013108009545-pat00068
Figure 112013108009545-pat00068

Figure 112013108009545-pat00069
Figure 112013108009545-pat00069

Figure 112013108009545-pat00070
Figure 112013108009545-pat00070

Figure 112013108009545-pat00071
Figure 112013108009545-pat00071

Figure 112013108009545-pat00072
Figure 112013108009545-pat00072

Figure 112013108009545-pat00073
Figure 112013108009545-pat00073

Figure 112013108009545-pat00074
Figure 112013108009545-pat00074

Figure 112013108009545-pat00075
Figure 112013108009545-pat00075

Figure 112013108009545-pat00076
Figure 112013108009545-pat00076

Figure 112013108009545-pat00077
Figure 112013108009545-pat00077

Figure 112013108009545-pat00078
Figure 112013108009545-pat00078

Figure 112013108009545-pat00079
Figure 112013108009545-pat00079

Figure 112013108009545-pat00080
Figure 112013108009545-pat00080

본 발명에서의 알킬은 탄소수 1 내지 40의 직쇄 또는 측쇄의 포화 탄화수소에서 유래되는 1가의 치환기이며, 이의 예로는 메틸, 에틸, 프로필, 이소부틸, sec-부틸, 펜틸, iso-아밀, 헥실 등을 들 수 있다.In the present invention, alkyl is a monovalent substituent derived from a linear or branched saturated hydrocarbon having 1 to 40 carbon atoms, and examples thereof include methyl, ethyl, propyl, isobutyl, sec-butyl, pentyl, iso-amyl, .

본 발명에서의 알케닐(alkenyl)은 탄소-탄소 이중 결합을 1개 이상 가진 탄소수 2 내지 40의 직쇄 또는 측쇄의 불포화 탄화수소에서 유래되는 1가의 치환기이며, 이의 예로는 비닐(vinyl), 알릴(allyl), 이소프로펜일(isopropenyl), 2-부텐일(2-butenyl) 등을 들 수 있다.The alkenyl in the present invention is a monovalent substituent derived from a linear or branched unsaturated hydrocarbon having 2 to 40 carbon atoms and having at least one carbon-carbon double bond. Examples thereof include vinyl, allyl, Isopropenyl, 2-butenyl, and the like.

본 발명에서의 알키닐(alkynyl)은 탄소-탄소 삼중 결합을 1개 이상 가진 탄소수 2 내지 40의 직쇄 또는 측쇄의 불포화 탄화수소에서 유래되는 1가의 치환기이며, 이의 예로는 에티닐(ethynyl), 2-프로파닐(2-propynyl) 등을 들 수 있다.Alkynyl in the present invention is a monovalent substituent derived from a linear or branched unsaturated hydrocarbon having 2 to 40 carbon atoms and having at least one carbon-carbon triple bond. Examples thereof include ethynyl, 2- 2-propynyl, and the like.

본 발명에서의 아릴은 단독 고리 또는 2이상의 고리가 조합된 탄소수 6 내지 60의 방향족 탄화수소로부터 유래된 1가의 치환기를 의미한다. 또한, 2 이상의 고리가 서로 단순 부착(pendant)되거나 축합된 형태도 포함될 수 있다. 이러한 아릴의 예로는 페닐, 나프틸, 페난트릴, 안트릴 등을 들 수 있다.The aryl in the present invention means a monovalent substituent derived from an aromatic hydrocarbon having 6 to 60 carbon atoms in which a single ring or two or more rings are combined. Also, a form in which two or more rings are pendant or condensed with each other may be included. Examples of such aryl include phenyl, naphthyl, phenanthryl, anthryl and the like.

본 발명에서의 헤테로아릴은 핵원자수 5 내지 40의 모노헤테로사이클릭 또는 폴리헤테로사이클릭 방향족 탄화수소로부터 유래된 1가의 치환기를 의미한다. 이때, 고리 중 하나 이상의 탄소, 바람직하게는 1 내지 3개의 탄소가 N, O, S 또는 Se와 같은 헤테로원자로 치환된다. 또한, 2 이상의 고리가 서로 단순 부착(pendant)되거나 축합된 형태도 포함될 수 있고, 아릴기와 축합된 형태도 포함할 수 있다. 이러한 헤테로아릴의 예로는 피리딜, 피라지닐, 피리미디닐, 피리다지닐, 트리아지닐과 같은 6-원 모노사이클릭 고리, 페녹사티에닐(phenoxathienyl), 인돌리지닐(indolizinyl), 인돌릴(indolyl), 퓨리닐(purinyl), 퀴놀릴(quinolyl), 벤조티아졸(benzothiazole), 카바졸릴(carbazolyl)과 같은 폴리사이클릭 고리, 2-퓨라닐, N-이미다졸릴, 2-이속사졸릴, 2-피리디닐, 2-피리미디닐 등을 들 수 있다.The heteroaryl in the present invention means a monovalent substituent derived from a monoheterocyclic or polyheterocyclic aromatic hydrocarbon having 5 to 40 nuclear atoms. Wherein at least one of the carbons, preferably one to three carbons, is replaced by a heteroatom such as N, O, S or Se. In addition, the ring may be pendant or condensed with each other, or may be condensed with an aryl group. Examples of such heteroaryls include 6-membered monocyclic rings such as pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, phenoxathienyl, indolizinyl, indolyl indolyl), purinyl, quinolyl, benzothiazole, carbazolyl, 2-furanyl, N-imidazolyl, 2- isoxazolyl , 2-pyridinyl, 2-pyrimidinyl, and the like.

본 발명에서의 아릴옥시는 RO-로 표시되는 1가의 치환기로 상기 R은 탄소수 5 내지 60의 아릴을 의미한다. 이러한 아릴옥시의 예로는 페닐옥시, 나프틸옥시, 디페닐옥시 등을 들 수 있다.In the present invention, aryloxy is a monovalent substituent represented by RO-, and R represents aryl having 5 to 60 carbon atoms. Examples of such aryloxy include phenyloxy, naphthyloxy, diphenyloxy and the like.

본 발명에서의 알킬옥시는 R'O-로 표시되는 1가의 치환기로 상기 R'는 1 내지 40개의 알킬을 의미하며, 직쇄(linear), 측쇄(branched) 또는 사이클릭(cyclic) 구조를 포함하는 것으로 해석한다. 이러한 알킬옥시의 예로는 메톡시, 에톡시, n-프로폭시, 1-프로폭시, t-부톡시, n-부톡시, 펜톡시 등을 들 수 있다.The alkyloxy in the present invention is a monovalent substituent group represented by R'O-, wherein R 'is an alkyl having 1 to 40 carbon atoms and includes a linear, branched or cyclic structure . Examples of such alkyloxy include methoxy, ethoxy, n-propoxy, 1-propoxy, t-butoxy, n-butoxy, pentoxy and the like.

본 발명에서의 아릴아민은 탄소수 6 내지 60의 아릴로 치환된 아민을 의미한다.The arylamine in the present invention means an amine substituted with aryl having 6 to 60 carbon atoms.

본 발명에서의 시클로알킬은 탄소수 3 내지 40의 모노사이클릭 또는 폴리사이클릭 비-방향족 탄화수소로부터 유래된 1가의 치환기를 의미한다. 이러한 사이클로알킬의 예로는 사이클로프로필, 사이클로펜틸, 사이클로헥실, 놀보닐(norbornyl), 아다만틴(adamantine) 등을 들 수 있다.The cycloalkyl in the present invention means a monovalent substituent derived from a monocyclic or polycyclic non-aromatic hydrocarbon having 3 to 40 carbon atoms. Examples of such cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, norbornyl, adamantine, and the like.

본 발명에서의 헤테로시클로알킬은 핵원자수 3 내지 40의 비-방향족 탄화수소로부터 유래된 1가의 치환기를 의미하며, 고리 중 하나 이상의 탄소, 바람직하게는 1 내지 3개의 탄소가 N, O, S 또는 Se와 같은 헤테로 원자로 치환된다. 이러한 헤테로시클로알킬의 예로는 모르폴린, 피페라진 등을 들 수 있다.Heterocycloalkyl in the present invention means a monovalent substituent derived from a non-aromatic hydrocarbon having 3 to 40 nuclear atoms, wherein at least one carbon of the ring, preferably 1 to 3 carbons, is N, O, S or Se. &Lt; / RTI &gt; Examples of such heterocycloalkyl include morpholine, piperazine and the like.

본 발명에서의 알킬실릴은 탄소수 1 내지 40의 알킬로 치환된 실릴이고, 아릴실릴은 탄소수 5 내지 40의 아릴로 치환된 실릴을 의미한다.The alkylsilyl in the present invention is silyl substituted with alkyl having 1 to 40 carbon atoms, and arylsilyl means silyl substituted with aryl having 5 to 40 carbon atoms.

본 발명에서의 축합 고리는 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리, 축합 헤테로방향족 고리 또는 이들의 조합된 형태를 의미한다.
The condensed ring in the present invention means a condensed aliphatic ring, a condensed aromatic ring, a condensed heteroaliphatic ring, a condensed heteroaromatic ring, or a combination thereof.

<유기 전계 발광 소자>&Lt; Organic electroluminescent device &

본 발명은 전술한 화합물을 포함하는 유기 전계 발광 소자를 제공한다.The present invention provides an organic electroluminescent device comprising the above-described compound.

구체적으로, 본 발명에 따른 유기 전계 발광 소자는 양극(anode), 음극(cathode) 및 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하며, 상기 1층 이상의 유기물층 중 적어도 하나는 본 발명의 화학식으로 표시되는 화합물을 포함한다. 이때, 상기 화합물은 단독으로 사용되거나, 또는 2 이상이 혼합되어 사용될 수 있다.Specifically, the organic electroluminescent device according to the present invention includes an anode, a cathode, and at least one organic layer sandwiched between the anode and the cathode, wherein at least one of the one or more organic layers includes And compounds represented by the formulas of the present invention. At this time, the compounds may be used alone or in combination of two or more.

상기 1층 이상의 유기물층은 정공주입층, 정공수송층, 발광층, 전자수송층 및 전자주입층 중 어느 하나 이상일 수 있고, 이 중에서 적어도 하나의 유기물층은 전술한 화학식 1의 화합물을 포함할 수 있다. 바람직하게는 본 발명의 화합물을 포함하는 유기물층은 발광층일 수 있다.The one or more organic layers may be at least one of a hole injecting layer, a hole transporting layer, a light emitting layer, an electron transporting layer, and an electron injecting layer, and at least one of the organic layers may include the compound of Formula 1 described above. Preferably, the organic layer containing the compound of the present invention may be a light emitting layer.

본 발명의 일례에 따르면, 유기 전계 발광 소자의 발광층은 호스트 재료를 포함할 수 있는데, 이때 호스트 재료로서 상기 화학식 1의 화합물을 포함할 수 있다. 이와 같이, 상기 화학식 1의 화합물을 유기 전계 발광 소자의 발광층 재료, 바람직하게는 청색, 녹색, 적색의 인광 호스트 재료로 포함할 경우, 발광층에서 정공과 전자의 결합력이 높아지기 때문에, 유기 전계 발광 소자의 효율(발광효율 및 전력효율), 수명, 휘도 및 구동전압 등이 향상될 수 있다.According to an embodiment of the present invention, the light emitting layer of the organic electroluminescent device may include a host material, and the host material may include the compound of the above formula (1). When the compound of Formula 1 is included in the light emitting layer material of the organic electroluminescent device, preferably blue, green, and red phosphorescent host materials, the bonding strength between holes and electrons in the light emitting layer increases, Efficiency (luminous efficiency and power efficiency), lifetime, luminance, driving voltage, and the like can be improved.

본 발명에 따른 유기 전계 발광 소자의 구조는 특별히 한정되지 않으며, 예컨대 기판, 양극, 정공주입층, 정공수송층, 발광층, 전자수송층 및 음극이 순차적으로 적층된 구조일 수 있다. 이때, 상기 정공주입층, 정공수송층, 발광층, 전자수송층 및 전자주입층 중 하나 이상은 본 발명의 화합물을 포함할 수 있고, 바람직하게는 발광층이 상기 화학식 1의 화합물을 포함할 수 있다. 이때, 상기 화학식 1의 화합물은 발광층의 인광 호스트 재료로 이용될 수 있다. 상기 전자수송층 위에는 전자주입층이 추가로 적층될 수 있다. The structure of the organic electroluminescent device according to the present invention is not particularly limited and may be a structure in which a substrate, an anode, a hole injecting layer, a hole transporting layer, a light emitting layer, an electron transporting layer, and a cathode are sequentially laminated. At least one of the hole injecting layer, the hole transporting layer, the light emitting layer, the electron transporting layer, and the electron injecting layer may include the compound of the present invention, and preferably the light emitting layer may include the compound of Formula 1. At this time, the compound of Formula 1 may be used as a phosphorescent host material of the light emitting layer. An electron injection layer may be further stacked on the electron transport layer.

또한, 본 발명에 따른 유기 전계 발광 소자의 구조는 양극, 1층 이상의 유기물층 및 음극이 순차적으로 적층될 뿐만 아니라, 전극과 유기물층 계면에 절연층 또는 접착층이 삽입된 구조일 수 있다.In addition, the structure of the organic electroluminescent device according to the present invention may be a structure in which an anode, one or more organic layers and an anode are sequentially laminated, and an insulating layer or an adhesive layer is inserted into the interface between the electrode and the organic layer.

본 발명에 따른 유기 전계 발광 소자는 상기 유기물층 중 1층 이상(예컨대, 발광층)이 상기 화학식 1의 화합물을 포함하도록 형성하는 것을 제외하고는, 당 기술 분야에 알려져 있는 재료 및 방법을 이용하여 다른 유기물층 및 전극을 형성하여 제조될 수 있다.The organic electroluminescent device according to the present invention can be formed by using materials and methods known in the art, except that one or more of the organic layers (for example, the light emitting layer) And electrodes.

상기 유기물층은 진공 증착법이나 용액 도포법에 의하여 형성될 수 있다. 상기 용액 도포법의 예로는 스핀 코팅, 딥코팅, 닥터 블레이딩, 잉크젯 프린팅 또는 열 전사법 등이 있으나, 이들에 한정되지 않는다.The organic material layer may be formed by a vacuum deposition method or a solution coating method. Examples of the solution coating method include, but are not limited to, spin coating, dip coating, doctor blading, inkjet printing, or thermal transfer.

본 발명에서 사용 가능한 기판으로는 특별히 한정되지 않으며, 실리콘 웨이퍼, 석영, 유리판, 금속판, 플라스틱 필름 및 시트 등이 사용될 수 있다.The substrate usable in the present invention is not particularly limited, and a silicon wafer, quartz, a glass plate, a metal plate, a plastic film and a sheet can be used.

또, 양극 물질로는 바나듐, 크롬, 구리, 아연, 금과 같은 금속 또는 이들의 합금; 아연산화물, 인듐산화물, 인듐 주석 산화물(ITO), 인듐 아연 산화물(IZO)과 같은 금속 산화물; ZnO:Al 또는 SnO2:Sb와 같은 금속과 산화물의 조합; 폴리티오펜, 폴리(3-메틸티오펜), 폴리[3,4-(에틸렌-1,2-디옥시)티오펜](PEDT), 폴리피롤 또는 폴리아닐린과 같은 전도성 고분자; 및 카본블랙 등이 있는데, 이에 한정되지 않는다.Examples of the positive electrode material include metals such as vanadium, chromium, copper, zinc, and gold, or alloys thereof; Metal oxides such as zinc oxide, indium oxide, indium tin oxide (ITO), and indium zinc oxide (IZO); ZnO: Al or SnO 2: a combination of a metal and an oxide such as Sb; Conductive polymers such as polythiophene, poly (3-methylthiophene), poly [3,4- (ethylene-1,2-dioxy) thiophene] (PEDT), polypyrrole or polyaniline; And carbon black, but are not limited thereto.

또, 음극 물질로는 마그네슘, 칼슘, 나트륨, 칼륨, 타이타늄, 인듐, 이트륨, 리튬, 가돌리늄, 알루미늄, 은, 주석, 또는 납과 같은 금속 또는 이들의 합금; 및 LiF/Al 또는 LiO2/Al과 같은 다층 구조 물질 등이 있는데, 이에 한정되지 않는다.The negative electrode material may be a metal such as magnesium, calcium, sodium, potassium, titanium, indium, yttrium, lithium, gadolinium, aluminum, silver, tin or lead or an alloy thereof; And multi-layer structure materials such as LiF / Al or LiO 2 / Al, but are not limited thereto.

또한, 정공 주입층, 정공 수송층, 전자 주입층 및 전자 수송층은 특별히 한정되는 것은 아니며, 당 업계에 알려진 통상의 물질이 사용될 수 있다.
The hole injecting layer, the hole transporting layer, the electron injecting layer and the electron transporting layer are not particularly limited, and conventional materials known in the art can be used.

이하 본 발명을 실시예를 통하여 상세히 설명하면 다음과 같다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited by the following examples.

[준비예 1] 화합물 IC-1 및 IC-2의 합성[Preparation Example 1] Synthesis of compound IC-1 and IC-2

<단계 1> N-(2,4-dibromophenyl)benzamide의 합성<Step 1> Synthesis of N- (2,4-dibromophenyl) benzamide

Figure 112013108009545-pat00081
Figure 112013108009545-pat00081

질소 기류 하에서 2,4-dibromoaniline (250 g, 1.0 mol) 및 디클로로메탄 (1L)을 교반시키고, 상온에서 benzoyl chloride (140.05 g, 1.0 mol)와 pyridine (157.62 mL, 1.99 mol)을 천천히 적가하였다.Benzoyl chloride (140.05 g, 1.0 mol) and pyridine (157.62 mL, 1.99 mol) were slowly added dropwise at room temperature while stirring 2,4-dibromoaniline (250 g, 1.0 mol) and dichloromethane (1 L) in a stream of nitrogen.

2시간 후 반응을 종결시키고, 디클로로메탄을 이용하여 유기층을 추출한 다음 MgSO4로 수분을 제거하고, 컬럼크로마토그래피 (Hexane:EA = 4:1 (v/v))로 정제하여 N-(2,4-dibromophenyl)benzamide (258.72 g, 수율 73%)를 얻었다. After 2 hours, the reaction was terminated and the organic layer was extracted with dichloromethane. The organic layer was dried over MgSO 4 and purified by column chromatography (Hexane: EA = 4: 1 (v / v) 4-dibromophenyl) benzamide (258.72 g, yield 73%).

1H-NMR: δ 7.53 (d, 1H), 7.60 (d, 1H), 7.65 (dd, 2H), 7.72 (t, 1H), 7.98 (s, 1H), 8.04 (d, 2H), 9.16 (s, 1H) 1 H-NMR: δ 7.53 ( d, 1H), 7.60 (d, 1H), 7.65 (dd, 2H), 7.72 (t, 1H), 7.98 (s, 1H), 8.04 (d, 2H), 9.16 ( s, 1 H)

<단계 2> 6-bromo-2-phenylbenzo[d]oxazole의 합성<Step 2> Synthesis of 6-bromo-2-phenylbenzo [d] oxazole

Figure 112013108009545-pat00082
Figure 112013108009545-pat00082

질소 기류 하에서 준비예 1의 <단계 2>에서 얻은 N-(2,4-dibromophenyl)benzamide (258.72 g, 0.73 mol), K2CO3 (201.04 g, 1.45 mol) 및 DMSO (5000 ml)를 혼합하고, 140 ℃에서 1.5 시간 동안 교반하였다.(2,4-dibromophenyl) benzamide (258.72 g, 0.73 mol), K 2 CO 3 (201.04 g, 1.45 mol) and DMSO (5000 ml) obtained in Step 2 of Preparation Example 1 were mixed And the mixture was stirred at 140 ° C for 1.5 hours.

반응이 종결된 후, 에틸아세테이트로 유기층을 추출한 다음 MgSO4로 수분을 제거하고, 컬럼크로마토그래피 (Hexane:EA = 9:1 (v/v))로 정제하여 6-bromo-2-phenylbenzo[d]oxazole (161.48 g, 수율 81 %)을 얻었다. After the reaction was completed, the organic layer was extracted with ethyl acetate, the water was removed with MgSO 4 and purified by column chromatography (Hexane: EA = 9: 1 (v / v)) to obtain 6-bromo-2- phenylbenzo [ ] oxazole (161.48 g, yield 81%).

1H-NMR: δ 7.42 (t, 1H) 7.44 (s, 1H), 7.53 (m, 3H), 7.62 (d, 1H), 8.07 (d, 2H) 1 H-NMR: δ 7.42 ( t, 1H) 7.44 (s, 1H), 7.53 (m, 3H), 7.62 (d, 1H), 8.07 (d, 2H)

<단계 3> 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo [d]oxazole 의 합성<Step 3> Synthesis of 2-phenyl-6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole

Figure 112013108009545-pat00083
Figure 112013108009545-pat00083

질소 기류 하에서 준비예 1의 <단계 2>에서 얻은 6-bromo-2-phenylbenzo[d]oxazole (161.48 g, 0.589 mol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (179.52 g, 0.707 mol), Pd(dppf)Cl2 (24.05 g, 29.46 mmol), KOAc (173.44 g, 1.77 mol) 및 1,4-Dioxane (3000 ml)를 혼합하고, 130 ℃에서 12시간 동안 교반하였다.6-bromo-2-phenylbenzo [d] oxazole (161.48 g, 0.589 mol), 4,4,4 ', 4', 5,5,5 ' Pd (dppf) Cl 2 (24.05 g, 29.46 mmol), KOAc (173.44 g, 1.77 mol), and N, N-dimethylformamide (179.52 g, 0.707 mol) 1,4-Dioxane (3000 ml) were mixed and stirred at 130 ° C for 12 hours.

반응이 종결된 후, 에틸아세테이트로 유기층을 추출한 다음 MgSO4로 수분을 제거하고, 컬럼크로마토그래피 (Hexane:EA = 7:1 (v/v))로 정제하여 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (149.48 g, 수율 79%)을 얻었다. After the reaction was completed, the organic layer was extracted with ethyl acetate, the water was removed with MgSO 4 , and the residue was purified by column chromatography (Hexane: EA = 7: 1 (v / v) 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole (149.48 g, yield 79%).

1H-NMR: δ 1.25 (s, 12H) 7.42 (d, 1H), 7.45 (s, 1H), 7.52 (dd, 2H), 7.63 (d, 1H), 7.76 (s, 1H), 8.07 (d, 2H) 1 H-NMR: δ 1.25 ( s, 12H) 7.42 (d, 1H), 7.45 (s, 1H), 7.52 (dd, 2H), 7.63 (d, 1H), 7.76 (s, 1H), 8.07 (d , 2H)

<단계 4> 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole의 합성<Step 4> Synthesis of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole

Figure 112013108009545-pat00084
Figure 112013108009545-pat00084

질소 기류 하에서 준비예 1의 <단계 3>에서 얻은 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (149.48 g, 0.465 mol), 4-bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol), Pd(PPh3)4 (24.45 g, 21.15 mmol), K2CO3 (175.43 g, 1.27 mol), THF/H2O (2000 ml/1000 ml)를 혼합하고, 80 ℃에서 12시간 동안 교반하였다.(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole (obtained in Step 3 of Preparation Example 1, 149.48 g , 0.465 mol), 4-bromo -2-iodo-1-nitrobenzene (138.73 g, 0.423 mol), Pd (PPh 3) 4 (24.45 g, 21.15 mmol), K 2 CO 3 (175.43 g, 1.27 mol), THF / H 2 O (2000 ml / 1000 ml) were mixed and stirred at 80 ° C for 12 hours.

반응이 종결된 후, 메틸렌클로라이드로 유기층을 추출하고 MgSO4를 넣고 여과하였다. 얻어진 유기층에서 용매를 제거한 후 컬럼 크로마토그래피 (Hexane:EA = 8:1 (v/v))로 정제하여 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 수율 68 %)을 얻었다. After the reaction was completed, the organic layer was extracted with methylene chloride, and the mixture was filtered with MgSO 4 . The solvent was removed from the obtained organic layer and then purified by column chromatography (Hexane: EA = 8: 1 (v / v)) to obtain 113.7 g of 6- (5-bromo-2- nitrophenyl) Yield: 68%).

1H-NMR: δ 7.42 (t, 1H) 7.49 (s, 1H), 7.55 (dd, 2H), 7.69 (d, 1H), 7.71 (s, 1H), 7.78 (d, 1H), 7.96 (d, 1H), 8.07 (d, 2H), 8.24 (d, 1H) 1 H-NMR: δ 7.42 ( t, 1H) 7.49 (s, 1H), 7.55 (dd, 2H), 7.69 (d, 1H), 7.71 (s, 1H), 7.78 (d, 1H), 7.96 (d , &Lt; / RTI &gt; 1H), 8.07 (d, 2H), 8.24

<단계 5> 7-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole 및 8-bromo-2-phenyl-5H-oxazolo[4,5-b]carbazole의 합성Synthesis of 7-bromo-2-phenyl-10H-oxazolo [5,4-a] carbazole and 8-bromo-2-phenyl-5H-oxazolo [4,5-b]

Figure 112013108009545-pat00085
Figure 112013108009545-pat00085

질소 기류 하에서 준비예 1의 <단계 4>에서 얻은 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol)과 triphenylphosphine (188.65 g, 0.72 mol), 1,2-dichlorobenzene (1500 ml)를 혼합한 후, 12 시간 동안 교반하였다.2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol), triphenylphosphine (188.65 g, 0.72 mol) obtained in Step 4 of Preparation Example 1, 1 , And 2-dichlorobenzene (1500 ml) were mixed and stirred for 12 hours.

반응 종료 후, 1,2-dichlorobenzene를 제거하고 디클로로메탄으로 유기층을 추출한 다음, MgSO4를 넣고 여과하였다. 얻어진 유기층에서 용매를 제거한 후 컬럼 크로마토그래피 (Hexane:MC = 4:1 (v/v))로 정제하여 화합물 mid-1 (7-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole)(47 g, 수율 45 %) 및 화합물 mid-2 (8-bromo-2-phenyl-5H-oxazolo[4,5-b]carbazole)(44.93 g, 수율 43 %)을 획득하였다.After completion of the reaction, 1,2-dichlorobenzene was removed, and the organic layer was extracted with dichloromethane, followed by addition of MgSO 4 and filtration. The solvent was removed from the obtained organic layer and then purified by column chromatography (Hexane: MC = 4: 1 (v / v)) to obtain the compound mid-1 (7-bromo-2-phenyl-10H-oxazolo [ carbazole) (47 g, yield 45%) and compound mid-2 (8-bromo-2-phenyl-5H-oxazolo [4,5- b] carbazole) (44.93 g, yield 43%).

화합물 mid-1의 1H-NMR: δ 7.22 (d, 1H), 7.33 (t, 1H) 7.43 (d, 1H), 7.53 (dd, 2H), 7.55 (d, 1H), 8.07 (m, 3H), 8.13 (d, 1H), 10.2 (s, 1H) 1 of the compound mid-1 H-NMR: δ 7.22 (d, 1H), 7.33 (t, 1H) 7.43 (d, 1H), 7.53 (dd, 2H), 7.55 (d, 1H), 8.07 (m, 3H ), 8.13 (d, IH), 10.2 (s, IH)

화합물 mid-2의 1H-NMR: δ 7.41 (m, 3H), 7.51 (d, 3H), 7.57 (s, 1H), 8.05 (m, 3H), 11.54 (s, 1H) 1 H-NMR of compound mid-2: 7.41 (m, 3H), 7.51 (d, 3H), 7.57 (s,

<단계 6> 7-bromo-2,10-diphenyl-10H-oxazolo[5,4-a]carbazole의 합성<Step 6> Synthesis of 7-bromo-2,10-diphenyl-10H-oxazolo [5,4-a]

Figure 112013108009545-pat00086
Figure 112013108009545-pat00086

질소 기류 하에서 준비예 1의 <단계 5>에서 얻은 7-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole (47 g, 129.4 mmol), iodobenzene (39.6 g, 194.1 mmol), Cu powder (0.82 g, 12.94 mmol), K2CO3 (17.88 g, 129.4 mmol), Na2SO4 (18.38 g, 129.4 mmol), nitrobenzene (800 ml)을 혼합하고, 200 ℃에서 12시간 동안 교반하였다. 10-oxazolo [5,4-a] carbazole (47 g, 129.4 mmol), iodobenzene (39.6 g, 194.1 mmol) obtained in Step 5 of Preparation Example 1, Cu powder from (0.82 g, 12.94 mmol), K 2 CO 3 (17.88 g, 129.4 mmol), Na 2 SO 4 (18.38 g, 129.4 mmol), mixture of nitrobenzene (800 ml) and, 200 ℃ was stirred for 12 hours .

반응 종결 후, nitrobenzene을 제거하고 메틸렌클로라이드로 유기층을 분리하여 MgSO4를 사용하여 물을 제거하였다. 물이 제거된 유기층에서 용매를 제거한 후 컬럼 크로마토그래피 (Hexane:MC = 3:1 (v/v))로 정제하여 7-bromo-2,10-diphenyl-10H-oxazolo[5,4-a]carbazole (29.56 g, 수율 52 %)을 얻었다.After completion of the reaction, the nitrobenzene was removed, the organic layer was separated with methylene chloride, and water was removed using MgSO 4 . The solvent was removed from the organic layer from which water had been removed and then purified by column chromatography (Hexane: MC = 3: 1 (v / v)) to obtain 7-bromo- 2,10- carbazole (29.56 g, yield 52%).

1H-NMR: δ 7.21 (d, 1H), 7.42 (t, 1H) 7.46 (m, 2H), 7.52 (d, 4H), 7.57 (d, 3H), 8.05 (m, 3H), 8.11 (d, 1H) 1 H-NMR: δ 7.21 ( d, 1H), 7.42 (t, 1H) 7.46 (m, 2H), 7.52 (d, 4H), 7.57 (d, 3H), 8.05 (m, 3H), 8.11 (d , 1H)

<단계 7> 7-(2-nitrophenyl)-2,10-diphenyl-10H-oxazolo[5,4-a]carbazole 의 합성<Step 7> Synthesis of 7- (2-nitrophenyl) -2,10-diphenyl-10H-oxazolo [5,4-a]

Figure 112013108009545-pat00087
Figure 112013108009545-pat00087

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol e (149.48 g, 0.465 mol) 대신 7-bromo-2,10-diphenyl-10H-oxazolo[5,4-a]carbazole (29.56 g, 67.29 mmol)을 사용하고, 4-bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 대신 2-nitrophenylboronic acid (10.21 g, 61.17 mmol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 7-(2-nitrophenyl)-2,10-diphenyl-10H-oxazolo[5,4-a]carbazole (17.38 g, 수율 59 %)을 얻었다.2-phenyl-6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole e used in Step 4 of Preparation Example 1 (149.48 g, Bromo-2-iodo-1-nitrobenzene (138.73 g, 67.29 mmol) was obtained by using 7-bromo-2,10- diphenyl-10H-oxazolo [5,4- , 2-nitrophenyl) -2,10-dihydroxybenzoic acid was prepared by the same procedure as Step 4 of Preparation Example 1, except that 2-nitrophenylboronic acid (10.21 g, 61.17 mmol) -diphenyl-10H-oxazolo [5,4-a] carbazole (17.38 g, yield 59%).

1H-NMR: δ 7.20 (d, 1H), 7.43 (t, 1H) 7.47 (m, 2H), 7.51 (d, 4H), 7.58 (d, 3H), 7.68 (d, 1H), 7.89 (d, 2H), 8.04 (m, 4H), 8.14 (d, 1H) 1 H-NMR: δ 7.20 ( d, 1H), 7.43 (t, 1H) 7.47 (m, 2H), 7.51 (d, 4H), 7.58 (d, 3H), 7.68 (d, 1H), 7.89 (d , 2H), 8.04 (m, 4H), 8.14 (d, IH)

<단계 8> 화합물 IC-1 및 IC-2의 합성<Step 8> Synthesis of Compound IC-1 and IC-2

Figure 112013108009545-pat00088
Figure 112013108009545-pat00088

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 1의 <단계 7>에서 얻은 7-(2-nitrophenyl)-2,10-diphenyl-10H-oxazolo[5,4-a]carbazole (17.38 g, 36.1 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 화합물 IC-1 (6.98 g, 수율 43 %) 및 화합물 IC-2 (7.63 g, 수율 47 %)을 얻었다.Obtained in Step 7 of Preparation Example 1 instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in <Step 5> Step 5 of Preparation Example 1 was repeated except that 2-nitrophenyl-2,10-diphenyl-10H-oxazolo [5,4-a] carbazole (17.38 g, 36.1 mmol) To obtain compound IC-1 (6.98 g, yield 43%) and compound IC-2 (7.63 g, yield 47%).

화합물 IC-1의 1H-NMR: δ, 7.23 (d, 1H), 7.29 (d, 1H), 7.43 (m, 3H), 7.50 (m, 5H), 7.55 (s, 1H), 7.58 (d, 2H), 7.63 (d, 1H), 8.05 (d, 2H), 8.12 (d, 2H), 11.70 (s, 1H) One of the compounds IC-1 H-NMR: δ , 7.23 (d, 1H), 7.29 (d, 1H), 7.43 (m, 3H), 7.50 (m, 5H), 7.55 (s, 1H), 7.58 (d 2H), 7.63 (d, IH), 8.05 (d, 2H), 8.12

화합물 IC-2의 1H-NMR: δ 7.24 (d, 1H), 7.31 (d, 1H), 7.42 (m, 3H), 7.52 (m, 5H), 7.59 (d, 2H), 7.65 (d, 1H), 7.96 (d, 1H), 8.04 (d, 2H), 8.13 (d, 2H), 11.56 (s, 1H)
Compound 1 H-NMR of the IC-2: δ 7.24 (d , 1H), 7.31 (d, 1H), 7.42 (m, 3H), 7.52 (m, 5H), 7.59 (d, 2H), 7.65 (d, 1H), 7.96 (d, 1H), 8.04 (d, 2H), 8.13 (d, 2H), 11.56

[준비예 2] 화합물 IC-3 및 IC-4의 합성[Preparation Example 2] Synthesis of compound IC-3 and IC-4

<단계 1> 8-bromo-2,5-diphenyl-5H-oxazolo[4,5-b]carbazole의 합성<Step 1> Synthesis of 8-bromo-2,5-diphenyl-5H-oxazolo [4,5-b] carbazole

Figure 112013108009545-pat00089
Figure 112013108009545-pat00089

준비예 1의 <단계 6>에서 사용된 7-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole (47 g, 129.4 mmol) 대신 준비예 1의 <단계 5>에서 얻은 8-bromo-2-phenyl-5H-oxazolo[4,5-b]carbazole (44.93 g, 123.7 mmol) 을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 6>와 동일한 과정을 수행하여 8-bromo-2,5-diphenyl-5H-oxazolo[4,5-b]carbazole (27.71 g, 수율 51 %)을 얻었다.Obtained in Step 5 of Preparation Example 1 was used instead of 7-bromo-2-phenyl-10H-oxazolo [5,4-a] carbazole (47 g, 129.4 mmol) used in Step 6 of Preparation Example 1, bromo-2-phenyl-5H-oxazolo [4,5-b] carbazole (44.93 g, 123.7 mmol) was used in place of 8-bromo -2,5-diphenyl-5H-oxazolo [4,5-b] carbazole (27.71 g, yield 51%).

1H-NMR: δ 7.40 (m, 3H), 7.45 (t, 1H), 7.50 (d, 2H), 7.52 (d, 3H), 7.57 (s, 1H), 7.62 (d, 2H), 8.04 (m, 3H), 11.51 (s, 1H) 1 H-NMR: δ 7.40 ( m, 3H), 7.45 (t, 1H), 7.50 (d, 2H), 7.52 (d, 3H), 7.57 (s, 1H), 7.62 (d, 2H), 8.04 ( m, 3 H), 11.51 (s, 1 H)

<단계 2> 8-(2-nitrophenyl)-2,5-diphenyl-5H-oxazolo[4,5-b]carbazole의 합성<Step 2> Synthesis of 8- (2-nitrophenyl) -2,5-diphenyl-5H-oxazolo [4,5-b]

Figure 112013108009545-pat00090
Figure 112013108009545-pat00090

준비예 1의 <단계 7>에서 사용된 7-bromo-2,10-diphenyl-10H-oxazolo[5,4-a]carbazole (29.56 g, 67.29 mmol) 대신 준비예 2의 <단계 1>에서 얻은 8-bromo-2,5-diphenyl-5H-oxazolo[4,5-b]carbazole (27.71 g, 63.08 mmol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 7>와 동일한 과정을 수행하여 8-(2-nitrophenyl)-2,5-diphenyl-5H-oxazolo[4,5-b]carbazole (16.84 g, 수율 61 %)을 얻었다.The procedure of Step 1 of Preparation Example 2 was repeated except that 7-bromo-2,10-diphenyl-10H-oxazolo [5,4-a] carbazole (29.56 g, 67.29 mmol) Step 7 of Preparation Example 1 was repeated except that 8-bromo-2,5-diphenyl-5H-oxazolo [4,5-b] carbazole (27.71 g, 63.08 mmol) To obtain 8- (2-nitrophenyl) -2,5-diphenyl-5H-oxazolo [4,5-b] carbazole (16.84 g, yield 61%).

1H-NMR: δ 7.42 (m, 3H), 7.45 (t, 1H), 7.52 (d, 2H), 7.53 (d, 3H), 7.56 (s, 1H), 7.63 (d, 2H), 7.71 (d, 1H), 7.90 (d, 1H), 8.00 (d, 1H), 8.07 (m, 4H), 11.52 (s, 1H) 1 H-NMR: δ 7.42 ( m, 3H), 7.45 (t, 1H), 7.52 (d, 2H), 7.53 (d, 3H), 7.56 (s, 1H), 7.63 (d, 2H), 7.71 ( (d, IH), 7.90 (d, IH), 8.00 (d, IH), 8.07 (m, 4H), 11.52

<단계 3> 화합물 IC-3 및 IC-4의 합성<Step 3> Synthesis of compounds IC-3 and IC-4

Figure 112013108009545-pat00091
Figure 112013108009545-pat00091

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 8-(2-nitrophenyl)-2,5-diphenyl-5H-oxazolo[4,5-b]carbazole (16.84 g, 34.97 mmol)을 사용하고, triphenylphosphine (188.65 g, 0.72 mol) 대신 triphenylphosphine (22.93 g, 87.44 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 화합물 IC-3 (7.86 g, 수율 50 %) 및 화합물 IC-4 (6.60 g, 수율 42 %)을 얻었다.Except that 8- (2-nitrophenyl) -2,5-dimethylpyridine was used instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in <Step 5> except that triphenylphosphine (22.93 g, 87.44 mmol) was used instead of triphenylphosphine (188.65 g, 0.72 mol) instead of diphenyl-5H-oxazolo [4,5- b] carbazole (16.84 g, 34.97 mmol) The compound IC-3 (7.86 g, yield 50%) and compound IC-4 (6.60 g, yield 42%) were obtained in the same manner as in <Step 5> of Preparation Example 1.

화합물 IC-3의 1H-NMR: δ 7.29 (d, 1H), 7.40 (m, 2H), 7.45 (t, 1H), 7.50 (m, 5H), 7.55 (s, 1H), 7.58 (d, 2H), 7.64 (d, 3H), 8.05 (d, 2H), 8.12 (d, 1H), 11.65 (s, 1H)Compound IC-3 1 H-NMR of: δ 7.29 (d, 1H) , 7.40 (m, 2H), 7.45 (t, 1H), 7.50 (m, 5H), 7.55 (s, 1H), 7.58 (d, 2H), 7.64 (d, 3H), 8.05 (d, 2H), 8.12

화합물 IC-4의 1H-NMR: δ 7.28 (d, 1H), 7.39 (m, 3H), 7.46 (t, 1H), 7.50 (m, 5H), 7.56 (s, 2H), 7.59 (d, 2H), 7.65 (d, 1H), 8.06 (d, 2H), 8.11 (d, 1H), 11.63 (s, 1H)
Compound IC-4 1 H-NMR of: δ 7.28 (d, 1H) , 7.39 (m, 3H), 7.46 (t, 1H), 7.50 (m, 5H), 7.56 (s, 2H), 7.59 (d, 2H), 7.65 (d, 1H), 8.06 (d, 2H), 8.11

[준비예 3] 화합물 IC-5 및 IC-6의 합성[Preparation Example 3] Synthesis of Compound IC-5 and IC-6

<단계 1> N-(2,5-dibromophenyl)benzamide의 합성<Step 1> Synthesis of N- (2,5-dibromophenyl) benzamide

Figure 112013108009545-pat00092
Figure 112013108009545-pat00092

준비예 1의 <단계 1>에서 사용된 2,4-dibromoaniline (250 g, 1.0 mol) 대신 2,5-dibromoaniline (250 g, 1.0 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 1>와 동일한 과정을 수행하여 N-(2,5-dibromophenyl)benzamide (251.14 g, 수율 71 %)을 얻었다.Except that 2,5-dibromoaniline (250 g, 1.0 mol) was used instead of 2,4-dibromoaniline (250 g, 1.0 mol) used in <Step 1> of Preparation Example 1, (2,51-dibromophenyl) benzamide (251.14 g, yield 71%) was obtained in the same manner as in step 1).

1H-NMR: δ 7.23 (d, 1H), 7.47 (d, 1H), 7.63 (d, 2H), 7.70 (t, 1H), 7.76 (s, 1H), 8.03 (d, 2H), 10.25 (s, 1H) 1 H-NMR: δ 7.23 ( d, 1H), 7.47 (d, 1H), 7.63 (d, 2H), 7.70 (t, 1H), 7.76 (s, 1H), 8.03 (d, 2H), 10.25 ( s, 1 H)

<단계 2> 5-bromo-2-phenylbenzo[d]oxazole의 합성<Step 2> Synthesis of 5-bromo-2-phenylbenzo [d] oxazole

Figure 112013108009545-pat00093
Figure 112013108009545-pat00093

준비예 1의 <단계 2>에서 사용된 N-(2,4-dibromophenyl)benzamide (258.72 g, 0.73 mol) 대신 준비예 3의 <단계 1>에서 얻은 N-(2,5-dibromophenyl)benzamide (251.14 g, 0.71 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 2>와 동일한 과정을 수행하여 5-bromo-2-phenylbenzo[d]oxazole (155.12 g, 수율 80 %)을 얻었다.(2,5-dibromophenyl) benzamide obtained in Step 1 of Preparation Example 3 instead of N- (2,4-dibromophenyl) benzamide (258.72 g, 0.73 mol) used in Step 2 of Preparation Example 1 5-bromo-2-phenylbenzo [d] oxazole (155.12 g, yield 80%) was obtained in the same manner as in <Step 2> of Preparation Example 1, except that 251.14 g .

1H-NMR: δ 7.42 (m, 2H), 7.51 (d, 2H), 7.60 (d, 1H), 7.68 (d, 1H), 8.05 (d, 2H) 1 H-NMR: δ 7.42 ( m, 2H), 7.51 (d, 2H), 7.60 (d, 1H), 7.68 (d, 1H), 8.05 (d, 2H)

<단계 3> 2-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo [d]oxazole의 합성<Step 3> Synthesis of 2-phenyl-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole

Figure 112013108009545-pat00094
Figure 112013108009545-pat00094

준비예 1의 <단계 3>에서 사용된 6-bromo-2-phenylbenzo[d]oxazole (161.48 g, 0.589 mol) 대신 준비예 3의 <단계 2>에서 얻은 5-bromo-2-phenylbenzo[d]oxazole (155.12 g, 0.566 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 3>와 동일한 과정을 수행하여 2-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (136.32 g, 수율 75 %)을 얻었다.Bromo-2-phenylbenzo [d] thiazole obtained in Step 2 of Preparation Example 3 was used instead of 6-bromo-2-phenylbenzo [d] oxazole (161.48 g, 0.589 mol) used in Step 3 of Preparation Example 1, 2-phenyl-5- (4,4,5,5-tetramethyl-1, 3-dihydroxyphenyl) propanoate was prepared by the same procedure as Step 3 of Preparation Example 1, except that oxazole (155.12 g, 0.566 mol) 3,2-dioxaborolan-2-yl) benzo [d] oxazole (136.32 g, yield 75%).

1H-NMR: δ 1.24 (s, 12H), 7.30 (s, 1H), 7.42 (t, 1H), 7.53 (d, 2H), 7.75 (d, 1H), 7.79 (d, 1H), 8.07 (d, 2H) 1 H-NMR: δ 1.24 ( s, 12H), 7.30 (s, 1H), 7.42 (t, 1H), 7.53 (d, 2H), 7.75 (d, 1H), 7.79 (d, 1H), 8.07 ( d, 2H)

<단계 4> 5-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole의 합성<Step 4> Synthesis of 5- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole

Figure 112013108009545-pat00095
Figure 112013108009545-pat00095

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (149.48 g, 0.465 mol) 대신 준비예 3의 <단계 3>에서 얻은 2-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (136.32 g, 0.434 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 5-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (108.27 g, 수율 71 %)을 얻었다.(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole used in Step 4 of Preparation Example 1 (149.48 g, 0.465 (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole (obtained in Step 3 of Preparation Example 3 2-nitrophenyl) -2-phenylbenzo [d] oxazole (108.27 g, 0.434 mol) was used in the same manner as Step 4 of Preparation Example 1, Yield: 71%).

1H-NMR: δ 7.42 (t, 1H), 7.52 (d, 2H), 7.72 (s, 1H), 7.79 (d, 1H), 7.85 (d, 1H), 7.98 (d, 1H), 8.04 (d, 2H), 8.09 (s, 1H), 8.21 (d, 1H) 1 H-NMR: δ 7.42 ( t, 1H), 7.52 (d, 2H), 7.72 (s, 1H), 7.79 (d, 1H), 7.85 (d, 1H), 7.98 (d, 1H), 8.04 ( d, 2H), 8.09 (s, IH), 8.21 (d, IH)

<단계 5> 8-bromo-2-phenyl-5H-oxazolo[5,4-b]carbazole 및 7-bromo-2-phenyl-10H-oxazolo[4,5-a]carbazole의 합성Step 5 Synthesis of 8-bromo-2-phenyl-5H-oxazolo [5,4-b] carbazole and 7-bromo-2-phenyl-10H-oxazolo [4,5-

Figure 112013108009545-pat00096
Figure 112013108009545-pat00096

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 3의 <단계 4>에서 얻은 5-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (108.27 g, 0.274 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 화합물 mid-3 (8-bromo-2-phenyl-5H-oxazolo[5,4-b]carbazole)(43.78 g, 수율 44 %) 및 화합물 mid-4 (7-bromo-2-phenyl-10H-oxazolo[4,5-a]carbazole)(41.79 g, 수율 42 %)을 얻었다.Obtained in Step 4 of Preparation Example 3 instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in Step 5 of Preparation Example 1, Step 5 of Preparation Example 1 was repeated except that 5-bromo-2-nitrophenyl-2-phenylbenzo [d] oxazole (108.27 g, 0.274 mol) Bromo-2-phenyl-10H-oxazolo [4, 5] benzoic acid (43.78 g, 44% 5-a] carbazole (41.79 g, yield 42%).

화합물 mid-3의 1H-NMR: δ 7.40 (m, 2H), 7.43 (d, 1H), 7.51 (d, 3H), 7.54 (s, 1H), 8.04 (m, 3H), 11.64 (s, 1H)Compound mid-3 1 of H-NMR: δ 7.40 (m , 2H), 7.43 (d, 1H), 7.51 (d, 3H), 7.54 (s, 1H), 8.04 (m, 3H), 11.64 (s, 1H)

화합물 mid-4의 1H-NMR: δ 7.00 (d, 1H), 7.42 (m, 2H), 7.52 (d, 3H), 8.05 (m, 3H), 8.12 (d, 1H), 11.68 (s, 1H)Compound mid-4 1 H-NMR of: δ 7.00 (d, 1H) , 7.42 (m, 2H), 7.52 (d, 3H), 8.05 (m, 3H), 8.12 (d, 1H), 11.68 (s, 1H)

<단계 6> 8-bromo-2,5-diphenyl-5H-oxazolo[5,4-b]carbazole의 합성<Step 6> Synthesis of 8-bromo-2,5-diphenyl-5H-oxazolo [5,4-b] carbazole

Figure 112013108009545-pat00097
Figure 112013108009545-pat00097

준비예 1의 <단계 6>에서 사용된 7-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole (47 g, 0.129 mmol) 대신 준비예 3의 <단계 6>에서 얻은 8-bromo-2-phenyl-5H-oxazolo[5,4-b]carbazole (43.78 g, 0.121 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 6>와 동일한 과정을 수행하여 8-bromo-2,5-diphenyl-5H-oxazolo[5,4-b]carbazole (28.06 g, 수율 53 %)을 얻었다.Obtained in Step 6 of Preparation Example 3 instead of 7-bromo-2-phenyl-10H-oxazolo [5,4-a] carbazole (47 g, 0.129 mmol) used in Step 6 of Preparation Example 1, bromo-2-phenyl-5H-oxazolo [5,4-b] carbazole (43.78 g, 0.121 mmol) was used in place of 8-bromo -2,5-diphenyl-5H-oxazolo [5,4-b] carbazole (28.06 g, yield 53%).

1H-NMR: δ 7.441 (m, 2H), 7.43 (d, 1H), 7.46 (t, 1H), 7.50 (m, 5H), 7.54 (s, 1H), 7.59 (d, 2H), 8.06 (m, 3H) 1 H-NMR: δ 7.441 ( m, 2H), 7.43 (d, 1H), 7.46 (t, 1H), 7.50 (m, 5H), 7.54 (s, 1H), 7.59 (d, 2H), 8.06 ( m, 3H)

<단계 7> 8-(2-nitrophenyl)-2,5-diphenyl-5H-oxazolo[5,4-b]carbazole의 합성Step 7 Synthesis of 8- (2-nitrophenyl) -2,5-diphenyl-5H-oxazolo [5,4-b] carbazole

Figure 112013108009545-pat00098
Figure 112013108009545-pat00098

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol e (149.48 g, 0.465 mol) 대신 8-bromo-2,5-diphenyl-5H-oxazolo[5,4-b]carbazole (28.06 g, 63.87 mmol)을 사용하고, 4-bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 대신 2-nitrophenylboronic acid (9.69 g, 58.07 mmol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 8-(2-nitrophenyl)-2,5-diphenyl-5H-oxazolo[5,4-b]carbazole (17.33 g, 수율 62 %)을 얻었다.2-phenyl-6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole e used in Step 4 of Preparation Example 1 (149.48 g, Bromo-2,5-diphenyl-5H-oxazolo [5,4-b] carbazole (28.06 g, 63.87 mmol) instead of 4-bromo-2-iodo-1-nitrobenzene , 2-nitrophenylboronic acid (9.69 g, 58.07 mmol) was used instead of 2-nitrophenylboronic acid (0.423 mol) in the same manner as in <Step 4> -diphenyl-5H-oxazolo [5,4-b] carbazole (17.33 g, yield 62%).

1H-NMR: δ 7.41 (m, 2H), 7.43 (d, 1H), 7.46 (t, 1H), 7.50 (m, 5H), 7.54 (s, 1H), 7.59 (d, 2H), 7.67 (d, 1H), 7.77 (s, 1H), 7.90 (d, 1H), 8.05 (d, 1H), 8.06 (d, 3H) 1 H-NMR: δ 7.41 ( m, 2H), 7.43 (d, 1H), 7.46 (t, 1H), 7.50 (m, 5H), 7.54 (s, 1H), 7.59 (d, 2H), 7.67 ( (d, IH), 7.77 (s, IH), 7.90 (d, IH), 8.05

<단계 8> 화합물 IC-5 및 IC-6의 합성<Step 8> Synthesis of compounds IC-5 and IC-6

Figure 112013108009545-pat00099
Figure 112013108009545-pat00099

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 3의 <단계 7>에서 얻은 8-(2-nitrophenyl)-2,5-diphenyl-5H-oxazolo[5,4-b]carbazole (17.33 g, 35.99 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 화합물 IC-5 (6.79 g, 수율 42 %) 및 화합물 IC-6 (6.63 g, 수율 41 %)을 얻었다.Obtained in Step 7 of Preparation Example 3 instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in Step 5 of Preparation Example 1, Step 5 of Preparation Example 1 was repeated except that 2-nitrophenyl-2,5-diphenyl-5H-oxazolo [5,4-b] carbazole (17.33 g, 35.99 mmol) To obtain compound IC-5 (6.79 g, yield 42%) and compound IC-6 (6.63 g, yield 41%).

화합물 IC-5의 1H-NMR: δ 7.29 (d, 1H), 7.40 (s, 2H), 7.43 (t, 2H), 7.51 (d, 5H), 7.55 (s, 2H), 7.58 (d, 2H), 7.64 (d, 1H), 8.05 (d, 2H), 8.12 (d, 1H), 11.63 (s, 1H)Compound IC-5 1 H-NMR of: δ 7.29 (d, 1H) , 7.40 (s, 2H), 7.43 (t, 2H), 7.51 (d, 5H), 7.55 (s, 2H), 7.58 (d, 2H), 7.64 (d, IH), 8.05 (d, 2H), 8.12

화합물 IC-6의 1H-NMR: δ 7.30 (d, 1H), 7.41 (s, 1H), 7.44 (t, 2H), 7.50 (d, 5H), 7.56 (s, 1H), 7.59 (d, 2H), 7.65 (d, 3H), 8.04 (d, 2H), 8.11 (d, 1H), 11.62 (s, 1H)
Compound IC-6 1 H-NMR of: δ 7.30 (d, 1H) , 7.41 (s, 1H), 7.44 (t, 2H), 7.50 (d, 5H), 7.56 (s, 1H), 7.59 (d, 2H), 7.65 (d, 3H), 8.04 (d, 2H), 8.11

[준비예 4] 화합물 IC-7 및 IC-8의 합성[Preparation Example 4] Synthesis of compound IC-7 and IC-8

<단계 1> 7-bromo-2,10-diphenyl-10H-oxazolo[4,5-a]carbazole의 합성<Step 1> Synthesis of 7-bromo-2,10-diphenyl-10H-oxazolo [4,5-a] carbazole

Figure 112013108009545-pat00100
Figure 112013108009545-pat00100

준비예 1의 <단계 6>에서 사용된 7-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole (47 g, 129.4 mmol) 대신 준비예 3의 <단계 5>에서 얻은 7-bromo-2-phenyl-10H-oxazolo[4,5-a]carbazole (41.79 g, 115.06 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 6>와 동일한 과정을 수행하여 7-bromo-2,10-diphenyl-10H-oxazolo[4,5-a]carbazole (25.79 g, 수율 51 %)을 얻었다.Obtained in Step 5 of Preparation Example 3 instead of 7-bromo-2-phenyl-10H-oxazolo [5,4-a] carbazole (47 g, 129.4 mmol) used in Step 6 of Preparation Example 1, bromo-2-phenyl-10H-oxazolo [4,5-a] carbazole (41.79 g, 115.06 mmol) was used in place of 7-bromo -2,10-diphenyl-10H-oxazolo [4,5-a] carbazole (25.79 g, yield 51%).

1H-NMR: δ 7.02 (d, 1H), 7.41 (m, 2H), 7.46 (t, 1H), 7.51 (d, 2H), 7.53 (d, 3H), 7.59 (d, 2H), 8.06 (m, 3H), 8.13 (d, 1H) 1 H-NMR: δ 7.02 ( d, 1H), 7.41 (m, 2H), 7.46 (t, 1H), 7.51 (d, 2H), 7.53 (d, 3H), 7.59 (d, 2H), 8.06 ( m, 3 H), 8.13 (d, 1 H)

<단계 2> 7-(2-nitrophenyl)-2,10-diphenyl-10H-oxazolo[4,5-a]carbazole 의 합성<Step 2> Synthesis of 7- (2-nitrophenyl) -2,10-diphenyl-10H-oxazolo [4,5-a] carbazole

Figure 112013108009545-pat00101
Figure 112013108009545-pat00101

준비예 1의 <단계 7>에서 사용된 7-bromo-2,10-diphenyl-10H-oxazolo[5,4-a]carbazole (29.56 g, 67.29 mmol) 대신 준비예 4의 <단계 1>에서 얻은 7-bromo-2,10-diphenyl-10H-oxazolo[4,5-a]carbazole (25.79 g, 58.71 mmol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 7>와 동일한 과정을 수행하여 7-(2-nitrophenyl)-2,10-diphenyl-10H-oxazolo[4,5-a]carbazole (15.16 g, 수율 59 %)을 얻었다.Step 1 of Preparation Example 4 was repeated except that 7-bromo-2,10-diphenyl-10H-oxazolo [5,4-a] carbazole (29.56 g, 67.29 mmol) used in <Step 7> Step 7 of Preparation Example 1 was repeated except that 7-bromo-2,10-diphenyl-10H-oxazolo [4,5-a] carbazole (25.79 g, 58.71 mmol) To obtain 7- (2-nitrophenyl) -2,10-diphenyl-10H-oxazolo [4,5-a] carbazole (15.16 g, yield 59%).

1H-NMR: δ 7.00 (d, 1H), 7.41 (t, 1H), 7.45 (t, 1H), 7.50 (d, 4H), 7.58 (d, 2H), 7.67 (d, 1H), 7.77 (s, 1H), 7.90 (d, 1H), 8.00 (d, 2H), 8.05 (d, 3H), 8.12 (d, 1H), 8.18 (d, 1H) 1 H-NMR: δ 7.00 ( d, 1H), 7.41 (t, 1H), 7.45 (t, 1H), 7.50 (d, 4H), 7.58 (d, 2H), 7.67 (d, 1H), 7.77 ( (d, 1H), 7.90 (d, 1H), 8.00 (d, 2H), 8.05

<단계 3> 화합물 IC-7 및 IC-8의 합성<Step 3> Synthesis of compounds IC-7 and IC-8

Figure 112013108009545-pat00102
Figure 112013108009545-pat00102

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 4의 <단계 2>에서 얻은 7-(2-nitrophenyl)-2,10-diphenyl-10H-oxazolo[4,5-a]carbazole (15.16 g, 31.49 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 화합물 IC-7 (6.09 g, 수율 43 %) 및 화합물 IC-8 (5.52 g, 수율 39 %)을 얻었다.Obtained in Step 2 of Preparation Example 4 instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in <Step 5> Step 5 of Preparation Example 1 was repeated except that 2-nitrophenyl-2,10-diphenyl-10H-oxazolo [4,5-a] carbazole (15.16 g, 31.49 mmol) To obtain compound IC-7 (6.09 g, yield 43%) and compound IC-8 (5.52 g, yield 39%).

화합물 IC-7의 1H-NMR: δ 7.01 (d, 1H), 7.42 (t, 1H), 7.45 (t, 1H), 7.51 (d, 4H), 7.57 (d, 2H), 7.68 (d, 1H), 7.91 (d, 1H), 8.01 (d, 2H), 8.06 (d, 3H), 8.11 (d, 1H), 8.19 (d, 1H), 11.66 (s, 1H)Compound IC-7 1 H-NMR of: δ 7.01 (d, 1H) , 7.42 (t, 1H), 7.45 (t, 1H), 7.51 (d, 4H), 7.57 (d, 2H), 7.68 (d, 1H), 7.91 (d, 1H), 8.01 (d, 2H), 8.06 (d, 3H), 8.11

화합물 IC-8의 1H-NMR: δ 7.00 (d, 1H), 7.41 (m, 2H), 7.45 (t, 1H), 7.50 (d, 4H), 7.54 (s, 1H), 7.58 (d, 2H), 7.67 (d, 1H), 7.90 (d, 1H), 8.00 (d, 1H), 8.05 (d, 3H), 8.12 (d, 1H), 11.65 (s, 1H)
Compound IC-8 1 H-NMR of: δ 7.00 (d, 1H) , 7.41 (m, 2H), 7.45 (t, 1H), 7.50 (d, 4H), 7.54 (s, 1H), 7.58 (d, 2H), 7.67 (d, IH), 7.90 (d, IH), 8.00 (d, IH), 8.05

[준비예 5] 화합물 IC-9 및 IC-10의 합성[Preparation Example 5] Synthesis of compound IC-9 and IC-10

<단계 1> N-(2,6-dibromophenyl)benzamide의 합성<Step 1> Synthesis of N- (2,6-dibromophenyl) benzamide

Figure 112013108009545-pat00103
Figure 112013108009545-pat00103

준비예 1의 <단계 1>에서 사용된 2,4-dibromoaniline (250 g, 1.0 mol) 대신 2,6-dibromoaniline (250 g, 1.0 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 1>와 동일한 과정을 수행하여 N-(2,6-dibromophenyl)benzamide (254.68 g, 수율 72 %)을 얻었다.Except that 2,6-dibromoaniline (250 g, 1.0 mol) was used instead of 2,4-dibromoaniline (250 g, 1.0 mol) used in <Step 1> of Preparation Example 1, (2,6-dibromophenyl) benzamide (254.68 g, yield 72%) was obtained by carrying out the same procedure as in the step 1].

1H-NMR: δ 6.69 (t, 1H), 7.63 (d, 2H), 7.70 (t, 1H), 7.74 (d, 2H), 8.03 (d, 2H), 10.25 (s, 1H) 1 H-NMR: δ 6.69 ( t, 1H), 7.63 (d, 2H), 7.70 (t, 1H), 7.74 (d, 2H), 8.03 (d, 2H), 10.25 (s, 1H)

<단계 2> 4-bromo-2-phenylbenzo[d]oxazole의 합성<Step 2> Synthesis of 4-bromo-2-phenylbenzo [d] oxazole

Figure 112013108009545-pat00104
Figure 112013108009545-pat00104

준비예 1의 <단계 2>에서 사용된 N-(2,4-dibromophenyl)benzamide (258.72 g, 0.73 mol) 대신 준비예 5의 <단계 1>에서 얻은 N-(2,6-dibromophenyl)benzamide (254.68 g, 0.72 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 2>와 동일한 과정을 수행하여 4-bromo-2-phenylbenzo[d]oxazole (155.34 g, 수율 79 %)을 얻었다.(2,6-dibromophenyl) benzamide obtained in Step 1 of Preparation Example 5 instead of N- (2,4-dibromophenyl) benzamide (258.72 g, 0.73 mol) used in Step 2 of Preparation Example 1 4-bromo-2-phenylbenzo [d] oxazole (155.34 g, yield 79%) was obtained by following the procedure of <Step 2> of Preparation Example 1, except that 254.68 g .

1H-NMR: δ 7.34 (t, 1H), 7.41 (t, 1H), 7.51 (d, 2H), 7.60 (d, 1H), 7.73 (d, 1H), 8.05 (d, 2H) 1 H-NMR: δ 7.34 ( t, 1H), 7.41 (t, 1H), 7.51 (d, 2H), 7.60 (d, 1H), 7.73 (d, 1H), 8.05 (d, 2H)

<단계 3> 2-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo [d]oxazole 의 합성<Step 3> Synthesis of 2-phenyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole

Figure 112013108009545-pat00105
Figure 112013108009545-pat00105

준비예 1의 <단계 3>에서 사용된 6-bromo-2-phenylbenzo[d]oxazole (161.48 g, 0.589 mol) 대신 준비예 5의 <단계 2>에서 얻은 4-bromo-2-phenylbenzo[d]oxazole (155.34 g, 0.567 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 3>와 동일한 과정을 수행하여 2-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (140.15 g, 수율 77 %)을 얻었다.Bromo-2-phenylbenzo [d] thiazole obtained in Step 2 of Preparation Example 5 was used instead of 6-bromo-2-phenylbenzo [d] oxazole (161.48 g, 0.589 mol) used in Step 3 of Preparation Example 1, 2-phenyl-4- (4,4,5,5-tetramethyl-1, 3-dihydroxyphenyl) propanoate was prepared by following the procedure of Step 3 of Preparation Example 1, except that oxazole (155.34 g, 0.567 mol) 3,2-dioxaborolan-2-yl) benzo [d] oxazole (140.15 g, yield 77%).

1H-NMR: δ 1.23 (s, 12H), 7.41 (t, 1H), 7.45 (t, 1H), 7.51 (d, 2H), 7.75 (d, 1H), 7.79 (d, 1H), 8.05 (d, 2H) 1 H-NMR: δ 1.23 ( s, 12H), 7.41 (t, 1H), 7.45 (t, 1H), 7.51 (d, 2H), 7.75 (d, 1H), 7.79 (d, 1H), 8.05 ( d, 2H)

<단계 4> 4-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole의 합성<Step 4> Synthesis of 4- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole

Figure 112013108009545-pat00106
Figure 112013108009545-pat00106

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazo le (149.48 g, 0.465 mol) 대신 준비예 5의 <단계 3>에서 얻은 2-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (140.15 g, 0.436 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 4-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (105.04 g, 수율 67 %)을 얻었다.2-phenyl-6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazo le used in Step 4 of Preparation Example 1 (149.48 g, (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole (140.15 g) obtained in Step 3 of Preparation Example 5 was used instead of 2-phenyl- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (105.04 g, 0.436 mol) was obtained in the same manner as in <Step 4> of Preparation Example 1, , Yield: 67%).

1H-NMR: δ 7.42 (t, 1H), 7.52 (d, 3H), 7.72 (s, 1H), 7.75 (d, 1H), 7.98 (d, 1H), 8.06 (d, 2H), 8.21 (d, 1H) 1 H-NMR: δ 7.42 ( t, 1H), 7.52 (d, 3H), 7.72 (s, 1H), 7.75 (d, 1H), 7.98 (d, 1H), 8.06 (d, 2H), 8.21 ( d, 1 H)

<단계 5> 9-bromo-2-phenyl-6H-oxazolo[5,4-c]carbazole 의 합성Step 5 Synthesis of 9-bromo-2-phenyl-6H-oxazolo [5,4-c] carbazole

Figure 112013108009545-pat00107
Figure 112013108009545-pat00107

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 5의 <단계 4>에서 얻은 4-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (105.04 g, 0.266 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 9-bromo-2-phenyl-6H-oxazolo[5,4-c]carbazole (44.41 g, 수율 46 %)을 얻었다.Obtained in Step 4 of Preparation Example 5 was used instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in Step 5 of Preparation Example 1, Step 5 of Preparation Example 1 was repeated except that 5-bromo-2-nitrophenyl-2-phenylbenzo [d] oxazole (105.04 g, 0.266 mol) -2-phenyl-6H-oxazolo [5,4-c] carbazole (44.41 g, yield 46%).

1H-NMR: δ 7.08 (d, 1H), 7.41 (m, 2H), 7.51 (d, 3H), 7.63 (d, 1H), 8.04 (m, 3H), 11.67 (s, 1H) 1 H-NMR: 8 7.08 (d, 1 H), 7.41 (m, 2 H), 7.51 (d, 3H), 7.63

<단계 6> 9-bromo-2,6-diphenyl-6H-oxazolo[5,4-c]carbazole의 합성<Step 6> Synthesis of 9-bromo-2,6-diphenyl-6H-oxazolo [5,4-c]

Figure 112013108009545-pat00108
Figure 112013108009545-pat00108

준비예 1의 <단계 6>에서 사용된 7-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole (47 g, 0.129 mmol) 대신 준비예 5의 <단계 5>에서 얻은 9-bromo-2-phenyl-6H-oxazolo[5,4-c]carbazole (44.41 g, 0.122 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 6>와 동일한 과정을 수행하여 9-bromo-2,6-diphenyl-6H-oxazolo[5,4-c]carbazole (29.01 g, 수율 54 %)을 얻었다.The 9-bromo-2-phenyl-10H-oxazolo [5,4-a] carbazole (47 g, 0.129 mmol) used in Step 6 of Preparation Example 1 was used instead of 7-bromo- bromo-2-phenyl-6H-oxazolo [5,4-c] carbazole (44.41 g, 0.122 mmol) was used in place of 9-bromo -2,6-diphenyl-6H-oxazolo [5,4-c] carbazole (29.01 g, yield 54%).

1H-NMR: δ 7.08 (d, 1H), 7.25 (d, 1H), 7.41 (t, 1H), 7.45 (t, 1H), 7.50 (d, 4H), 7.58 (d, 2H), 7.63 (d, 1H), 7.72 (s, 1H), 7.83 (d, 1H), 8.05 (d, 2H) 1 H-NMR: δ 7.08 ( d, 1H), 7.25 (d, 1H), 7.41 (t, 1H), 7.45 (t, 1H), 7.50 (d, 4H), 7.58 (d, 2H), 7.63 ( (d, IH), 7.72 (s, IH), 7.83 (d,

<단계 7> 9-(2-nitrophenyl)-2,6-diphenyl-6H-oxazolo[5,4-c]carbazole의 합성<Step 7> Synthesis of 9- (2-nitrophenyl) -2,6-diphenyl-6H-oxazolo [5,4-c] carbazole

Figure 112013108009545-pat00109
Figure 112013108009545-pat00109

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol e (149.48 g, 0.465 mol) 대신 준비예 5의 <단계 8>에서 얻은 9-bromo-2,6-diphenyl-6H-oxazolo[5,4-c]carbazole (29.01 g, 66.04 mmol)을 사용하고, 4-bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 대신 2-nitrophenylboronic acid (10.02 g, 60.03 mmol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 9-(2-nitrophenyl)-2,6-diphenyl-6H-oxazolo[5,4-c]carbazole (15.32 g, 수율 53 %)을 얻었다.2-phenyl-6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole e used in Step 4 of Preparation Example 1 (149.48 g, Bromo-2,6-diphenyl-6H-oxazolo [5,4-c] carbazole (29.01 g, 66.04 mmol) obtained in Step 8 of Preparation Example 5 was used instead of 4-bromo- Step 4 of Preparation Example 1 was repeated except that 2-nitrophenylboronic acid (10.02 g, 60.03 mmol) was used instead of 2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) - (2-nitrophenyl) -2,6-diphenyl-6H-oxazolo [5,4-c] carbazole (15.32 g, yield 53%).

1H-NMR: δ 7.07 (d, 1H), 7.40 (t, 1H), 7.46 (t, 1H), 7.51 (d, 4H), 7.58 (d, 2H), 7.66 (d, 2H), 7.77 (s, 1H), 7.82 (d, 1H), 7.90 (d, 1H), 8.00 (d, 1H), 8.06 (d, 3H), 8.19 (d, 1H) 1 H-NMR: δ 7.07 ( d, 1H), 7.40 (t, 1H), 7.46 (t, 1H), 7.51 (d, 4H), 7.58 (d, 2H), 7.66 (d, 2H), 7.77 ( (d, 1H), 7.82 (d, 1H), 7.90 (d,

<단계 8> 화합물 IC-9 및 IC-10의 합성<Step 8> Synthesis of compounds IC-9 and IC-10

Figure 112013108009545-pat00110
Figure 112013108009545-pat00110

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 5의 <단계 7>에서 얻은 9-(2-nitrophenyl)-2,6-diphenyl-6H-oxazolo[5,4-c]carbazole (15.32 g, 31.82 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 화합물 IC-9 (6.01 g, 수율 42 %) 및 화합물 IC-10 (5.72 g, 수율 40 %)을 얻었다.The procedure of Example 5 was repeated except that 9- (4-chlorophenyl) -2-phenylbenzo [d] oxazole was used instead of 6- (5-bromo- Step 5 of Preparation Example 1 was repeated except that 2-nitrophenyl 2,6-diphenyl-6H-oxazolo [5,4-c] carbazole (15.32 g, 31.82 mmol) To obtain compound IC-9 (6.01 g, yield 42%) and compound IC-10 (5.72 g, yield 40%).

화합물 IC-9의 1H-NMR: δ 7.07 (d, 1H), 7.29 (d, 1H), 7.40 (m, 2H), 7.46 (t, 1H), 7.50 (d, 5H), 7.55 (s, 1H), 7.58 (d, 2H), 7.64 (d, 2H), 8.06 (d, 2H), 8.12 (d, 1H), 11.67 (s, 1H)Compound IC-9 1 H-NMR of: δ 7.07 (d, 1H) , 7.29 (d, 1H), 7.40 (m, 2H), 7.46 (t, 1H), 7.50 (d, 5H), 7.55 (s, 1H), 7.58 (d, 2H), 7.64 (d, 2H), 8.06 (d, 2H), 8.12

화합물 IC-10의 1H-NMR: δ 7.06 (d, 1H), 7.29 (d, 1H), 7.41 (t, 1H), 7.47 (t, 1H), 7.50 (m, 6H), 7.59 (d, 2H), 7.82 (d, 1H), 7.95 (d, 2H), 8.06 (d, 2H), 8.12 (d, 1H), 11.65 (s, 1H)
Compound IC-10 1 H-NMR of: δ 7.06 (d, 1H) , 7.29 (d, 1H), 7.41 (t, 1H), 7.47 (t, 1H), 7.50 (m, 6H), 7.59 (d, 2H), 7.82 (d, 1H), 7.95 (d, 2H), 8.06

[준비예 6] 화합물 IC-11 및 IC-12의 합성[Preparation Example 6] Synthesis of compound IC-11 and IC-12

<단계 1> 6-(4-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole의 합성<Step 1> Synthesis of 6- (4-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole

Figure 112013108009545-pat00111
Figure 112013108009545-pat00111

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (149.48 g, 0.465 mol) 대신 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (149.48 g, 0.465 mol)을 사용하고, 4-bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 대신 4-bromo-1-iodo-2-nitrobenzene (138.73 g, 0.423 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 6-(4-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (110.36 g, 수율 66 %)을 얻었다.(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole used in Step 4 of Preparation Example 1 (149.48 g, 0.465 2-yl) benzo [d] oxazole (149.48 g, 0.465 mol) instead of 2-phenyl-6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan- except that 4-bromo-1-iodo-2-nitrobenzene (138.73 g, 0.423 mol) was used in place of bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 4-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (110.36 g, yield 66%).

1H-NMR: δ 7.40 (t, 1H), 7.48 (s, 1H), 7.51 (d, 2H), 7.68 (d, 1H), 7.79 (d, 1H), 7.94 (d, 1H), 8.05 (d, 3H), 8.63 (d, 1H) 1 H-NMR: δ 7.40 ( t, 1H), 7.48 (s, 1H), 7.51 (d, 2H), 7.68 (d, 1H), 7.79 (d, 1H), 7.94 (d, 1H), 8.05 ( d, 3H), 8.63 (d, IH)

<단계 2> 8-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole의 합성<Step 2> Synthesis of 8-bromo-2-phenyl-10H-oxazolo [5,4-a]

Figure 112013108009545-pat00112
Figure 112013108009545-pat00112

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 6의 <단계 1>에서 얻은 6-(4-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (110.36 g, 0.279 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 8-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole (48.68 g, 수율 48 %)을 얻었다.Obtained in Step 1 of Preparation Example 6 instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in <Step 5> The same procedure as in <Step 5> of Preparation Example 1 was carried out except that 4-bromo-2-nitrophenyl-2-phenylbenzo [d] oxazole (110.36 g, 0.279 mol) -2-phenyl-10H-oxazolo [5,4-a] carbazole (48.68 g, yield 48%).

1H-NMR: δ 7.23 (d, 1H), 7.34 (d, 1H), 7.42 (t, 1H), 7.50 (d, 2H), 7.57 (s, 1H), 8.01 (d, 1H), 8.04 (d, 2H), 8.12 (d, 1H), 11.67 (s, 1H) 1 H-NMR: δ 7.23 ( d, 1H), 7.34 (d, 1H), 7.42 (t, 1H), 7.50 (d, 2H), 7.57 (s, 1H), 8.01 (d, 1H), 8.04 ( d, 2H), 8.12 (d, 1 H), 11.67 (s, 1 H)

<단계 3> 8-bromo-2,10-diphenyl-10H-oxazolo[5,4-a]carbazole의 합성<Step 3> Synthesis of 8-bromo-2,10-diphenyl-10H-oxazolo [5,4-a]

Figure 112013108009545-pat00113
Figure 112013108009545-pat00113

준비예 1의 <단계 6>에서 사용된 7-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole (47 g, 0.129 mmol) 대신 준비예 6의 <단계 2>에서 얻은 8-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole (48.68 g, 0.134 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 6>와 동일한 과정을 수행하여 8-bromo-2,10-diphenyl-10H-oxazolo[5,4-a]carbazole (32.38 g, 수율 55 %)을 얻었다.Obtained in Step 2 of Preparation Example 6 instead of 7-bromo-2-phenyl-10H-oxazolo [5,4-a] carbazole (47 g, 0.129 mmol) used in Step 6 of Preparation Example 1, bromo-2-phenyl-10H-oxazolo [5,4-a] carbazole (48.68 g, 0.134 mmol) was used in place of 8-bromo -2,10-diphenyl-10H-oxazolo [5,4-a] carbazole (32.38 g, yield 55%).

1H-NMR: δ 7.17 (d, 1H), 7.23 (d, 1H), 7.41 (t, 1H), 7.45 (t, 1H), 7.50 (d, 4H), 7.58 (d, 2H), 8.04 (d, 2H), 8.12 (d, 1H), 8.32 (d, 1H), 8.75 (s, 1H) 1 H-NMR: δ 7.17 ( d, 1H), 7.23 (d, 1H), 7.41 (t, 1H), 7.45 (t, 1H), 7.50 (d, 4H), 7.58 (d, 2H), 8.04 ( (d, IH), 8.12 (d, IH), 8.32

<단계 4> 8-(2-nitrophenyl)-2,10-diphenyl-10H-oxazolo[5,4-a]carbazole의 합성<Step 4> Synthesis of 8- (2-nitrophenyl) -2,10-diphenyl-10H-oxazolo [5,4-a]

Figure 112013108009545-pat00114
Figure 112013108009545-pat00114

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (149.48 g, 0.465 mol) 대신 준비예 6의 <단계 3>에서 얻은 8-bromo-2,10-diphenyl-10H-oxazolo[5,4-a]carbazole (32.38 g, 73.71 mmol)을 사용하고, 4-bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 대신 2-nitrophenylboronic acid (14.76 g, 88.45 mmol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 8-(2-nitrophenyl)-2,10-diphenyl-10H-oxazolo[5,4-a]carbazole (19.16 g, 수율 54 %)을 얻었다.(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole used in Step 4 of Preparation Example 1 (149.48 g, 0.465 bromo-2,10-diphenyl-10H-oxazolo [5,4-a] carbazole (32.38 g, 73.71 mmol) obtained in Step 3 of Preparation Example 6 was used instead of 4-bromo- Step 4 of Preparation Example 1 was repeated except that 2-nitrophenylboronic acid (14.76 g, 88.45 mmol) was used instead of -iodo-1-nitrobenzene (138.73 g, 0.423 mol) (2-nitrophenyl) -2,10-diphenyl-10H-oxazolo [5,4-a] carbazole (19.16 g, yield 54%).

1H-NMR: δ 7.23 (d, 1H), 7.41 (t, 1H), 7.45 (t, 1H), 7.50 (d, 4H), 7.58 (d, 2H), 7.62 (s, 1H), 7.66 (d, 1H), 7.89 (d, 1H), 7.99 (d, 1H), 8.05 (d, 3H), 8.10 (d, 1H), 8.12 (d, 1H), 8.49 (d, 1H) 1 H-NMR: δ 7.23 ( d, 1H), 7.41 (t, 1H), 7.45 (t, 1H), 7.50 (d, 4H), 7.58 (d, 2H), 7.62 (s, 1H), 7.66 ( (d, IH), 8.12 (d, IH), 8.49 (d, IH)

<단계 5> 화합물 IC-11 및 IC-12의 합성<Step 5> Synthesis of Compound IC-11 and IC-12

Figure 112013108009545-pat00115
Figure 112013108009545-pat00115

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 6의 <단계 4>에서 얻은 8-(2-nitrophenyl)-2,10-diphenyl-10H-oxazolo[5,4-a]carbazole (19.16 g, 39.79 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 화합물 IC-11 (7.33 g, 수율 41 %) 및 화합물 IC-12 (7.15 g, 수율 40 %)을 얻었다.Obtained in Step 4 of Preparation Example 6 instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in Step 5 of Preparation Example 1, Step 5 of Preparation Example 1 was repeated except that 2-nitrophenyl-2,10-diphenyl-10H-oxazolo [5,4-a] carbazole (19.16 g, 39.79 mmol) To obtain compound IC-11 (7.33 g, yield 41%) and compound IC-12 (7.15 g, yield 40%).

화합물 IC-11의 1H-NMR: δ 7.23 (d, 1H), 7.28 (d, 1H), 7.40 (t, 1H), 7.44 (t, 1H), 7.49 (d, 5H), 7.58 (d, 2H), 7.63 (d, 1H), 7.88 (d, 1H), 8.04 (d, 2H), 8.11 (d, 2H), 8.43 (d, 1H), 11.70 (s, 1H)Compound 1 H-NMR of the IC-11: δ 7.23 (d , 1H), 7.28 (d, 1H), 7.40 (t, 1H), 7.44 (t, 1H), 7.49 (d, 5H), 7.58 (d, 2H), 7.63 (d, IH), 7.88 (d, IH), 8.04 (d, 2H), 8.11

화합물 IC-12의 1H-NMR: δ 7.23 (d, 1H), 7.28 (d, 1H), 7.41 (m, 2H), 7.45 (t, 1H), 7.50 (d, 5H), 7.55 (s, 1H), 7.58 (d, 2H), 7.63 (d, 1H), 7.98 (d, 1H), 8.05 (d, 2H), 8.12 (d, 1H), 11.68 (s, 1H)
Compound IC-12 1 H-NMR of: δ 7.23 (d, 1H) , 7.28 (d, 1H), 7.41 (m, 2H), 7.45 (t, 1H), 7.50 (d, 5H), 7.55 (s, 1H), 7.58 (d, 2H), 7.63 (d, IH), 7.98 (d, IH), 8.05

[준비예 7] 화합물 IC-13 및 IC-14의 합성[Preparation Example 7] Synthesis of compound IC-13 and IC-14

<단계 1> 7-bromo-2-phenyl-5H-oxazolo[4,5-b]carbazole의 합성<Step 1> Synthesis of 7-bromo-2-phenyl-5H-oxazolo [4,5-b] carbazole

Figure 112013108009545-pat00116
Figure 112013108009545-pat00116

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 6-(4-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (110.36 g, 0.279 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 7-bromo-2-phenyl-5H-oxazolo[4,5-b]carbazole (43.61 g, 수율 43 %)을 얻었다.Bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in Step 5 of Preparation Example 1 was used instead of 6- (5-bromo- Bromo-2-phenyl-5H-oxazolo [4] was obtained by following the procedure of Step 5 of Preparation Example 1, except that 2-phenylbenzo [d] oxazole (110.36 g, 0.279 mol) , 5-b] carbazole (43.61 g, yield 43%).

1H-NMR: δ 7.34 (d, 1H), 7.40 (m, 2H), 7.50 (d, 2H), 7.55 (s, 1H), 7.57 (s, 1H), 8.00 (d, 1H), 8.04 (d, 2H) 1 H-NMR:? 7.34 (d, 1 H), 7.40 (m, 2H), 7.50 (d, 2H), 7.55 d, 2H)

<단계 2> 7-bromo-2,5-diphenyl-5H-oxazolo[4,5-b]carbazole의 합성<Step 2> Synthesis of 7-bromo-2,5-diphenyl-5H-oxazolo [4,5-b] carbazole

Figure 112013108009545-pat00117
Figure 112013108009545-pat00117

준비예 1의 <단계 6>에서 사용된 7-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole (47 g, 0.129 mmol) 대신 준비예 7의 <단계 1>에서 얻은 7-bromo-2-phenyl-5H-oxazolo[4,5-b]carbazole (43.61 g, 0.120 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 6>와 동일한 과정을 수행하여 7-bromo-2,5-diphenyl-5H-oxazolo[4,5-b]carbazole (26.90 g, 수율 51 %)을 얻었다.Obtained in Step 1 of Preparation Example 7 instead of 7-bromo-2-phenyl-10H-oxazolo [5,4-a] carbazole (47 g, 0.129 mmol) used in Step 6 of Preparation Example 1, bromo-2-phenyl-5H-oxazolo [4,5-b] carbazole (43.61 g, 0.120 mmol) was used in place of 7-bromo -2,5-diphenyl-5H-oxazolo [4,5-b] carbazole (26.90 g, yield 51%).

1H-NMR: δ 7.17 (d, 1H), 7.41 (m, 2H), 7.46 (t, 1H), 7.49 (d, 4H), 7.55 (s, 1H), 7.59 (d, 2H), 8.04 (d, 2H), 8.32 (d, 1H), 8.75 (s, 1H) 1 H-NMR: δ 7.17 ( d, 1H), 7.41 (m, 2H), 7.46 (t, 1H), 7.49 (d, 4H), 7.55 (s, 1H), 7.59 (d, 2H), 8.04 ( d, 2 H), 8.32 (d, 1 H), 8.75 (s, 1 H)

<단계 3> 7-(2-nitrophenyl)-2,5-diphenyl-5H-oxazolo[4,5-b]carbazole의 합성<Step 3> Synthesis of 7- (2-nitrophenyl) -2,5-diphenyl-5H-oxazolo [4,5-b]

Figure 112013108009545-pat00118
Figure 112013108009545-pat00118

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol e (149.48 g, 0.465 mol) 대신 7-bromo-2,5-diphenyl-5H-oxazolo[4,5-b]carbazole (26.9 g, 61.23 mmol)을 사용하고, 4-bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 대신 2-nitrophenylboronic acid (12.27 g, 73.48 mmol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 7-(2-nitrophenyl)-2,5-diphenyl-5H-oxazolo[4,5-b]carbazole (15.33 g, 수율 52 %)을 얻었다.2-phenyl-6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole e used in Step 4 of Preparation Example 1 (149.48 g, Bromo-2,5-diphenyl-5H-oxazolo [4,5-b] carbazole (26.9 g, 61.23 mmol) instead of 4-bromo-2-iodo-1-nitrobenzene , 2-nitrophenylboronic acid (12.27 g, 73.48 mmol) was used instead of 2-nitrophenylboronic acid (0.423 mol) -diphenyl-5H-oxazolo [4,5-b] carbazole (15.33 g, yield 52%).

1H-NMR: δ 7.40 (m, 2H), 7.46 (t, 1H), 7.50 (d, 2H), 7.52 (d, 2H), 7.55 (s, 1H), 7.58 (d, 2H), 7.62 (s, 1H), 7.67 (d, 1H), 7.90 (d, 1H), 8.00 (d, 1H), 8.04 (d, 3H), 8.10 (d, 1H), 8.49 (d, 1H) 1 H-NMR: δ 7.40 ( m, 2H), 7.46 (t, 1H), 7.50 (d, 2H), 7.52 (d, 2H), 7.55 (s, 1H), 7.58 (d, 2H), 7.62 ( (d, 1H), 7.67 (d, IH), 7.90 (d, IH), 8.00

<단계 4> 화합물 IC-13 및 IC-14의 합성<Step 4> Synthesis of compound IC-13 and IC-14

Figure 112013108009545-pat00119
Figure 112013108009545-pat00119

준비예 1의 <단계 4>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 7의 <단계 3>에서 얻은 7-(2-nitrophenyl)-2,5-diphenyl-5H-oxazolo[4,5-b]carbazole (15.33 g, 31.84 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 화합물 IC-13 (6.15g, 수율 43 %) 및 화합물 IC-14 (6.01 g, 수율 42 %)을 얻었다.Obtained in Step 3 of Preparation Example 7 was used instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in <Step 4> Step 5 of Preparation Example 1 was repeated except that 2-nitrophenyl-2,5-diphenyl-5H-oxazolo [4,5-b] carbazole (15.33 g, 31.84 mmol) To obtain compound IC-13 (6.15 g, yield 43%) and compound IC-14 (6.01 g, yield 42%).

화합물 IC-13의 1H-NMR: δ 7.29 (d, 1H), 7.41 (m, 3H), 7.45 (t, 1H), 7.50 (d, 3H), 7.53 (d, 2H), 7.56 (s, 2H), 7.58 (d, 2H), 7.64 (d, 1H), 8.03 (d, 2H), 8.13 (d, 1H), 11.69 (s, 1H)Compound IC-13 1 H-NMR of: δ 7.29 (d, 1H) , 7.41 (m, 3H), 7.45 (t, 1H), 7.50 (d, 3H), 7.53 (d, 2H), 7.56 (s, 2H), 7.58 (d, 2H), 7.64 (d, IH), 8.03

화합물 IC-14의 1H-NMR: δ 7.28 (d, 1H), 7.39 (m, 2H), 7.46 (t, 1H), 7.49 (d, 3H), 7.52 (d, 2H), 7.55 (s, 1H), 7.58 (d, 3H), 7.63 (d, 1H), 8.04 (d, 2H), 8.12 (d, 2H), 11.67 (s, 1H)
Compound IC-14 1 H-NMR of: δ 7.28 (d, 1H) , 7.39 (m, 2H), 7.46 (t, 1H), 7.49 (d, 3H), 7.52 (d, 2H), 7.55 (s, 1H), 7.58 (d, 3H), 7.63 (d, IH), 8.04 (d, 2H), 8.12

[준비예 8] 화합물 IC-15 및 IC-16의 합성[Preparation Example 8] Synthesis of compound IC-15 and IC-16

<단계 1> 5-(4-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole의 합성<Step 1> Synthesis of 5- (4-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole

Figure 112013108009545-pat00120
Figure 112013108009545-pat00120

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (149.48 g, 0.465 mol) 대신 2-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (120 g, 0.374 mol)을 사용하고, 4-bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 대신 4-bromo-1-iodo-2-nitrobenzene (111.37 g, 0.340 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 5-(4-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (93.96 g, 수율 70 %)을 얻었다.(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole used in Step 4 of Preparation Example 1 (149.48 g, 0.465 benzo [d] oxazole (120 g, 0.374 mol) instead of 2-phenyl-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan- except that 4-bromo-1-iodo-2-nitrobenzene (111.37 g, 0.340 mol) was used in place of bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 4-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (93.96 g, yield 70%).

1H-NMR: δ 7.40 (t 1H), 7.50 (d, 2H), 7.79 (d, 1H), 7.85 (d, 1H), 7.94 (d, 1H), 8.04 (d, 3H), 8.09 (s, 1H), 8.62 (s, 1H) 1 H-NMR: δ 7.40 ( t 1H), 7.50 (d, 2H), 7.79 (d, 1H), 7.85 (d, 1H), 7.94 (d, 1H), 8.04 (d, 3H), 8.09 (s , &Lt; / RTI &gt; 1H), 8.62 (s, 1H)

<단계 2> 7-bromo-2-phenyl-5H-oxazolo[5,4-b]carbazole의 합성<Step 2> Synthesis of 7-bromo-2-phenyl-5H-oxazolo [5,4-b] carbazole

Figure 112013108009545-pat00121
Figure 112013108009545-pat00121

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 8의 <단계 1>에서 얻은 5-(4-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (93.96 g, 0.238 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 7-bromo-2-phenyl-5H-oxazolo[5,4-b]carbazole (44.04 g, 수율 51 %)을 얻었다.Obtained in Step 1 of Preparation Example 8 instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in Step 5 of Preparation Example 1, Bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (93.96 g, 0.238 mol) was used in place of 7-bromo -2-phenyl-5H-oxazolo [5,4-b] carbazole (44.04 g, yield 51%).

1H-NMR: δ 7.34 (d, 1H), 7.40 (m, 2H), 7.50 (d, 2H), 7.56 (s, 2H), 8.01 (d, 1H), 8.05 (d, 2H), 11.66 (s, H) 1 H-NMR: δ 7.34 ( d, 1H), 7.40 (m, 2H), 7.50 (d, 2H), 7.56 (s, 2H), 8.01 (d, 1H), 8.05 (d, 2H), 11.66 ( s, H)

<단계 3> 7-bromo-2,5-diphenyl-5H-oxazolo[5,4-b]carbazole의 합성<Step 3> Synthesis of 7-bromo-2,5-diphenyl-5H-oxazolo [5,4-b]

Figure 112013108009545-pat00122
Figure 112013108009545-pat00122

준비예 1의 <단계 6>에서 사용된 7-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole (47 g, 0.129 mmol) 대신 준비예 8의 <단계 2>에서 얻은 7-bromo-2-phenyl-5H-oxazolo[5,4-b]carbazole (44.04 g, 0.121 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 6>와 동일한 과정을 수행하여 7-bromo-2,5-diphenyl-5H-oxazolo[5,4-b]carbazole (30.36 g, 수율 57 %)을 얻었다.Obtained in Step 2 of Preparation Example 8 instead of 7-bromo-2-phenyl-10H-oxazolo [5,4-a] carbazole (47 g, 0.129 mmol) used in Step 6 of Preparation Example 1, bromo-2-phenyl-5H-oxazolo [5,4-b] carbazole (44.04 g, 0.121 mmol) was used in place of 7-bromo -2,5-diphenyl-5H-oxazolo [5,4-b] carbazole (30.36 g, yield 57%).

1H-NMR: δ 7.34 (d, 1H), 7.40 (m, 2H), 7.45 (t, 1H), 7.50 (d, 4H), 7.55 (s, 1H), 7.58 (m, 3H), 8.01 (d, 1H), 8.04 (d, 2H), 1 H-NMR: δ 7.34 ( d, 1H), 7.40 (m, 2H), 7.45 (t, 1H), 7.50 (d, 4H), 7.55 (s, 1H), 7.58 (m, 3H), 8.01 ( d, 1 H), 8.04 (d, 2 H), 8.04

<단계 4> 7-(2-nitrophenyl)-2,5-diphenyl-5H-oxazolo[5,4-b]carbazole의 합성<Step 4> Synthesis of 7- (2-nitrophenyl) -2,5-diphenyl-5H-oxazolo [5,4-b]

Figure 112013108009545-pat00123
Figure 112013108009545-pat00123

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol e (149.48 g, 0.465 mol) 대신 준비예 8의 <단계 3>에서 얻은 7-bromo-2,5-diphenyl-5H-oxazolo[5,4-b]carbazole (30.36 g, 69.11 mmol)을 사용하고, 4-bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 대신 2-nitrophenylboronic acid (13.84 g, 82.93 mmol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 7-(2-nitrophenyl)-2,5-diphenyl-5H-oxazolo[5,4-b]carbazole (18.30 g, 수율 55 %)을 얻었다.2-phenyl-6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole e used in Step 4 of Preparation Example 1 (149.48 g, Bromo-2,5-diphenyl-5H-oxazolo [5,4-b] carbazole (30.36 g, 69.11 mmol) obtained in Step 3 of Preparation Example 8 was used instead of 4-bromo- Step 4 of Preparation Example 1 was repeated except that 2-nitrophenylboronic acid (13.84 g, 82.93 mmol) was used instead of 2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) - (2-nitrophenyl) -2,5-diphenyl-5H-oxazolo [5,4-b] carbazole (18.30 g, yield 55%).

1H-NMR: δ 7.39 (m, 2H), 7.45 (t, 1H), 7.50 (d, 4H), 7.54 (s, 1H), 7.57 (d, 2H), 7.62 (s, 1H), 7.67 (d, 1H),7.79 (d, 1H), 7.90 (d, 1H), 8.00 (d, 1H), 8.06 (d, 3H), 8.18 (d, 1H) 1 H-NMR: δ 7.39 ( m, 2H), 7.45 (t, 1H), 7.50 (d, 4H), 7.54 (s, 1H), 7.57 (d, 2H), 7.62 (s, 1H), 7.67 ( (d, IH), 7.79 (d, IH), 7.90 (d, IH), 8.00

<단계 5> 화합물 IC-15 및 IC-16의 합성<Step 5> Synthesis of compound IC-15 and IC-16

Figure 112013108009545-pat00124
Figure 112013108009545-pat00124

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 8의 <단계 4>에서 얻은 7-(2-nitrophenyl)-2,5-diphenyl-5H-oxazolo[5,4-b]carbazole (18.30 g, 38.01 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 화합물 IC-15 (6.49 g, 수율 38 %) 및 화합물 IC-16 (5.98 g, 수율 35 %)을 얻었다.Obtained in Step 4 of Preparation Example 8 instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in Step 5 of Preparation Example 1, Step 5 of Preparation Example 1 was repeated except that 2-nitrophenyl-2,5-diphenyl-5H-oxazolo [5,4-b] carbazole (18.30 g, 38.01 mmol) To obtain compound IC-15 (6.49 g, yield 38%) and compound IC-16 (5.98 g, yield 35%).

화합물 IC-15의 1H-NMR: δ 7.29 (d, 1H), 7.39 (m, 2H), 7.44 (t, 1H), 7.49 (d, 5H), 7.54 (s, 1H), 7.58 (d, 3H), 7.62 (d, 1H), 8.07 (d, 2H), 8.11 (d, 2H), 11.68 (s, 1H)Compound IC-15 1 H-NMR of: δ 7.29 (d, 1H) , 7.39 (m, 2H), 7.44 (t, 1H), 7.49 (d, 5H), 7.54 (s, 1H), 7.58 (d, 1H), 7.62 (d, 1H), 8.07 (d, 2H), 8.11 (d, 2H), 11.68

화합물 IC-16의 1H-NMR: δ 7.28 (d, 1H), 7.40 (m, 3H), 7.46 (t, 1H), 7.51 (d, 5H), 7.55 (m, 2H), 7.59 (d, 2H), 7.64 (d, 1H), 8.07 (d, 3H), 11.67 (s, 1H)
Compound IC-16 1 H-NMR of: δ 7.28 (d, 1H) , 7.40 (m, 3H), 7.46 (t, 1H), 7.51 (d, 5H), 7.55 (m, 2H), 7.59 (d, 2H), 7.64 (d, IH), 8.07 (d, 3H), 11.67 (s, IH)

[준비예 9] 화합물 IC-17 및 IC-18의 합성[Preparation Example 9] Synthesis of compound IC-17 and IC-18

<단계 1> 8-bromo-2-phenyl-10H-oxazolo[4,5-a]carbazole의 합성<Step 1> Synthesis of 8-bromo-2-phenyl-10H-oxazolo [4,5-a]

Figure 112013108009545-pat00125
Figure 112013108009545-pat00125

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 5-(4-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (100 g, 0.253 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 8-bromo-2-phenyl-10H-oxazolo[4,5-a]carbazole (38.60 g, 수율 42 %)을 얻었다.Bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in Step 5 of Preparation Example 1 was used instead of 6- (5-bromo- Bromo-2-phenyl-10H-oxazolo [4, 5-d] pyrimidine was prepared by following the procedure of Step 5 of Preparation Example 1, except that 2-phenylbenzo [d] oxazole , 5-a] carbazole (38.60 g, yield 42%).

1H-NMR: δ 7.00 (d, 1H), 7.34 (d, 1H), 7.40 (t, 1H), 7.50 (d, 2H), 7.57 (s, 1H), 8.01 (d, 1H), 8.06 (d, 2H), 8.11 (d, 1H), 11.69 (s, 1H) 1 H-NMR: δ 7.00 ( d, 1H), 7.34 (d, 1H), 7.40 (t, 1H), 7.50 (d, 2H), 7.57 (s, 1H), 8.01 (d, 1H), 8.06 ( d, 2 H), 8.11 (d, 1 H), 11.69 (s, 1 H)

<단계 2> 8-bromo-2,10-diphenyl-10H-oxazolo[4,5-a]carbazole의 합성<Step 2> Synthesis of 8-bromo-2,10-diphenyl-10H-oxazolo [4,5-a] carbazole

Figure 112013108009545-pat00126
Figure 112013108009545-pat00126

준비예 1의 <단계 6>에서 사용된 7-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole (47 g, 0.129 mmol) 대신 준비예 9의 <단계 1>에서 얻은 8-bromo-2-phenyl-10H-oxazolo[4,5-a]carbazole (38.60 g, 0.106 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 6>와 동일한 과정을 수행하여 8-bromo-2,10-diphenyl-10H-oxazolo[4,5-a]carbazole (23.34 g, 수율 50 %)을 얻었다.Obtained in Step 1 of Preparation Example 9 instead of 7-bromo-2-phenyl-10H-oxazolo [5,4-a] carbazole (47 g, 0.129 mmol) used in Step 6 of Preparation Example 1, bromo-2-phenyl-10H-oxazolo [4,5-a] carbazole (38.60 g, 0.106 mmol) was used in place of 8-bromo -2,10-diphenyl-10H-oxazolo [4,5-a] carbazole (23.34 g, yield 50%).

1H-NMR: δ 7.00 (d, 1H), 7.17 (d, 1H), 7.40 (t, 1H), 7.46 (t, 1H), 7.50 (d, 4H), 7.58 (d, 2H), 8.04 (d, 2H), 8.13 (d, 1H), 8.32 (d, 1H), 8.78 (s, 1H) 1 H-NMR: δ 7.00 ( d, 1H), 7.17 (d, 1H), 7.40 (t, 1H), 7.46 (t, 1H), 7.50 (d, 4H), 7.58 (d, 2H), 8.04 ( (d, 2H), 8.13 (d, 1H), 8.32 (d,

<단계 3> 8-(2-nitrophenyl)-2,10-diphenyl-10H-oxazolo[4,5-a]carbazole의 합성<Step 3> Synthesis of 8- (2-nitrophenyl) -2,10-diphenyl-10H-oxazolo [4,5-a]

Figure 112013108009545-pat00127
Figure 112013108009545-pat00127

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (149.48 g, 0.465 mol) 대신 준비예 9의 <단계 2>에서 얻은 8-bromo-2,10-diphenyl-10H-oxazolo[4,5-a]carbazole (23.34 g, 53.13 mmol)을 사용하고, 4-bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 대신 2-nitrophenylboronic acid (10.64 g, 63.76 mmol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 8-(2-nitrophenyl)-2,10-diphenyl-10H-oxazolo[4,5-a]carbazole (14.07 g, 수율 55 %)을 얻었다.(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole used in Step 4 of Preparation Example 1 (149.48 g, 0.465 bromo-2,10-diphenyl-10H-oxazolo [4,5-a] carbazole (23.34 g, 53.13 mmol) obtained in Step 2 of Preparation Example 9 was used instead of 4-bromo- Step 4 of Preparation Example 1 was repeated except that 2-nitrophenylboronic acid (10.64 g, 63.76 mmol) was used in place of -iodo-1-nitrobenzene (138.73 g, 0.423 mol) (2-nitrophenyl) -2,10-diphenyl-10H-oxazolo [4,5-a] carbazole (14.07 g, yield 55%).

1H-NMR: δ 7.01 (d, 1H), 7.39 (t, 1H), 7.44 (t, 1H), 7.49 (d, 4H), 7.57 (d, 2H), 7.62 (s, 1H), 7.66 (d, 1H), 7.90 (d, 1H), 8.00 (d,1H), 8.06 (d, 3H), 8.11 (d, 2H), 8.48 (d, 1H) 1 H-NMR: δ 7.01 ( d, 1H), 7.39 (t, 1H), 7.44 (t, 1H), 7.49 (d, 4H), 7.57 (d, 2H), 7.62 (s, 1H), 7.66 ( (d, IH), 7.90 (d, IH), 8.00 (d, IH), 8.06 (d,

<단계 4> 화합물 IC-17 및 IC-18의 합성<Step 4> Synthesis of Compound IC-17 and IC-18

Figure 112013108009545-pat00128
Figure 112013108009545-pat00128

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 9의 <단계 3>에서 얻은 8-(2-nitrophenyl)-2,10-diphenyl-10H-oxazolo[4,5-a]carbazole (14.07 g, 29.22 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 화합물 IC-17 (5.78 g, 수율 44 %) 및 화합물 IC-18 (5.12 g, 수율 39 %)을 얻었다.Obtained in Step 3 of Preparation Example 9 instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in Step 5 of Preparation Example 1, Step 5 of Preparation Example 1 was repeated except that 2-nitrophenyl-2,10-diphenyl-10H-oxazolo [4,5-a] carbazole (14.07 g, 29.22 mmol) To obtain compound IC-17 (5.78 g, yield 44%) and compound IC-18 (5.12 g, yield 39%).

화합물 IC-17의 1H-NMR: δ 7.00 (d, 1H), 7.29 (d, 1H), 7.40 (m, 2H), 7.44 (t, 1H), 7.49 (d, 5H), 7.56 (d, 3H), 7.62 (d, 1H), 8.06 (d, 2H), 8.10 (d, 2H), 11.67 (s, 1H)Compound IC-17 1 H-NMR of: δ 7.00 (d, 1H) , 7.29 (d, 1H), 7.40 (m, 2H), 7.44 (t, 1H), 7.49 (d, 5H), 7.56 (d, 1H), 7.62 (d, 1H), 8.06 (d, 2H), 8.10 (d, 2H), 11.67

화합물 IC-18의 1H-NMR: δ 7.00 (d, 1H), 7.29 (d, 1H), 7.38 (t, 1H), 7.44 (t, 1H), 7.51 (d, 5H), 7.57 (d, 3H), 7.62 (d, 1H), 8.05 (d, 2H), 8.11 (d, 3H), 11.66 (s, 1H)
Compound 1 H-NMR of the IC-18: δ 7.00 (d , 1H), 7.29 (d, 1H), 7.38 (t, 1H), 7.44 (t, 1H), 7.51 (d, 5H), 7.57 (d, 3H), 7.62 (d, IH), 8.05 (d, 2H), 8.11

[준비예 10] 화합물 IC-19 및 IC-20의 합성[Preparation Example 10] Synthesis of compound IC-19 and IC-20

<단계 1> 4-(4-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole의 합성<Step 1> Synthesis of 4- (4-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole

Figure 112013108009545-pat00129
Figure 112013108009545-pat00129

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (149.48 g, 0.465 mol) 대신 2-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (100 g, 0.311 mol)을 사용하고, 4-bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 대신 4-bromo-1-iodo-2-nitrobenzene (92.81 g, 0.283 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 4-(4-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (80.54 g, 수율 72 %)을 얻었다.(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole used in Step 4 of Preparation Example 1 (149.48 g, 0.465 d] oxazole (100 g, 0.311 mol) instead of 2-phenyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan- except that 4-bromo-1-iodo-2-nitrobenzene (92.81 g, 0.283 mol) was used in place of bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) (4-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (80.54 g, yield 72%) was obtained.

1H-NMR: δ 7.40 (t, 1H), 7.50 (m, 3H), 7.75 (d, 1H), 7.79 (d, 1H), 7.94 (d, 1H), 8.05 (d, 3H), 8.63 (s, 1H) 1 H-NMR: δ 7.40 ( t, 1H), 7.50 (m, 3H), 7.75 (d, 1H), 7.79 (d, 1H), 7.94 (d, 1H), 8.05 (d, 3H), 8.63 ( s, 1 H)

<단계 2> 8-bromo-2-phenyl-6H-oxazolo[5,4-c]carbazole의 합성<Step 2> Synthesis of 8-bromo-2-phenyl-6H-oxazolo [5,4-c]

Figure 112013108009545-pat00130
Figure 112013108009545-pat00130

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 10의 <단계 1>에서 얻은 4-(4-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (80.54 g, 0.204 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 8-bromo-2-phenyl-6H-oxazolo[5,4-c]carbazole (42.19 g, 수율 57 %)을 얻었다.Obtained in Step 1 of Preparation Example 10 instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in Step 5 of Preparation Example 1, Step 5 of Preparation Example 1 was repeated except that 4-bromo-2-nitrophenyl-2-phenylbenzo [d] oxazole (80.54 g, 0.204 mol) -2-phenyl-6H-oxazolo [5,4-c] carbazole (42.19 g, yield 57%).

1H-NMR: δ 7.08 (d, 1H), 7.34 (d, 1H), 7.40 (t, 1H), 7.50 (d, 2H), 7.57 (s, 1H), 7.63 (d, 1H), 8.01 (d, 1H), 8.04 (d, 2H), 11.66 (s, 1H) 1 H-NMR: δ 7.08 ( d, 1H), 7.34 (d, 1H), 7.40 (t, 1H), 7.50 (d, 2H), 7.57 (s, 1H), 7.63 (d, 1H), 8.01 ( d, 1 H), 8.04 (d, 2H), 11.66 (s, 1 H)

<단계 3> 8-bromo-2,6-diphenyl-6H-oxazolo[5,4-c]carbazole의 합성<Step 3> Synthesis of 8-bromo-2,6-diphenyl-6H-oxazolo [5,4-c]

Figure 112013108009545-pat00131
Figure 112013108009545-pat00131

준비예 1의 <단계 6>에서 사용된 7-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole (47 g, 0.129 mmol) 대신 준비예 10의 <단계 2>에서 얻은 8-bromo-2-phenyl-6H-oxazolo[5,4-c]carbazole (42.19 g, 0.116 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 6>와 동일한 과정을 수행하여 8-bromo-2,6-diphenyl-6H-oxazolo[5,4-c]carbazole (26.02 g, 수율 51 %)을 얻었다.Obtained in Step 2 of Preparation Example 10 instead of 7-bromo-2-phenyl-10H-oxazolo [5,4-a] carbazole (47 g, 0.129 mmol) used in Step 6 of Preparation Example 1, 6-bromo-2-phenyl-6H-oxazolo [5,4-c] carbazole (42.19 g, 0.116 mmol) -2,6-diphenyl-6H-oxazolo [5,4-c] carbazole (26.02 g, yield 51%).

1H-NMR: δ 7.08 (d, 1H), 7.17 (d, 1H), 7.40 (t, 1H), 7.44 (d, 1H), 7.50 (d, 4H), 7.57 (d, 2H), 7.62 (d, 1H), 8.04 (d, 2H), 8.33 (d, 1H), 8.77 (s, 1H) 1 H-NMR: δ 7.08 ( d, 1H), 7.17 (d, 1H), 7.40 (t, 1H), 7.44 (d, 1H), 7.50 (d, 4H), 7.57 (d, 2H), 7.62 ( (d, IH), 8.04 (d, 2H), 8.33 (d, IH), 8.77

<단계 4> 8-(2-nitrophenyl)-2,6-diphenyl-6H-oxazolo[5,4-c]carbazole의 합성Step 4 Synthesis of 8- (2-nitrophenyl) -2,6-diphenyl-6H-oxazolo [5,4-c] carbazole

Figure 112013108009545-pat00132
Figure 112013108009545-pat00132

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (149.48 g, 0.465 mol) 대신 준비예 10의 <단계 3>에서 얻은 8-bromo-2,6-diphenyl-6H-oxazolo[5,4-c]carbazole (26.02 g, 59.23 mmol)을 사용하고, 4-bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 대신 2-nitrophenylboronic acid (11.86 g, 71.08 mmol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 8-(2-nitrophenyl)-2,6-diphenyl-6H-oxazolo[5,4-c]carbazole (17.11 g, 수율 60 %)을 얻었다.(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole used in Step 4 of Preparation Example 1 (149.48 g, 0.465 bromo-2,6-diphenyl-6H-oxazolo [5,4-c] carbazole (26.02 g, 59.23 mmol) obtained in Step 3 of Preparation Example 10 was used instead of 4-bromo- Step 4 of Preparation Example 1 was repeated except that 2-nitrophenylboronic acid (11.86 g, 71.08 mmol) was used instead of -iodo-1-nitrobenzene (138.73 g, 0.423 mol) (2-nitrophenyl) -2,6-diphenyl-6H-oxazolo [5,4-c] carbazole (17.11 g, yield 60%).

1H-NMR: δ 7.08 (d, 1H), 7.41 (t, 1H), 7.45 (t, 1H), 7.51 (d, 4H), 7.57 (d, 2H), 7.63 (m, 2H), 7.69 (d, 1H), 7.90 (d, 1H), 8.00 (d, 1H), 8.05 (d, 3H), 8.10 (d, 1H), 8.49 (d, 1H) 1 H-NMR: δ 7.08 ( d, 1H), 7.41 (t, 1H), 7.45 (t, 1H), 7.51 (d, 4H), 7.57 (d, 2H), 7.63 (m, 2H), 7.69 ( (d, IH), 7.90 (d, IH), 8.00 (d, IH), 8.05

<단계 5> 화합물 IC-19 및 IC-20의 합성<Step 5> Synthesis of Compound IC-19 and IC-20

Figure 112013108009545-pat00133
Figure 112013108009545-pat00133

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 10의 <단계 4>에서 얻은 8-(2-nitrophenyl)-2,6-diphenyl-6H-oxazolo[5,4-c]carbazole (17.11 g, 35.54 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 화합물 IC-19 (7.35 g, 수율 46 %) 및 화합물 IC-20 (7.19 g, 수율 45 %)을 얻었다.Obtained in Step 4 of Preparation Example 10 instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in Step 5 of Preparation Example 1, Step 5 of Preparation Example 1 was repeated except that 2-nitrophenyl 2,6-diphenyl-6H-oxazolo [5,4-c] carbazole (17.11 g, 35.54 mmol) To obtain compound IC-19 (7.35 g, yield 46%) and compound IC-20 (7.19 g, yield 45%).

화합물 IC-19의 1H-NMR: δ 7.07 (d, 1H), 7.30 (d, 1H), 7.42 (t, 1H), 7.46 (t, 1H), 7.52 (d, 5H), 7.58 (d, 3H), 7.64 (d, 2H), 8.06 (d, 2H), 8.13 (d, 2H), 11.68 (s, 1H)Compound IC-19 1 H-NMR of: δ 7.07 (d, 1H) , 7.30 (d, 1H), 7.42 (t, 1H), 7.46 (t, 1H), 7.52 (d, 5H), 7.58 (d, 2H), 8.16 (d, 2H), 7.63 (d,

화합물 IC-20의 1H-NMR: δ 7.09 (d, 1H), 7.28 (d, 1H), 7.40 (m, 2H), 7.45 (t, 1H), 7.51 (d, 5H), 7.56 (m, 3H), 7.62 (d, 2H), 8.05 (d, 2H), 8.11 (d, 1H), 11.69 (s, 1H)
One of the compounds IC-20 H-NMR: δ 7.09 (d, 1H), 7.28 (d, 1H), 7.40 (m, 2H), 7.45 (t, 1H), 7.51 (d, 5H), 7.56 (m, (S, 3H), 7.62 (d, 2H), 8.05 (d, 2H), 8.11

[준비예 11] 화합물 IC-21 및 IC-22의 합성[Preparation Example 11] Synthesis of compound IC-21 and IC-22

<단계 1> N-(2,4-dibromophenyl)benzothioamide의 합성<Step 1> Synthesis of N- (2,4-dibromophenyl) benzothioamide

Figure 112013108009545-pat00134
Figure 112013108009545-pat00134

반응기에 N-(2,4-dibromophenyl)benzamide (200 g, 0.56 mol)을 투입하고, toluene (2500 ml)를 가한 후 교반하였다. 반응기에 Lawesson's reagent (172.14 g, 0.39 mol)을 적가하고 혼합한 다음, 110 ℃에서 4시간 동안 교반하였다. N- (2,4-dibromophenyl) benzamide (200 g, 0.56 mol) was added to the reactor, and toluene (2500 ml) was added thereto and stirred. Lawesson's reagent (172.14 g, 0.39 mol) was added dropwise to the reactor and mixed, followed by stirring at 110 ° C for 4 hours.

반응이 종결된 후, 메틸렌클로라이드로 유기층을 추출한 다음 MgSO4로 수분을 제거하고, 컬럼크로마토그래피 (Hexane:EA = 7:1 (v/v))로 정제하여 N-(2,4-dibromophenyl)benzothioamide (192.33 g, 수율 92 %)를 얻었다. After the reaction was completed, the organic layer was extracted with methylene chloride, the water was removed with MgSO 4 , and the residue was purified by column chromatography (Hexane: EA = 7: 1 (v / v)) to give N- (2,4-dibromophenyl) benzothioamide (192.33 g, yield 92%).

1H-NMR: δ 6.41 (d, 1H), 7.29 (d, 1H), 7.44-7.45 (m, 3H), 7.75 (s, 1H), 7.98 (d, 2H), 8.59 (b, 1H) 1 H-NMR: δ 6.41 ( d, 1H), 7.29 (d, 1H), 7.44-7.45 (m, 3H), 7.75 (s, 1H), 7.98 (d, 2H), 8.59 (b, 1H)

<단계 2> 6-bromo-2-phenylbenzo[d]thiazole 의 합성<Step 2> Synthesis of 6-bromo-2-phenylbenzo [d] thiazole

Figure 112013108009545-pat00135
Figure 112013108009545-pat00135

준비예 1의 <단계 2>에서 사용된 N-(2,4-dibromophenyl)benzamide (258.72 g, 0.73 mol) 대신 N-(2,4-dibromophenyl)benzothioamide (192.32 g, 518.26 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 2>와 동일한 과정을 수행하여 6-bromo-2-phenylbenzo[d]thiazole (106.78 g, 수율 71 %)을 얻었다.Preparation Example 1 <Step 2> The N- (2,4-dibromophenyl) benzamide ( 258.72 g, 0.73 mol) in the use of N- (2,4-dibromophenyl) benzothioamide ( 192.32 g, 518.26 mmol) instead of 6-bromo-2-phenylbenzo [d] thiazole (106.78 g, yield 71%) was obtained in the same manner as in <Step 2> of Preparation Example 1,

1H-NMR: δ 7.41 (t, 1H) 7.51 (dd, 2H), 7.64 (d, 1H), 7.72 (d, 1H), 8.03 (d, 2H), 8.83 (s, 1H) 1 H-NMR: δ 7.41 ( t, 1H) 7.51 (dd, 2H), 7.64 (d, 1H), 7.72 (d, 1H), 8.03 (d, 2H), 8.83 (s, 1H)

<단계 3> 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo [d]thiazole의 합성Synthesis of 2-phenyl-6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] thiazole

Figure 112013108009545-pat00136
Figure 112013108009545-pat00136

준비예 1의 <단계 3>에서 사용된 6-bromo-2-phenylbenzo[d]oxazole (161.48 g, 0.589 mol) 대신 준비예 11의 <단계 2>에서 얻은 6-bromo-2-phenylbenzo[d]thiazole (106.78 g, 0.367.98 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 3>와 동일한 과정을 수행하여 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole (93.07 g, 수율 75 %)을 얻었다.Bromo-2-phenylbenzo [d] thiazole obtained in Step 2 of Preparation Example 11 was used instead of 6-bromo-2-phenylbenzo [d] oxazole (161.48 g, 0.589 mol) used in Step 3 of Preparation Example 1, thiazole (106.78 g, 0.367.98 mol) was used in place of 2-phenyl-6- (4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl) benzo [d] thiazole (93.07 g, yield 75%).

1H-NMR: δ 1.24 (s, 12H) 7.38 (d, 1H), 7.41 (t, 1H), 7.51 (dd, 2H), 7.75 (d, 1H), 7.95 (s, 1H), 8.03 (d, 2H) 1 H-NMR: δ 1.24 ( s, 12H) 7.38 (d, 1H), 7.41 (t, 1H), 7.51 (dd, 2H), 7.75 (d, 1H), 7.95 (s, 1H), 8.03 (d , 2H)

<단계 4> 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]thiazole의 합성<Step 4> Synthesis of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] thiazole

Figure 112013108009545-pat00137
Figure 112013108009545-pat00137

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (149.48 g, 0.465 mol) 대신 준비예 11의 <단계 3>에서 얻은 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole (93.07 g, 0.276 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]thiazole (65 g, 수율 63 %)을 얻었다.(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole used in Step 4 of Preparation Example 1 (149.48 g, 0.465 instead of 2-phenyl-6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] thiazole (obtained in Step 3 of Preparation Example 11 2-nitrophenyl) -2-phenylbenzo [d] thiazole (65 g, 0.276 mol) was used in the same manner as Step 4 of Preparation Example 1, Yield: 63%).

1H-NMR: δ 7.41 (t, 1H), 7.51 (dd, 2H), 7.72 (s, 1H), 7.77 (d, 1H), 7.81 (d, 1H), 7.98 (d, 1H), 8.03 (d, 2H), 8.21 (d, 1H), 8.34 (s, 1H) 1 H-NMR: δ 7.41 ( t, 1H), 7.51 (dd, 2H), 7.72 (s, 1H), 7.77 (d, 1H), 7.81 (d, 1H), 7.98 (d, 1H), 8.03 ( d, 2 H), 8.21 (d, 1 H), 8.34 (s, 1 H)

<단계 5> 7-bromo-2-phenyl-10H-thiazolo[5,4-a]carbazole 의 합성Step 5 Synthesis of 7-bromo-2-phenyl-10H-thiazolo [5,4-a]

Figure 112013108009545-pat00138
Figure 112013108009545-pat00138

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 11의 <단계 4>에서 얻은 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]thiazole (65 g, 0.158 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 7-bromo-2-phenyl-10H-thiazolo[5,4-a]carbazole (25.18 g, 수율 42 %)을 얻었다.Obtained in Step 4 of Preparation Example 11 instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in Step 5 of Preparation Example 1, Step 5 of Preparation Example 1 was repeated except that 5-bromo-2-nitrophenyl-2-phenylbenzo [d] thiazole (65 g, 0.158 mol) -2-phenyl-10H-thiazolo [5,4-a] carbazole (25.18 g, yield 42%).

1H-NMR: δ 7.41-7.42 (m, 2H), 7.51-7.55 (m, 4H), 7.75 (d, 1H), 8.03-8.05 (m, 3H), 10.1 (b, 1H) 1 H-NMR:? 7.41-7.42 (m, 2H), 7.51-7.55 (m, 4H), 7.75

<단계 6> 7-bromo-2,10-diphenyl-10H-thiazolo[5,4-a]carbazole의 합성Step 6 Synthesis of 7-bromo-2,10-diphenyl-10H-thiazolo [5,4-a] carbazole

Figure 112013108009545-pat00139
Figure 112013108009545-pat00139

준비예 1의 <단계 6>에서 사용된 7-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole (47 g, 0.129 mol) 대신 준비예 11의 <단계 5>에서 얻은 7-bromo-2-phenyl-10H-thiazolo[5,4-a]carbazole (25.18 g, 66.39 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 6>와 동일한 과정을 수행하여 7-bromo-2,10-diphenyl-10H-thiazolo[5,4-a]carbazole (14.18 g, 수율 49 %)을 얻었다. Obtained in Step 5 of Preparation Example 11 instead of 7-bromo-2-phenyl-10H-oxazolo [5,4-a] carbazole (47 g, 0.129 mol) used in Step 6 of Preparation Example 1, bromo-2-phenyl-10H-thiazolo [5,4-a] carbazole (25.18 g, 66.39 mmol) was used in place of 7-bromo -2,10-diphenyl-10H-thiazolo [5,4-a] carbazole (14.18 g, yield 49%).

1H-NMR: δ 7.25 (d, 1H), 7.41 (t, 1H), 7.46 (t, 1H), 7.50 (d, 4H), 7.55 (d, 1H), 7.58 (d, 2H), 7.72 (s, 1H), 7.75 (d, 1H), 7.83 (d, 1H), 8.03 (d, 2H) 1 H-NMR: δ 7.25 ( d, 1H), 7.41 (t, 1H), 7.46 (t, 1H), 7.50 (d, 4H), 7.55 (d, 1H), 7.58 (d, 2H), 7.72 ( s), 7.75 (d, IH), 7.83 (d, IH), 8.03

<단계 7> 7-(2-nitrophenyl)-2,10-diphenyl-10H-thiazolo[5,4-a]carbazole 의 합성<Step 7> Synthesis of 7- (2-nitrophenyl) -2,10-diphenyl-10H-thiazolo [5,4-a]

Figure 112013108009545-pat00140
Figure 112013108009545-pat00140

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (149.48 g, 0.465 mol) 대신 준비예 11의 <단계 6>에서 얻은 7-bromo-2,10-diphenyl-10H-thiazolo[5,4-a]carbazole (14.81 g, 32.52 mmol)을 사용하고, 4-bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 대신 2-nitrophenylboronic acid (6.51 g, 39.03 mmol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 7-(2-nitrophenyl)-2,10-diphenyl-10H-thiazolo[5,4-a]carbazole (8.41 g, 수율 52 %)을 얻었다.(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole used in Step 4 of Preparation Example 1 (149.48 g, 0.465 bromo-2,10-diphenyl-10H-thiazolo [5,4-a] carbazole (14.81 g, 32.52 mmol) obtained in Step 6 of Preparation Example 11 was used instead of 4-bromo- Step 4 of Preparation Example 1 was repeated except that 2-nitrophenylboronic acid (6.51 g, 39.03 mmol) was used in place of -iodo-1-nitrobenzene (138.73 g, 0.423 mol) (2-nitrophenyl) -2,10-diphenyl-10H-thiazolo [5,4-a] carbazole (8.41 g, yield 52%).

1H-NMR: δ 7.40 (t, 1H), 7.46 (t, 1H), 7.51 (d, 4H), 7.55 (d, 1H), 7.59 (d, 2H), 7.67 (d, 1H), 7.75 (d, 1H), 7.77 (s, 1H), 7.90 (d, 1H), 8.00 (d, 2H), 8.04 (d, 3H), 8.18 (d, 1H) 1 H-NMR: δ 7.40 ( t, 1H), 7.46 (t, 1H), 7.51 (d, 4H), 7.55 (d, 1H), 7.59 (d, 2H), 7.67 (d, 1H), 7.75 ( (d, IH), 7.77 (s, IH), 7.90 (d, IH), 8.00

<단계 8> 화합물 IC-21 및 IC-22의 합성<Step 8> Synthesis of Compound IC-21 and IC-22

Figure 112013108009545-pat00141
Figure 112013108009545-pat00141

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 11의 <단계 7>에서 얻은 7-(2-nitrophenyl)-2,10-diphenyl-10H-thiazolo[5,4-a]carbazole (8.41 g, 16.9 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 화합물 IC-21 (3.23 g, 수율 41 %) 및 화합물 IC-22 (3.15 g, 수율 40 %)을 얻었다.Obtained in Step 7 of Preparation Example 11 instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in <Step 5> Step 5 of Preparation Example 1 was repeated except that 2-nitrophenyl-2,10-diphenyl-10H-thiazolo [5,4-a] carbazole (8.41 g, 16.9 mmol) To obtain compound IC-21 (3.23 g, yield 41%) and compound IC-22 (3.15 g, yield 40%).

화합물 IC-21의 1H-NMR: δ 7.29 (d, 1H), 7.41 (m, 2H), 7.45 (t, 1H), 7.50 (d, 5H), 7.55 (m, 2H), 7.60 (d, 2H), 7.64 (d, 1H), 7.76 (d, 1H), 8.04 (d, 2H), 8.11 (d, 1H), 11.66 (s, 1H)Compound IC-21 1 H-NMR of: δ 7.29 (d, 1H) , 7.41 (m, 2H), 7.45 (t, 1H), 7.50 (d, 5H), 7.55 (m, 2H), 7.60 (d, 2H), 7.64 (d, IH), 7.76 (d, IH), 8.04

화합물 IC-22의 1H-NMR: δ 7.28 (d, 1H), 7.40 (t, 1H), 7.46 (t, 1H), 7.50 (d, 5H), 7.56 (d, 1H), 7.57 (d, 2H), 7.75 (d, 1H), 7.95 (d, 2H), 7.64 (d, 1H), 8.11 (d, 3H), 11.64 (s, 1H)
One of the compounds IC-22 H-NMR: δ 7.28 (d, 1H), 7.40 (t, 1H), 7.46 (t, 1H), 7.50 (d, 5H), 7.56 (d, 1H), 7.57 (d, 2H), 7.75 (d, 1H), 7.95 (d, 2H), 7.64 (d,

[준비예 12] 화합물 IC-23 및 IC-24의 합성[Preparation Example 12] Synthesis of compounds IC-23 and IC-24

<단계 1> 8-bromo-2-phenyl-5H-thiazolo[4,5-b]carbazole의 합성<Step 1> Synthesis of 8-bromo-2-phenyl-5H-thiazolo [4,5-b] carbazole

Figure 112013108009545-pat00142
Figure 112013108009545-pat00142

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]thiazole (50 g, 0.122 mol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 8-bromo-2-phenyl-5H-thiazolo[4,5-b]carbazole (20.75 g, 수율 45 %)을 얻었다.Bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in Step 5 of Preparation Example 1 was used instead of 6- (5-bromo- Bromo-2-phenyl-5H-thiazolo [4, 5] thiazole was obtained by following the procedure of Step 5 of Preparation Example 1, except that 2-phenylbenzo [d] thiazole , 5-b] carbazole (20.75 g, yield 45%).

1H-NMR: δ 7.41 (m, 2H), 7.52 (d, 3H), 8.01 (d, 2H), 8.05 (s, 1H), 8.12 (s, 1H), 8.23 (s, 1H), 11.68 (s, 1H) 1 H-NMR: δ 7.41 ( m, 2H), 7.52 (d, 3H), 8.01 (d, 2H), 8.05 (s, 1H), 8.12 (s, 1H), 8.23 (s, 1H), 11.68 ( s, 1 H)

<단계 2> 8-bromo-2,5-diphenyl-5H-thiazolo[4,5-b]carbazole의 합성<Step 2> Synthesis of 8-bromo-2,5-diphenyl-5H-thiazolo [4,5-b] carbazole

Figure 112013108009545-pat00143
Figure 112013108009545-pat00143

준비예 1의 <단계 6>에서 사용된 7-bromo-2-phenyl-10H-oxazolo[5,4-a]carbazole (47 g, 0.129 mol) 대신 준비예 12의 <단계 1>에서 얻은 8-bromo-2-phenyl-5H-thiazolo[4,5-b]carbazole (20.75 g, 54.71 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 6>와 동일한 과정을 수행하여 8-bromo-2,5-diphenyl-5H-thiazolo[4,5-b]carbazole (12.95 g, 수율 52 %)을 얻었다.Obtained in Step 1 of Preparation Example 12 instead of 7-bromo-2-phenyl-10H-oxazolo [5,4-a] carbazole (47 g, 0.129 mol) used in Step 6 of Preparation Example 1, bromo-2-phenyl-5H-thiazolo [4,5-b] carbazole (20.75 g, 54.71 mmol) was used in place of 8-bromo -2,5-diphenyl-5H-thiazolo [4,5-b] carbazole (12.95 g, yield 52%).

1H-NMR: δ 7.23 (d, 1H), 7.42 (t, 1H), 7.47 (t, 1H), 7.51 (d, 4H), 7.58 (d, 2H), 7.71 (s, 1H), 7.82 (d, 1H), 8.02 (d, 2H), 8.13 (s, 1H), 8.24 (s, 1H) 1 H-NMR: δ 7.23 ( d, 1H), 7.42 (t, 1H), 7.47 (t, 1H), 7.51 (d, 4H), 7.58 (d, 2H), 7.71 (s, 1H), 7.82 ( (d, IH), 8.02 (d, 2H), 8.13 (s, IH), 8.24

<단계 3> 8-(2-nitrophenyl)-2,5-diphenyl-5H-thiazolo[4,5-b]carbazole의 합성<Step 3> Synthesis of 8- (2-nitrophenyl) -2,5-diphenyl-5H-thiazolo [4,5-b] carbazole

Figure 112013108009545-pat00144
Figure 112013108009545-pat00144

준비예 1의 <단계 4>에서 사용된 2-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (149.48 g, 0.465 mol) 대신 준비예 12의 <단계 2>에서 얻은 8-bromo-2,5-diphenyl-5H-thiazolo[4,5-b]carbazole (12.95 g, 28.44 mmol)을 사용하고, 4-bromo-2-iodo-1-nitrobenzene (138.73 g, 0.423 mol) 대신 2-nitrophenylboronic acid (5.7 g, 34.13 mmol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 4>와 동일한 과정을 수행하여 8-(2-nitrophenyl)-2,5-diphenyl-5H-thiazolo[4,5-b]carbazole (7.22 g, 수율 51 %)을 얻었다.(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzo [d] oxazole used in Step 4 of Preparation Example 1 (149.48 g, 0.465 bromo-2,5-diphenyl-5H-thiazolo [4,5-b] carbazole (12.95 g, 28.44 mmol) obtained in Step 2 of Preparation Example 12 was used instead of 4-bromo- Step 4 of Preparation Example 1 was repeated except that 2-nitrophenylboronic acid (5.7 g, 34.13 mmol) was used instead of -iodo-1-nitrobenzene (138.73 g, 0.423 mol) (2-nitrophenyl) -2,5-diphenyl-5H-thiazolo [4,5-b] carbazole (7.22 g, yield 51%).

1H-NMR: δ 7.42 (t, 1H), 7.47 (t, 1H), 7.51 (d, 4H), 7.58 (d, 2H), 7.67 (d, 1H), 7.77 (s, 1H), 7.91 (d, 1H), 8.01 (d, 4H), 8.05 (d, 1H), 8.13 (s, 1H), 8.18 (d, 1H), 8.24 (s, 1H) 1 H-NMR: δ 7.42 ( t, 1H), 7.47 (t, 1H), 7.51 (d, 4H), 7.58 (d, 2H), 7.67 (d, 1H), 7.77 (s, 1H), 7.91 ( (d, IH), 8.01 (d, 4H), 8.05 (d, IH), 8.13

<단계 4> 화합물 IC-23 및 IC-24의 합성<Step 4> Synthesis of compounds IC-23 and IC-24

Figure 112013108009545-pat00145
Figure 112013108009545-pat00145

준비예 1의 <단계 5>에서 사용된 6-(5-bromo-2-nitrophenyl)-2-phenylbenzo[d]oxazole (113.7 g, 0.29 mol) 대신 준비예 12의 <단계 3>에서 얻은 8-(2-nitrophenyl)-2,5-diphenyl-5H-thiazolo[4,5-b]carbazole (7.22 g, 14.51 mmol)을 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 5>와 동일한 과정을 수행하여 화합물 IC-23 (2.84 g, 수율 42 %) 및 화합물 IC-24 (2.7 g, 수율 40 %)을 얻었다.Obtained in Step 3 of Preparation Example 12 instead of 6- (5-bromo-2-nitrophenyl) -2-phenylbenzo [d] oxazole (113.7 g, 0.29 mol) used in Step 5 of Preparation Example 1, Step 5 of Preparation Example 1 was repeated except that 2-nitrophenyl-2,5-diphenyl-5H-thiazolo [4,5-b] carbazole (7.22 g, 14.51 mmol) To obtain compound IC-23 (2.84 g, yield 42%) and compound IC-24 (2.7 g, yield 40%).

화합물 IC-23의 1H-NMR: δ 7.27 (d, 1H), 7.39 (s, 1H), 7.42 (t, 1H), 7.47 (t, 1H), 7.51 (d, 5H), 7.54 (s, 1H), 7.58 (d, 2H), 7.63 (d, 1H), 8.01 (d, 2H), 8.13 (m, 2H), 8.24 (s, 1H), 11.64 (s, 1H)Compound IC-23 1 H-NMR of: δ 7.27 (d, 1H) , 7.39 (s, 1H), 7.42 (t, 1H), 7.47 (t, 1H), 7.51 (d, 5H), 7.54 (s, 1H), 7.54 (d, 2H), 7.63 (s, 1H), 8.01 (d, 2H), 8.13

화합물 IC-24의 1H-NMR: δ 7.41 (t, 1H), 7.48 (t, 1H), 7.51 (d, 5H), 7.58 (d, 2H), 7.62 (d, 1H), 7.68 (d, 1H), 7.29 (d, 1H), 8.02 (d, 3H), 8.12 (m, 2H), 8.23 (s, 1H), 11.65 (s, 1H)
The compounds of the IC-24 1 H-NMR: δ 7.41 (t, 1H), 7.48 (t, 1H), 7.51 (d, 5H), 7.58 (d, 2H), 7.62 (d, 1H), 7.68 (d, 1H), 7.29 (d, 1H), 8.02 (d, 3H), 8.12 (m, 2H), 8.23

[합성예 1] 화합물 Inv-3의 합성[Synthesis Example 1] Synthesis of Compound Inv-3

Figure 112013108009545-pat00146
Figure 112013108009545-pat00146

질소 기류 하에서 준비예 1에서 합성된 화합물 IC-1 (3 g, 6.67 mmol), 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol), Pd(OAc)2 (0.07 g, 5 mol%), NaO(t-bu) (1.92 g, 20.02 mmol), P(t-bu)3 (0.14 g, 0.67 mmol) 및 Toluene (100 ml)을 혼합하고, 110 ℃에서 12시간 동안 교반하였다.(3 g, 6.67 mmol), 2- (3-chlorophenyl) triphenylene (2.71 g, 8.01 mmol) and Pd (OAc) 2 (0.07 g, 5 mol%) synthesized in Preparation Example 1, (1.92 g, 20.02 mmol), P (t-bu) 3 (0.14 g, 0.67 mmol) and Toluene (100 ml) were mixed and stirred at 110 ° C for 12 hours.

반응이 종결된 후, 에틸아세테이트로 유기층을 추출한 다음, 상기 유기층에서 MgSO4로 수분을 제거하고, 컬럼크로마토그래피 (Hexane:EA = 5:1 (v/v))로 정제하여 화합물 Inv-3 (3.46 g, 수율 69 %)을 얻었다. After the reaction was completed, the organic layer was extracted with ethyl acetate, the organic layer was dried over MgSO 4 and purified by column chromatography (Hexane: EA = 5: 1 (v / v) 3.46 g, yield 69%).

GC-Mass (이론치: 751.26 g/mol, 측정치: 751 g/mol)
GC-Mass (calculated: 751.26 g / mol, measured: 751 g / mol)

[합성예 2] 화합물 Inv-11의 합성[Synthesis Example 2] Synthesis of compound Inv-11

Figure 112013108009545-pat00147
Figure 112013108009545-pat00147

합성예 1에서 사용된 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 1-chloro-4-phenylisoquinoline (1.92 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-11 (3.18 g, 수율 73 %)를 얻었다.Except that 1-chloro-4-phenylisoquinoline (1.92 g, 8.01 mmol) was used in place of 2- (3-chlorophenyl) triphenylene (2.71 g, 8.01 mmol) used in Synthesis Example 1 (3.18 g, yield 73%) of the compound Inv-11.

GC-Mass (이론치: 652.23 g/mol, 측정치: 652 g/mol)
GC-Mass (calculated: 652.23 g / mol, measured: 652 g / mol)

[합성예 3] 화합물 Inv-23의 합성[Synthesis Example 3] Synthesis of compound Inv-23

Figure 112013108009545-pat00148
Figure 112013108009545-pat00148

합성예 1에서 사용된 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 4-chloro-2-phenylpyrimidine (1.53 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-23 (2.90 g, 수율 72 %)를 얻었다.Except that 4-chloro-2-phenylpyrimidine (1.53 g, 8.01 mmol) was used instead of 2- (3-chlorophenyl) triphenylene (2.71 g, 8.01 mmol) used in Synthesis Example 1 Was performed to obtain the compound Inv-23 (2.90 g, yield 72%).

GC-Mass (이론치: 603.21 g/mol, 측정치: 603 g/mol)
GC-Mass (theory: 603.21 g / mol, measured: 603 g / mol)

[합성예 4] 화합물 Inv-28의 합성[Synthesis Example 4] Synthesis of Compound Inv-28

Figure 112013108009545-pat00149
Figure 112013108009545-pat00149

질소 기류 하에서 준비예 1에서 합성된 화합물 IC-1 (3 g, 6.67 mmol), 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol), Cu powder (0.04 g, 0.67 mmol), K2CO3 (0.92 g, 6.67 mmol), Na2SO4 (0.95 g, 6.67 mmol), nitrobenzene (100 ml)를 혼합하고, 200 ℃에서 24시간 동안 교반하였다. 4-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol), Cu powder (0.04 g, 0.67 mmol), K 2 CO 3 (0.92 g, 6.67 mmol), Na 2 SO 4 (0.95 g, 6.67 mmol) and nitrobenzene (100 ml) were mixed and stirred at 200 ° C for 24 hours.

반응 종결 후, nitrobenzene을 제거하고 메틸렌클로라이드로 유기층을 분리한 다음, MgSO4를 사용하여 상기 유기층에서 물을 제거하였다. 물이 제거된 유기층에서 용매를 제거한 후 컬럼 크로마토그래피 (Hexane:EA = 5:1 (v/v))로 정제하여 화합물 Inv-28 (2.17 g, 수율 52 %)을 얻었다.After termination of the reaction, nitrobenzene was removed, the organic layer was separated with methylene chloride, and water was removed from the organic layer using MgSO 4 . The solvent was removed from the organic layer from which water had been removed, and then purified by column chromatography (Hexane: EA = 5: 1 (v / v)) to obtain Compound Inv-28 (2.17 g, yield 52%).

GC-Mass (이론치: 626.21 g/mol, 측정치: 626 g/mol)
GC-Mass (calculated: 626.21 g / mol, measured: 626 g / mol)

[합성예 5] 화합물 Inv-39의 합성[Synthesis Example 5] Synthesis of Compound Inv-39

Figure 112013108009545-pat00150
Figure 112013108009545-pat00150

질소 하에서 준비예 1에서 합성된 화합물 IC-1 (3 g, 6.67 mmol)을 DMF 100 ml에 녹인 다음, 여기에 NaH (0.40 g, 16.69 mmol)를 넣고 1시간 동안 교반하였다. 여기에, DMF (100ml)에 녹인 2-chloro-4,6-diphenyl-1,3,5-triazine (3.57 g, 13.35 mmol)을 천천히 첨가하였다. 3시간 동안 교반한 후, 반응을 종료시키고, 혼합물을 실리카 필터링한 다음, 물과 메탄올로 씻은 후 용매를 제거하였다. 용매가 제거된 고체 생성물을 컬럼 크로마토그래피 (Hexane:EA = 3:1 (v/v))로 정제하여 화합물 Inv-39 (2.00 g, 수율 44 %)을 얻었다.The compound IC-1 (3 g, 6.67 mmol) synthesized in Preparation Example 1 under nitrogen was dissolved in 100 ml of DMF. NaH (0.40 g, 16.69 mmol) was added thereto and stirred for 1 hour. 2-chloro-4,6-diphenyl-1,3,5-triazine (3.57 g, 13.35 mmol) dissolved in DMF (100 ml) was slowly added thereto. After stirring for 3 hours, the reaction was terminated, the mixture was filtered through silica, washed with water and methanol, and then the solvent was removed. The solvent-removed solid product was purified by column chromatography (Hexane: EA = 3: 1 (v / v)) to obtain Compound Inv-39 (2.00 g, yield 44%).

GC-Mass (이론치: 680.23 g/mol, 측정치: 680 g/mol)
GC-Mass (calculated: 680.23 g / mol, measured: 680 g / mol)

[합성예 6] 화합물 Inv-54의 합성[Synthesis Example 6] Synthesis of Compound Inv-54

Figure 112013108009545-pat00151
Figure 112013108009545-pat00151

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 1에서 합성된 화합물 IC-2 (3 g, 6.67 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 3-bromo-9-phenyl-9H-carbazole (3.23 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-54 (2.31 g, 수율 50 %)를 얻었다.Except that the compound IC-2 (3 g, 6.67 mmol) synthesized in Preparation Example 1 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4, and 2.58 g of 4'-bromobiphenyl-3-carbonitrile The same procedure as in Synthesis Example 4 was carried out except that 3-bromo-9-phenyl-9H-carbazole (3.23 g, 10.01 mmol) was used in place of the compound (Inv-54, 50%).

GC-Mass (이론치: 690.79 g/mol, 측정치: 690 g/mol)
GC-Mass (calculated: 690.79 g / mol, measured: 690 g / mol)

[합성예 7] 화합물 Inv-66의 합성[Synthesis Example 7] Synthesis of Compound Inv-66

Figure 112013108009545-pat00152
Figure 112013108009545-pat00152

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 1에서 합성된 화합물 IC-2 (3 g, 6.67 mmol)을 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 2-chloroquinazoline (1.32 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-66 (2.51 g, 수율 65 %)를 얻었다.2- (3-chlorophenyl) triphenylene (2.71 g, 6.67 mmol) was used instead of the compound IC-2 (3 g, 6.67 mmol) synthesized in Preparation Example 1 in place of the compound IC- , Inv-66 (2.51 g, yield 65%) was obtained by following the same procedure as in Synthesis Example 1, except that 2-chloroquinazoline (1.32 g, 8.01 mmol)

GC-Mass (이론치: 577.19 g/mol, 측정치: 577 g/mol)
GC-Mass (calculated: 577.19 g / mol, measured: 577 g / mol)

[합성예 8] 화합물 Inv-79의 합성[Synthesis Example 8] Synthesis of Compound Inv-79

Figure 112013108009545-pat00153
Figure 112013108009545-pat00153

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 1에서 합성된 화합물 IC-2 (3 g, 6.67 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 4'-bromobiphenyl-4-carbonitrile (2.58 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 Inv-79 (2.01 g, 수율 48 %)를 얻었다.Except that the compound IC-2 (3 g, 6.67 mmol) synthesized in Preparation Example 1 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4, and 2.58 g of 4'-bromobiphenyl-3-carbonitrile Inv-79 (2.01 g, yield 48%) was obtained by following the same procedure as in Synthesis Example 4, except that 4'-bromobiphenyl-4-carbonitrile (2.58 g, 10.01 mmol) .

GC-Mass (이론치: 626.21 g/mol, 측정치: 626 g/mol)
GC-Mass (calculated: 626.21 g / mol, measured: 626 g / mol)

[합성예 9] 화합물 Inv-81의 합성[Synthesis Example 9] Synthesis of Compound Inv-81

Figure 112013108009545-pat00154
Figure 112013108009545-pat00154

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 IC-2 (3 g, 6.67 mmol)를 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 6-chloro-3,3'-bipyridine (1.53 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 Inv-81 (2.74 g, 수율 68 %)를 얻었다.Instead of 2- (3-chlorophenyl) triphenylene (2.71 g, 8.01 mmol) was used instead of compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 1 instead of IC- Inv-81 (2.74 g, yield 68%) was obtained by following the same procedure as in Synthesis Example 1, except that chloro-3,3'-bipyridine (1.53 g, 8.01 mmol) was used.

GC-Mass (이론치: 603.21 g/mol, 측정치: 603 g/mol)
GC-Mass (theory: 603.21 g / mol, measured: 603 g / mol)

[합성예 10] 화합물 Inv-113의 합성[Synthesis Example 10] Synthesis of Compound Inv-113

Figure 112013108009545-pat00155
Figure 112013108009545-pat00155

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 2에서 합성된 화합물 IC-3 (3 g, 6.67 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 6-bromo-2,3'-bipyridine (2.35 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-113 (2.05 g, 수율 51 %)를 얻었다.Except that the compound IC-3 (3 g, 6.67 mmol) synthesized in Preparation Example 2 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4 and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , Inv-113 (2.05 g, yield 51%) was obtained by following the same procedure as in Synthesis Example 4, except that 6-bromo-2,3'-bipyridine (2.35 g, 10.01 mmol) %).

GC-Mass (이론치: 603.21 g/mol, 측정치: 603 g/mol)
GC-Mass (theory: 603.21 g / mol, measured: 603 g / mol)

[합성예 11] 화합물 Inv-125의 합성[Synthesis Example 11] Synthesis of Compound Inv-125

Figure 112013108009545-pat00156
Figure 112013108009545-pat00156

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 2에서 합성된 화합물 IC-3 (3 g, 6.67 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 3-bromo-N,N-diphenylaniline (3.25 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-125 (2.54 g, 수율 55 %)를 얻었다.Except that the compound IC-3 (3 g, 6.67 mmol) synthesized in Preparation Example 2 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4 and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , Inv-125 (2.54 g, yield 55%) was obtained by following the same procedure as in Synthesis Example 4, except that 3-bromo-N, N-diphenylaniline (3.25 g, 10.01 mmol) ).

GC-Mass (이론치: 692.26 g/mol, 측정치: 692 g/mol)
GC-Mass (calculated: 692.26 g / mol, measured: 692 g / mol)

[합성예 12] 화합물 Inv-145의 합성[Synthesis Example 12] Synthesis of compound Inv-145

Figure 112013108009545-pat00157
Figure 112013108009545-pat00157

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 2에서 합성된 화합물 IC-4 (3 g, 6.67 mmol)를 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 4-chloro-2-phenylpyrimidine (1.53 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-145 (2.78 g, 수율 69 %)를 얻었다.2- (3-chlorophenyl) triphenylene (2.71 g, 6.67 mmol) was used instead of the compound IC-4 (3 g, 6.67 mmol) synthesized in Preparation Example 2 in place of the compound IC- , Inv-145 (2.78 g, yield 69%) was obtained by following the same procedure as in Synthesis Example 1, except that 4-chloro-2-phenylpyrimidine (1.53 g, 8.01 mmol) .

GC-Mass (이론치: 603.21 g/mol, 측정치: 603 g/mol)
GC-Mass (theory: 603.21 g / mol, measured: 603 g / mol)

[합성예 13] 화합물 Inv-152의 합성[Synthesis Example 13] Synthesis of Compound Inv-152

Figure 112013108009545-pat00158
Figure 112013108009545-pat00158

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 2에서 합성된 화합물 IC-4 (3 g, 6.67 mmol)를 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 2-chloro-4,6-diphenylpyrimidine (2.14 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-152 (3.27 g, 수율 72 %)를 얻었다.2- (3-chlorophenyl) triphenylene (2.71 g, 6.67 mmol) was used instead of the compound IC-4 (3 g, 6.67 mmol) synthesized in Preparation Example 2 in place of the compound IC- (3.27 g, yield 72%) was obtained by following the same procedure as in Synthesis Example 1, except that 2-chloro-4,6-diphenylpyrimidine (2.14 g, 8.01 mmol) ).

GC-Mass (이론치: 679.24 g/mol, 측정치: 679 g/mol)
GC-Mass (calculated: 679.24 g / mol, measured: 679 g / mol)

[합성예 14] 화합물 Inv-173의 합성[Synthesis Example 14] Synthesis of compound Inv-173

Figure 112013108009545-pat00159
Figure 112013108009545-pat00159

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 3에서 합성된 화합물 IC-5 (3 g, 6.67 mmol)를 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 6-bromo-2,3'-bipyridine (2.35 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-173 (1.97 g, 수율 49 %)를 얻었다.Except that the compound IC-5 (3 g, 6.67 mmol) synthesized in Preparation Example 3 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthetic Example 4 and 4'-bromobiphenyl-3-carbonitrile , Inv-173 (1.97 g, yield 49%) was obtained by following the same procedure as in Synthesis Example 4, except that 6-bromo-2,3'-bipyridine (2.35 g, 10.01 mmol) %).

GC-Mass (이론치: 603.21 g/mol, 측정치: 603 g/mol)
GC-Mass (theory: 603.21 g / mol, measured: 603 g / mol)

[합성예 15] 화합물 Inv-179의 합성[Synthesis Example 15] Synthesis of compound Inv-179

Figure 112013108009545-pat00160
Figure 112013108009545-pat00160

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 3에서 합성된 화합물 IC-5 (3 g, 6.67 mmol)를 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 3'-chlorobiphenyl-4-carbonitrile (1.71 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-179 (2.72 g, 수율 65 %)를 얻었다.(3 g, 6.67 mmol) was used instead of the compound IC-5 (3 g, 6.67 mmol) used in Synthesis Example 1, and 2- (3-chlorophenyl) triphenylene , Inv-179 (2.72 g, yield 65%) was obtained in the same manner as in Synthesis Example 1, except that 3'-chlorobiphenyl-4-carbonitrile (1.71 g, 8.01 mmol) .

GC-Mass (이론치: 626.21 g/mol, 측정치: 626 g/mol)
GC-Mass (calculated: 626.21 g / mol, measured: 626 g / mol)

[합성예 16] 화합물 Inv-211의 합성[Synthesis Example 16] Synthesis of Compound Inv-211

Figure 112013108009545-pat00161
Figure 112013108009545-pat00161

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 3에서 합성된 화합물 IC-6 (3 g, 6.67 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 2-bromo-4,6-diphenylpyridine (3.11 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-211 (2.40 g, 수율 53 %)를 얻었다.Except that the compound IC-6 (3 g, 6.67 mmol) synthesized in Preparation Example 3 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4 and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , Inv-211 (2.40 g, yield 53%) was obtained by following the same procedure as in Synthesis Example 4, except that 2-bromo-4,6-diphenylpyridine (3.11 g, 10.01 mmol) ).

GC-Mass (이론치: 678.24 g/mol, 측정치: 678 g/mol)
GC-Mass (theory: 678.24 g / mol, measured: 678 g / mol)

[합성예 17] 화합물 Inv-219의 합성[Synthesis Example 17] Synthesis of Compound Inv-219

Figure 112013108009545-pat00162
Figure 112013108009545-pat00162

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 3에서 합성된 화합물 IC-6 (3 g, 6.67 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 3-bromobenzonitrile (1.82 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-219 (1.98 g, 수율 54 %)를 얻었다.Except that the compound IC-6 (3 g, 6.67 mmol) synthesized in Preparation Example 3 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4 and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , Inv-219 (1.98 g, yield 54%) was obtained by following the same procedure as in Synthesis Example 4, except that 3-bromobenzonitrile (1.82 g, 10.01 mmol)

GC-Mass (이론치: 550.18 g/mol, 측정치: 550 g/mol)
GC-Mass (calculated: 550.18 g / mol, measured: 550 g / mol)

[합성예 18] 화합물 Inv-230의 합성[Synthesis Example 18] Synthesis of Compound Inv-230

Figure 112013108009545-pat00163
Figure 112013108009545-pat00163

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 4에서 합성된 화합물 IC-7 (3 g, 6.67 mmol)를 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 2-chloroquinoline (1.31 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-230 (3.16 g, 수율 82 %)를 얻었다.(3 g, 6.67 mmol) prepared in Preparation Example 4 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 1 and 2- (3-chlorophenyl) triphenylene , Inv-230 (3.16 g, yield 82%) was obtained in the same manner as in Synthesis Example 1, except that 2-chloroquinoline (1.31 g, 8.01 mmol)

GC-Mass (이론치: 576.20 g/mol, 측정치: 576 g/mol)
GC-Mass (calculated: 576.20 g / mol, measured: 576 g / mol)

[합성예 19] 화합물 Inv-236의 합성[Synthesis Example 19] Synthesis of compound Inv-236

Figure 112013108009545-pat00164
Figure 112013108009545-pat00164

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 4에서 합성된 IC-7 (3 g, 6.67 mmol)를 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 4-chloro-2-(pyridin-3-yl)pyrimidine (1.53 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-236 (2.78 g, 수율 69 %)를 얻었다.2- (3-chlorophenyl) triphenylene (2.71 g, 6.67 mmol) prepared in Preparation Example 4 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 1, The same procedure as in Synthesis Example 1 was carried out except that 4-chloro-2- (pyridin-3-yl) pyrimidine (1.53 g, 8.01 mmol) , Yield: 69%).

GC-Mass (이론치: 604.20 g/mol, 측정치: 604 g/mol)
GC-Mass (theory: 604.20 g / mol, measured: 604 g / mol)

[합성예 20] 화합물 Inv-274의 합성[Synthesis Example 20] Synthesis of Compound Inv-274

Figure 112013108009545-pat00165
Figure 112013108009545-pat00165

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 4에서 합성된 화합물 IC-8 (3 g, 6.67 mmol)을 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 4-chloro-2,6-diphenylpyrimidine (2.14 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-274 (3.31 g, 수율 73 %)를 얻었다.2- (3-chlorophenyl) triphenylene (2.71 g, 6.67 mmol) was used instead of the compound IC-8 (3 g, 6.67 mmol) synthesized in Preparation Example 4 instead of the compound IC- , Inv-274 (3.31 g, yield 73%) was obtained by following the same procedure as in Synthesis Example 1, except that 4-chloro-2,6-diphenylpyrimidine (2.14 g, 8.01 mmol) ).

GC-Mass (이론치: 679.24 g/mol, 측정치: 679 g/mol)
GC-Mass (calculated: 679.24 g / mol, measured: 679 g / mol)

[합성예 21] 화합물 Inv-280의 합성[Synthesis Example 21] Synthesis of Compound Inv-280

Figure 112013108009545-pat00166
Figure 112013108009545-pat00166

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 4에서 합성된 화합물 IC-8 (3 g, 6.67 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 4-bromobenzonitrile (1.82 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-280 (1.91 g, 수율 52 %)를 얻었다.Except that the compound IC-8 (3 g, 6.67 mmol) synthesized in Preparation Example 4 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4 and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , Inv-280 (1.91 g, yield 52%) was obtained by following the same procedure as in Synthesis Example 4, except that 4-bromobenzonitrile (1.82 g, 10.01 mmol)

GC-Mass (이론치: 550.18 g/mol, 측정치: 550 g/mol)
GC-Mass (calculated: 550.18 g / mol, measured: 550 g / mol)

[합성예 22] 화합물 Inv-287의 합성[Synthesis Example 22] Synthesis of compound Inv-287

Figure 112013108009545-pat00167
Figure 112013108009545-pat00167

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 5에서 합성된 화합물 IC-9 (3 g, 6.67 mmol)를 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 9-(4-bromophenyl)-9H-carbazole (3.23 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-287 (2.58 g, 수율 56 %)를 얻었다.Except that the compound IC-9 (3 g, 6.67 mmol) synthesized in Preparation Example 5 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4, and 2.58 g of 4'-bromobiphenyl-3-carbonitrile The same procedure as in Synthesis Example 4 was carried out, except that 9- (4-bromophenyl) -9H-carbazole (3.23 g, 10.01 mmol) 56%).

GC-Mass (이론치: 690.24 g/mol, 측정치: 690 g/mol)
GC-Mass (theory: 690.24 g / mol, measured: 690 g / mol)

[합성예 23] 화합물 Inv-288의 합성[Synthesis Example 23] Synthesis of compound Inv-288

Figure 112013108009545-pat00168
Figure 112013108009545-pat00168

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 5에서 합성된 화합물 IC-9 (3 g, 6.67 mmol)를 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 1-chloro-4-phenylisoquinoline (1.92 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-288 (2.88 g, 수율 66 %)를 얻었다.(3 g, 6.67 mmol) was used instead of the compound IC-9 (3 g, 6.67 mmol) used in Synthesis Example 1 and 2- (3-chlorophenyl) triphenylene , Inv-288 (2.88 g, yield 66%) was obtained by following the same procedure as in Synthesis Example 1, except that 1-chloro-4-phenylisoquinoline (1.92 g, 8.01 mmol) .

GC-Mass (이론치: 652.23 g/mol, 측정치: 652 g/mol)
GC-Mass (calculated: 652.23 g / mol, measured: 652 g / mol)

[합성예 24] 화합물 Inv-322의 합성[Synthesis Example 24] Synthesis of Compound Inv-322

Figure 112013108009545-pat00169
Figure 112013108009545-pat00169

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 6에서 합성된 화합물 IC-11 (3 g, 6.67 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 2-bromo-6-phenylpyridine (2.34 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-322 (1.77 g, 수율 44 %)를 얻었다.Except that the compound IC-11 (3 g, 6.67 mmol) synthesized in Preparation Example 6 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4, and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , Inv-322 (1.77 g, yield 44%) was obtained by following the same procedure as in Synthesis Example 4, except that 2-bromo-6-phenylpyridine (2.34 g, 10.01 mmol) .

GC-Mass (이론치: 602.21 g/mol, 측정치: 602 g/mol)
GC-Mass (theory: 602.21 g / mol, measurement: 602 g / mol)

[합성예 25] 화합물 Inv-338의 합성[Synthesis Example 25] Synthesis of compound Inv-338

Figure 112013108009545-pat00170
Figure 112013108009545-pat00170

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 6에서 합성된 화합물 IC-11 (3 g, 6.67 mmol)을 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 2-(3-chlorophenyl)-4,6-diphenyl-1,3,5-triazine (2.75 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-338 (3.89 g, 수율 77 %)를 얻었다.(3 g, 6.67 mmol) prepared in Preparation Example 6 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 1 and 2- (3-chlorophenyl) triphenylene , 8.01 mmol) instead of 2- (3-chlorophenyl) -4,6-diphenyl-1,3,5-triazine (2.75 g, 8.01 mmol) To obtain Compound Inv-338 (3.89 g, yield 77%).

GC-Mass (이론치: 756.26 g/mol, 측정치: 756 g/mol)
GC-Mass (calculated: 756.26 g / mol, measured: 756 g / mol)

[합성예 26] 화합물 Inv-353의 합성[Synthesis Example 26] Synthesis of compound Inv-353

Figure 112013108009545-pat00171
Figure 112013108009545-pat00171

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 6에서 합성된 화합물 IC-12 (3 g, 6.67 mmol)를 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 6-bromo-2,3'-bipyridine (2.35 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-353 (1.61 g, 수율 40 %)를 얻었다.Except that the compound IC-12 (3 g, 6.67 mmol) synthesized in Preparation Example 6 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4, and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , Inv-353 (1.61 g, yield 40%) was obtained by following the same procedure as in Synthesis Example 4, except that 6-bromo-2,3'-bipyridine (2.35 g, 10.01 mmol) %).

GC-Mass (이론치: 603.21 g/mol, 측정치: 603 g/mol)
GC-Mass (theory: 603.21 g / mol, measured: 603 g / mol)

[합성예 27] 화합물 Inv-364의 합성[Synthesis Example 27] Synthesis of compound Inv-364

Figure 112013108009545-pat00172
Figure 112013108009545-pat00172

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 6에서 합성된 화합물 IC-12 (3 g, 6.67 mmol)를 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 4-chloro-2,6-diphenylpyrimidine (2.14 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-364 (3.40 g, 수율 75 %)를 얻었다.Except that the compound IC-12 (3 g, 6.67 mmol) synthesized in Preparation Example 6 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 1 and 2- (3-chlorophenyl) triphenylene , Inv-364 (3.40 g, yield 75%) was obtained by following the same procedure as in Synthesis Example 1, except that 4-chloro-2,6-diphenylpyrimidine (2.14 g, 8.01 mmol) ).

GC-Mass (이론치: 679.24 g/mol, 측정치: 679 g/mol)
GC-Mass (calculated: 679.24 g / mol, measured: 679 g / mol)

[합성예 28] 화합물 Inv-388의 합성[Synthesis Example 28] Synthesis of Compound Inv-388

Figure 112013108009545-pat00173
Figure 112013108009545-pat00173

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 7에서 합성된 화합물 IC-13 (3 g, 6.67 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 4'-bromobiphenyl-4-carbonitrile (2.58 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-388 (1.92 g, 수율 46 %)를 얻었다.Except that the compound IC-13 (3 g, 6.67 mmol) synthesized in Preparation Example 7 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4 and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , Inv-388 (1.92 g, yield 46%) was obtained by following the same procedure as in Synthesis Example 4, except that 4'-bromobiphenyl-4-carbonitrile (2.58 g, 10.01 mmol) .

GC-Mass (이론치: 626.21 g/mol, 측정치: 626 g/mol)
GC-Mass (calculated: 626.21 g / mol, measured: 626 g / mol)

[합성예 29] 화합물 Inv-397의 합성[Synthesis Example 29] Synthesis of compound Inv-397

Figure 112013108009545-pat00174
Figure 112013108009545-pat00174

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 7에서 합성된 화합물 IC-13 (3 g, 6.67 mmol)을 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 2-(4-chlorophenyl)-4,6-diphenyl-1,3,5-triazine (2.75 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-397 (3.84 g, 수율 76 %)를 얻었다.(3 g, 6.67 mmol) was used instead of the compound IC-13 (3 g, 6.67 mmol) used in Synthesis Example 1, and 2- (3-chlorophenyl) triphenylene , 8.01 mmol) instead of 2- (4-chlorophenyl) -4,6-diphenyl-1,3,5-triazine (2.75 g, 8.01 mmol) To obtain Compound Inv-397 (3.84 g, yield 76%).

GC-Mass (이론치: 756.26 g/mol, 측정치: 756 g/mol)
GC-Mass (calculated: 756.26 g / mol, measured: 756 g / mol)

[합성예 30] 화합물 Inv-413의 합성[Synthesis Example 30] Synthesis of compound Inv-413

Figure 112013108009545-pat00175
Figure 112013108009545-pat00175

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 7에서 합성된 화합물 IC-14 (3 g, 6.67 mmol)를 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 6-bromo-2,3'-bipyridine (2.35 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-413 (1.66 g, 수율 41 %)를 얻었다.Except that the compound IC-14 (3 g, 6.67 mmol) synthesized in Preparation Example 7 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4 and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , Inv. 413 (1.66 g, yield 41%) was obtained by following the same procedure as in Synthesis Example 4, except that 6-bromo-2,3'-bipyridine (2.35 g, 10.01 mmol) %).

GC-Mass (이론치: 606.21 g/mol, 측정치: 606 g/mol)
GC-Mass (theory: 606.21 g / mol, measurement: 606 g / mol)

[합성예 31] 화합물 Inv-430의 합성[Synthesis Example 31] Synthesis of Compound Inv-430

Figure 112013108009545-pat00176
Figure 112013108009545-pat00176

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 7에서 합성된 화합물 IC-14 (3 g, 6.67 mmol)를 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 4-bromobenzonitrile (1.82 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-430 (1.76 g, 수율 48 %)를 얻었다.Except that the compound IC-14 (3 g, 6.67 mmol) synthesized in Preparation Example 7 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4 and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , Inv-430 (1.76 g, yield 48%) was obtained by following the same procedure as in Synthesis Example 4, except that 4-bromobenzonitrile (1.82 g, 10.01 mmol) was used instead of 4-

GC-Mass (이론치: 550.18 g/mol, 측정치: 550 g/mol)
GC-Mass (calculated: 550.18 g / mol, measured: 550 g / mol)

[합성예 32] 화합물 Inv-440의 합성[Synthesis Example 32] Synthesis of Compound Inv-440

Figure 112013108009545-pat00177
Figure 112013108009545-pat00177

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 8에서 합성된 화합물 IC-15 (3 g, 6.67 mmol)를 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 2-chloroquinoline (1.31 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-440 (2.58 g, 수율 67 %)를 얻었다.(3-chlorophenyl) triphenylene (2.71 g, 6.67 mmol) was used instead of the compound IC-15 (3 g, 6.67 mmol) synthesized in Preparation Example 8, instead of the compound IC- , Inv-440 (2.58 g, yield 67%) was obtained in the same manner as in Synthesis Example 1, except that 2-chloroquinoline (1.31 g, 8.01 mmol)

GC-Mass (이론치: 576.20 g/mol, 측정치: 576 g/mol)
GC-Mass (calculated: 576.20 g / mol, measured: 576 g / mol)

[합성예 33] 화합물 Inv-452의 합성[Synthesis Example 33] Synthesis of compound Inv-452

Figure 112013108009545-pat00178
Figure 112013108009545-pat00178

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 8에서 합성된 화합물 IC-15 (3 g, 6.67 mmol)를 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 2-chloro-4,6-diphenylpyrimidine (2.14 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-452 (3.45 g, 수율 76 %)를 얻었다.(3-chlorophenyl) triphenylene (2.71 g, 6.67 mmol) was used instead of the compound IC-15 (3 g, 6.67 mmol) synthesized in Preparation Example 8, instead of the compound IC- , Inv-452 (3.45 g, yield 76%) was obtained by following the same procedure as in Synthesis Example 1, except that 2-chloro-4,6-diphenylpyrimidine (2.14 g, 8.01 mmol) ).

GC-Mass (이론치: 679.24 g/mol, 측정치: 679 g/mol)
GC-Mass (calculated: 679.24 g / mol, measured: 679 g / mol)

[합성예 34] 화합물 Inv-462의 합성[Synthesis Example 34] Synthesis of compound Inv-462

Figure 112013108009545-pat00179
Figure 112013108009545-pat00179

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 8에서 합성된 화합물 IC-16 (3 g, 6.67 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 3-bromobiphenyl (2.33 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-462 (2.09 g, 수율 52 %)를 얻었다.Except that the compound IC-16 (3 g, 6.67 mmol) synthesized in Preparation Example 8 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4, and 2.58 g of 4'-bromobiphenyl- , Inv-462 (2.09 g, yield 52%) was obtained by following the same procedure as in Synthesis Example 4, except that 3-bromobiphenyl (2.33 g, 10.01 mmol)

GC-Mass (이론치: 601.22 g/mol, 측정치: 601 g/mol)
GC-Mass (theory: 601.22 g / mol, measurement: 601 g / mol)

[합성예 35] 화합물 Inv-487의 합성[Synthesis Example 35] Synthesis of compound Inv-487

Figure 112013108009545-pat00180
Figure 112013108009545-pat00180

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 8에서 합성된 화합물 IC-16 (3 g, 6.67 mmol)을 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 2-(4-chlorophenyl)-4,6-diphenyl-1,3,5-triazine (2.75 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-487 (3.74 g, 수율 74 %)를 얻었다.2- (3-chlorophenyl) triphenylene (2.71 g, 6.67 mmol) was used instead of the compound IC-16 (3 g, 6.67 mmol) synthesized in Preparation Example 8 instead of the compound IC- , 8.01 mmol) instead of 2- (4-chlorophenyl) -4,6-diphenyl-1,3,5-triazine (2.75 g, 8.01 mmol) To obtain Compound Inv-487 (3.74 g, yield 74%).

GC-Mass (이론치: 756.26 g/mol, 측정치: 756 g/mol)
GC-Mass (calculated: 756.26 g / mol, measured: 756 g / mol)

[합성예 36] 화합물 Inv-510의 합성[Synthesis Example 36] Synthesis of Compound Inv-510

Figure 112013108009545-pat00181
Figure 112013108009545-pat00181

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 9에서 합성된 화합물 IC-17 (3 g, 6.67 mmol)을 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 2-(4-chlorophenyl)-4-phenylpyrimidine (2.14 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-510 (3.18 g, 수율 70 %)를 얻었다.(3 g, 6.67 mmol) synthesized in Preparation Example 9 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 1 and 2- (3-chlorophenyl) triphenylene (3.18 g, yield: 98%) was obtained by following the same procedure as in Synthesis Example 1, except that 2- (4-chlorophenyl) -4-phenylpyrimidine (2.14 g, 8.01 mmol) 70%).

GC-Mass (이론치: 679.24 g/mol, 측정치: 679 g/mol)
GC-Mass (calculated: 679.24 g / mol, measured: 679 g / mol)

[합성예 37] 화합물 Inv-529의 합성[Synthesis Example 37] Synthesis of compound Inv-529

Figure 112013108009545-pat00182
Figure 112013108009545-pat00182

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 9에서 합성된 화합물 IC-18 (3 g, 6.67 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 2-(4-bromophenyl)-1-phenyl-2,7a-dihydro-1H-benzo[d]imidazole (3.52 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-529 (2.64 g, 수율 55 %)를 얻었다.Except that the compound IC-18 (3 g, 6.67 mmol) synthesized in Preparation Example 9 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4 and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , 10.01 mmol) was used instead of 2- (4-bromophenyl) -1-phenyl-2,7a-dihydro-1H-benzo [d] imidazole (3.52 g, 10.01 mmol) The same procedure was followed to obtain compound Inv-529 (2.64 g, yield 55%).

GC-Mass (이론치: 719.27 g/mol, 측정치: 719 g/mol)
GC-Mass (calculated: 719.27 g / mol, measured: 719 g / mol)

[합성예 38] 화합물 Inv-563의 합성[Synthesis Example 38] Synthesis of compound Inv-563

Figure 112013108009545-pat00183
Figure 112013108009545-pat00183

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 10에서 합성된 화합물 IC-19 (3 g, 6.67 mmol)를 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 6-bromo-2,3'-bipyridine (2.35 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-563 (1.97 g, 수율 49 %)를 얻었다.Except that the compound IC-19 (3 g, 6.67 mmol) synthesized in Preparation Example 10 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4 and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , Inv-563 (1.97 g, yield 49%) was obtained by following the same procedure as in Synthesis Example 4, except that 6-bromo-2,3'-bipyridine (2.35 g, 10.01 mmol) %).

GC-Mass (이론치: 603.21 g/mol, 측정치: 603 g/mol)
GC-Mass (theory: 603.21 g / mol, measured: 603 g / mol)

[합성예 39] 화합물 Inv-575의 합성[Synthesis Example 39] Synthesis of compound Inv-575

Figure 112013108009545-pat00184
Figure 112013108009545-pat00184

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 10에서 합성된 화합물 IC-19 (3 g, 6.67 mmol)를 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 3-bromo-N,N-diphenylaniline (3.25 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-575 (2.31 g, 수율 45 %)를 얻었다.Except that the compound IC-19 (3 g, 6.67 mmol) synthesized in Preparation Example 10 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4 and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , Inv-575 (2.31 g, yield 45%) was obtained by following the same procedure as in Synthesis Example 4, except that 3-bromo-N, N-diphenylaniline (3.25 g, 10.01 mmol) ).

GC-Mass (이론치: 692.26 g/mol, 측정치: 692 g/mol)
GC-Mass (calculated: 692.26 g / mol, measured: 692 g / mol)

[합성예 40] 화합물 Inv-598의 합성[Synthesis Example 40] Synthesis of Compound Inv-598

Figure 112013108009545-pat00185
Figure 112013108009545-pat00185

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 10에서 합성된 화합물 IC-20 (3 g, 6.67 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 4'-bromobiphenyl-4-carbonitrile (2.58 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-598 (1.71 g, 수율 41 %)를 얻었다.Except that the compound IC-20 (3 g, 6.67 mmol) synthesized in Preparation Example 10 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4 and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , Inv-598 (1.71 g, yield 41%) was obtained by following the same procedure as in Synthesis Example 4, except that 4'-bromobiphenyl-4-carbonitrile (2.58 g, 10.01 mmol) .

GC-Mass (이론치: 626.21 g/mol, 측정치: 626 g/mol)
GC-Mass (calculated: 626.21 g / mol, measured: 626 g / mol)

[합성예 41] 화합물 Inv-604의 합성[Synthesis Example 41] Synthesis of compound Inv-604

Figure 112013108009545-pat00186
Figure 112013108009545-pat00186

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 10에서 합성된 화합물 IC-20 (3 g, 6.67 mmol)을 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 4-chloro-2,6-diphenylpyrimidine (2.14 g, 8.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-604 (3.40 g, 수율 75 %)를 얻었다.2- (3-chlorophenyl) triphenylene (2.71 g, 6.67 mmol) was used instead of the compound IC-20 (3 g, 6.67 mmol) synthesized in Preparation Example 10 instead of the compound IC- , Inv-604 (3.40 g, yield 75%) was obtained by following the same procedure as in Synthesis Example 1, except that 4-chloro-2,6-diphenylpyrimidine (2.14 g, 8.01 mmol) ).

GC-Mass (이론치: 679.24 g/mol, 측정치: 679 g/mol)
GC-Mass (calculated: 679.24 g / mol, measured: 679 g / mol)

[합성예 42] 화합물 Inv-615의 합성[Synthesis Example 42] Synthesis of compound Inv-615

Figure 112013108009545-pat00187
Figure 112013108009545-pat00187

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 11에서 합성된 화합물 IC-21 (3 g, 6.44 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 4-bromo-6-phenyldibenzo[b,d]thiophene (3.28 g, 9.67 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-615 (1.73 g, 수율 37 %)를 얻었다.Except that the compound IC-21 (3 g, 6.44 mmol) synthesized in Preparation Example 11 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4, and 2.58 g of 4'-bromobiphenyl- , Inv-615 (1.73 g, 9.67 mmol) was obtained by following the same procedure as in Synthesis Example 4, except that 4-bromo-6-phenyldibenzo [b, d] thiophene , Yield: 37%).

GC-Mass (이론치: 723.18 g/mol, 측정치: 723 g/mol)
GC-Mass (calculated: 723.18 g / mol, measured: 723 g / mol)

[합성예 43] 화합물 Inv-633의 합성[Synthesis Example 43] Synthesis of compound Inv-633

Figure 112013108009545-pat00188
Figure 112013108009545-pat00188

질소 하에서 준비예 11에서 합성된 화합물 IC-21 (3 g, 6.44 mmol)을 DMF (100 ml)에 녹인 다음, 여기에 NaH (0.39 g, 16.11 mmol)를 넣고 1시간 동안 교반하였다. 여기에, DMF (100 ml)에 녹인 2-chloro-4,6-diphenyl-1,3,5-triazine (3.45 g, 12.89 mmol)을 천천히 첨가하였다. 3시간 동안 교반한 후 반응을 종료시키고, 혼합물을 실리카 필터링한 다음, 물과 메탄올로 씻은 후 용매를 제거하였다. 용매가 제거된 고체 생성물을 컬럼 크로마토그래피 (Hexane:EA = 3:1 (v/v))로 정제하여 화합물 Inv-633 (1.84 g, 수율 41 %)을 얻었다.Compound IC-21 (3 g, 6.44 mmol) synthesized in Preparation Example 11 under nitrogen was dissolved in DMF (100 ml), NaH (0.39 g, 16.11 mmol) was added thereto, and the mixture was stirred for 1 hour. 2-chloro-4,6-diphenyl-1,3,5-triazine (3.45 g, 12.89 mmol) dissolved in DMF (100 ml) was slowly added thereto. After stirring for 3 hours, the reaction was terminated, and the mixture was filtered with silica, washed with water and methanol, and then the solvent was removed. The solvent-removed solid product was purified by column chromatography (Hexane: EA = 3: 1 (v / v)) to give compound Inv-633 (1.84 g, yield 41%).

GC-Mass (이론치: 696.82 g/mol, 측정치: 696 g/mol)
GC-Mass (calculated: 696.82 g / mol, measured: 696 g / mol)

[합성예 44] 화합물 Inv-646의 합성[Synthesis Example 44] Synthesis of compound Inv-646

Figure 112013108009545-pat00189
Figure 112013108009545-pat00189

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 11에서 합성된 화합물 IC-22 (3 g, 6.44 mmol)를 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 4-(3-bromophenyl)-6-phenyldibenzo[b,d]thiophene (4.01 g, 9.67 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-646 (2.68 g, 수율 52 %)를 얻었다.Except that the compound IC-22 (3 g, 6.44 mmol) synthesized in Preparation Example 11 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4, and 2.58 g of 4'-bromobiphenyl- The same procedure as in Synthesis Example 4 was carried out except that 4- (3-bromophenyl) -6-phenyldibenzo [b, d] thiophene (4.01 g, 9.67 mmol) 646 (2.68 g, yield 52%).

GC-Mass (이론치: 799.21 g/mol, 측정치: 799 g/mol)
GC-Mass (calculated: 799.21 g / mol, measured: 799 g / mol)

[합성예 45] 화합물 Inv-660의 합성[Synthesis Example 45] Synthesis of compound Inv-660

Figure 112013108009545-pat00190
Figure 112013108009545-pat00190

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 11에서 합성된 화합물 IC-22 (3 g, 6.44 mmol)를 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 2-(4-chlorophenyl)-4-phenylpyrimidine (2.06 g, 7.73 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-660 (2.87 g, 수율 64 %)를 얻었다.(3-chlorophenyl) triphenylene (2.71 g, 6.44 mmol) was used instead of the compound IC-22 (3 g, 6.44 mmol) synthesized in Preparation Example 11, , Inv-660 (2.87 g, yield: 97%) was obtained by following the same procedure as in Synthesis Example 1, except for using 2- (4-chlorophenyl) -4-phenylpyrimidine (2.06 g, 7.73 mmol) 64%).

GC-Mass (이론치: 695.21 g/mol, 측정치: 695 g/mol)
GC-Mass (calculated: 695.21 g / mol, measured: 695 g / mol)

[합성예 46] 화합물 Inv-681의 합성[Synthesis Example 46] Synthesis of Compound Inv-681

Figure 112013108009545-pat00191
Figure 112013108009545-pat00191

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 12에서 합성된 화합물 IC-23 (3 g, 6.44 mmol)을 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 2-chloroquinazoline (1.27 g, 7.73 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-681 (2.52 g, 수율 66 %)를 얻었다.Instead of the compound IC-23 (3 g, 6.44 mmol) synthesized in Preparation Example 12 instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 1, 2- (3-chlorophenyl) triphenylene , Inv-681 (2.52 g, yield 66%) was obtained by following the same procedure as in Synthesis Example 1, except that 2-chloroquinazoline (1.27 g, 7.73 mmol)

GC-Mass (이론치: 593.17 g/mol, 측정치: 593 g/mol)
GC-Mass (calculated: 593.17 g / mol, measured: 593 g / mol)

[합성예 47] 화합물 Inv-691의 합성[Synthesis Example 47] Synthesis of compound Inv-691

Figure 112013108009545-pat00192
Figure 112013108009545-pat00192

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 12에서 합성된 화합물 IC-23 (3 g, 6.44 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 4-bromo-2,6-diphenylpyridine (3.00 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-691 (2.46 g, 수율 55 %)를 얻었다.Except that the compound IC-23 (3 g, 6.44 mmol) synthesized in Preparation Example 12 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4 and 2.58 g of 4'-bromobiphenyl-3-carbonitrile , Inv-691 (2.46 g, yield 55%) was obtained by following the same procedure as in Synthesis Example 4, except that 4-bromo-2,6-diphenylpyridine (3.00 g, 10.01 mmol) ).

GC-Mass (이론치: 694.22 g/mol, 측정치: 694 g/mol)
GC-Mass (calculated: 694.22 g / mol, measured: 694 g / mol)

[합성예 48] 화합물 Inv-713의 합성[Synthesis Example 48] Synthesis of Compound Inv-713

Figure 112013108009545-pat00193
Figure 112013108009545-pat00193

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 12에서 합성된 화합물 IC-24 (3 g, 6.44 mmol)를 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 6-bromo-2,3'-bipyridine (2.27 g, 9.67 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-713 (1.96 g, 수율 49 %)를 얻었다.Except that the compound IC-24 (3 g, 6.44 mmol) synthesized in Preparation Example 12 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4, and 2.58 g of 4'-bromobiphenyl- , Inv-713 (1.96 g, yield 49%) was obtained by following the same procedure as in Synthesis Example 4, except that 6-bromo-2,3'-bipyridine (2.27 g, 9.67 mmol) %).

GC-Mass (이론치: 619.18 g/mol, 측정치: 619 g/mol)
GC-Mass (calculated: 619.18 g / mol, measured: 619 g / mol)

[합성예 49] 화합물 Inv-728의 합성[Synthesis Example 49] Synthesis of Compound Inv-728

Figure 112013108009545-pat00194
Figure 112013108009545-pat00194

합성예 1에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 12에서 합성된 화합물 IC-24 (3 g, 6.44 mmol)를 사용하고, 2-(3-chlorophenyl)triphenylene (2.71 g, 8.01 mmol) 대신 2-(3-chlorophenyl)-4,6-diphenyl-1,3,5-triazine (2.66 g, 7.73 mmol)을 사용하는 것을 제외하고는, 상기 합성예 1과 동일한 과정을 수행하여 화합물 Inv-728 (3.74 g, 수율 75 %)를 얻었다.(3 g, 6.44 mmol) synthesized in Preparation Example 12 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 1 and 2- (3-chlorophenyl) triphenylene , 8.01 mmol) instead of 2- (3-chlorophenyl) -4,6-diphenyl-1,3,5-triazine (2.66 g, 7.73 mmol) To obtain a compound Inv-728 (3.74 g, yield 75%).

GC-Mass (이론치: 772.24 g/mol, 측정치: 772 g/mol)
GC-Mass (calculated: 772.24 g / mol, measured: 772 g / mol)

[합성예 50] 화합물 Inv-742의 합성[Synthesis Example 50] Synthesis of compound Inv-742

Figure 112013108009545-pat00195
Figure 112013108009545-pat00195

합성예 4에서 사용된 화합물 IC-1 (3 g, 6.67 mmol) 대신 준비예 5에서 합성된 화합물 IC-10 (3 g, 6.67 mmol)을 사용하고, 4'-bromobiphenyl-3-carbonitrile (2.58 g, 10.01 mmol) 대신 3'-bromobiphenyl-4-carbonitrile (2.58 g, 10.01 mmol)을 사용하는 것을 제외하고는, 상기 합성예 4과 동일한 과정을 수행하여 화합물 Inv-742 (2.17 g, 수율 52 %)를 얻었다.Except that the compound IC-10 (3 g, 6.67 mmol) synthesized in Preparation Example 5 was used instead of the compound IC-1 (3 g, 6.67 mmol) used in Synthesis Example 4 and 2.58 g of 4'-bromobiphenyl-3-carbonitrile Inv-742 (2.17 g, yield 52%) was obtained by following the same procedure as in Synthesis Example 4, except that 3'-bromobiphenyl-4-carbonitrile (2.58 g, 10.01 mmol) .

GC-Mass (이론치: 626.21 g/mol, 측정치: 626 g/mol)
GC-Mass (calculated: 626.21 g / mol, measured: 626 g / mol)

[실시예 1] 녹색 유기 EL 소자의 제작[Example 1] Production of green organic EL device

합성예 1에서 합성된 화합물 Inv-3을 통상적으로 알려진 방법으로 고순도 승화정제를 한 후 아래의 과정에 따라 녹색 유기 EL 소자를 제작하였다.Compound Inv-3 synthesized in Synthesis Example 1 was subjected to high-purity sublimation purification by a conventionally known method, and a green organic EL device was fabricated according to the following procedure.

먼저, ITO (Indium tin oxide)가 1500 Å 두께로 박막 코팅된 유리 기판을 증류수 초음파로 세척하였다. 증류수 세척이 끝나면, 이소프로필 알코올, 아세톤, 메탄올 등의 용제로 초음파 세척을 하고 건조시킨 후, UV OZONE 세정기 (Power sonic 405, 화신테크)로 이송시킨 다음, UV를 이용하여 상기 기판을 5분간 세정하고 진공 증착기로 기판을 이송하였다.First, glass substrate coated with ITO (Indium tin oxide) thin film of 1500 Å thickness was cleaned with distilled water ultrasonic wave. After the distilled water was washed, the substrate was ultrasonically washed with a solvent such as isopropyl alcohol, acetone, or methanol, and dried. Then, the substrate was transferred to a UV OZONE cleaner (Power sonic 405, Hoshin Tech) And the substrate was transferred to a vacuum evaporator.

이렇게 준비된 ITO 투명 전극 위에 m-MTDATA (60 nm)/TCTA (80 nm)/합성예 1의 화합물 Inv-3 + 10 % Ir(ppy)3 (30nm)/BCP (10 nm)/Alq3 (30 nm)/LiF (1 nm)/Al (200 nm) 순으로 적층하여 유기 EL 소자를 제작하였다. M-MTDATA (60 nm) / TCTA (80 nm) / Inv-3 + 10% Ir (ppy) 3 (30 nm) / BCP (10 nm) / Alq 3 nm) / LiF (1 nm) / Al (200 nm) were stacked in this order to fabricate an organic EL device.

m-MTDATA, TCTA, Ir(ppy)3, 및 BCP의 구조는 하기와 같다.The structures of m-MTDATA, TCTA, Ir (ppy) 3 and BCP are as follows.

Figure 112013108009545-pat00196
Figure 112013108009545-pat00196

Figure 112013108009545-pat00197
Figure 112013108009545-pat00197

[실시예 2] ~ [실시예 50] 녹색 유기 EL 소자의 제작[Example 2] - [Example 50] Production of green organic EL device

실시예 1에서 발광층 형성시 발광 호스트 물질로 사용된 화합물 Inv-3 대신 합성예 2 내지 50에서 각각 합성된 화합물 Inv-11 내지 Inv-742을 사용하는 것을 제외하고는, 실시예 1과 동일하게 수행하여 녹색 유기 EL 소자를 제작하였다.
Inv-11 to Inv-742 synthesized in Synthesis Examples 2 to 50, respectively, were used instead of the compound Inv-3 used as a luminescent host material in the formation of the light emitting layer in Example 1, Thereby preparing a green organic EL device.

[비교예 1] 유기 EL 소자의 제작[Comparative Example 1] Fabrication of organic EL device

실시예 1에서 발광층 형성시 발광 호스트 물질로 사용된 합성예 1의 화합물 Inv-3 대신 CBP를 사용하는 것을 제외하고는, 실시예 1과 동일한 과정으로 유기 EL 소자를 제작하였다. 사용된 CBP의 구조는 하기와 같다.An organic EL device was fabricated in the same manner as in Example 1, except that CBP was used instead of the compound Inv-3 of Synthesis Example 1 used as a light emitting host material in the formation of the light emitting layer in Example 1. The structure of CBP used is as follows.

Figure 112013108009545-pat00198

Figure 112013108009545-pat00198

[평가예 1][Evaluation Example 1]

실시예 1 내지 50 및 비교예 1에서 각각 제작된 유기 EL 소자에 대하여, 전류밀도 10 mA/㎠에서의 구동전압, 전류효율 및 발광 피크를 측정하였고, 그 결과를 하기 표 1에 나타내었다.The organic EL devices manufactured in Examples 1 to 50 and Comparative Example 1 were measured for driving voltage, current efficiency and emission peak at a current density of 10 mA / cm 2, and the results are shown in Table 1 below.

샘플Sample 호스트Host 구동 전압 (V)The driving voltage (V) EL 피크 (nm)EL peak (nm) 전류효율 (cd/A)Current efficiency (cd / A) 실시예 1Example 1 Inv-3Inv-3 6.716.71 516516 40.240.2 실시예 2Example 2 Inv-11Inv-11 6.796.79 517517 39.839.8 실시예 3Example 3 Inv-23Inv-23 6.756.75 515515 41.541.5 실시예 4Example 4 Inv-28Inv-28 6.716.71 516516 38.438.4 실시예 5Example 5 Inv-39Inv-39 6.766.76 516516 41.141.1 실시예 6Example 6 Inv-54Inv-54 6.816.81 517517 40.740.7 실시예 7Example 7 Inv-66Inv-66 6.766.76 516516 40.540.5 실시예 8Example 8 Inv-79Inv-79 6.796.79 516516 39.739.7 실시예 9Example 9 Inv-81Inv-81 6.836.83 517517 39.139.1 실시예 10Example 10 Inv-113Inv-113 6.756.75 516516 41.141.1 실시예 11Example 11 Inv-125Inv-125 6.766.76 516516 41.141.1 실시예 12Example 12 Inv-145Inv-145 6.816.81 517517 40.740.7 실시예 13Example 13 Inv-152Inv-152 6.816.81 517517 39.239.2 실시예 14Example 14 Inv-173Inv-173 6.836.83 518518 38.838.8 실시예 15Example 15 Inv-179Inv-179 6.836.83 517517 39.139.1 실시예 16Example 16 Inv-211Inv-211 6.856.85 516516 38.438.4 실시예 17Example 17 Inv-219Inv-219 6.776.77 515515 40.140.1 실시예 18Example 18 Inv-230Inv-230 6.796.79 516516 39.739.7 실시예 19Example 19 Inv-236Inv-236 6.836.83 517517 39.139.1 실시예 20Example 20 Inv-274Inv-274 6.756.75 516516 41.141.1 실시예 21Example 21 Inv-280Inv-280 6.766.76 516516 41.141.1 실시예 22Example 22 Inv-287Inv-287 6.816.81 517517 39.239.2 실시예 23Example 23 Inv-288Inv-288 6.836.83 518518 38.838.8 실시예 24Example 24 Inv-322Inv-322 6.836.83 517517 39.139.1 실시예 25Example 25 Inv-338Inv-338 6.716.71 516516 40.240.2 실시예 26Example 26 Inv-353Inv-353 6.766.76 516516 41.141.1 실시예 27Example 27 Inv-364Inv-364 6.816.81 517517 40.740.7 실시예 28Example 28 Inv-388Inv-388 6.766.76 516516 40.540.5 실시예 29Example 29 Inv-397Inv-397 6.796.79 516516 39.739.7 실시예 30Example 30 Inv-413Inv-413 6.836.83 517517 39.139.1 실시예 31Example 31 Inv-430Inv-430 6.796.79 517517 39.839.8 실시예 32Example 32 Inv-440Inv-440 6.756.75 515515 41.541.5 실시예 33Example 33 Inv-452Inv-452 6.716.71 516516 38.438.4 실시예 34Example 34 Inv-462Inv-462 6.726.72 517517 41.241.2 실시예 35Example 35 Inv-487Inv-487 6.886.88 519519 38.538.5 실시예 36Example 36 Inv-510Inv-510 6.886.88 516516 39.239.2 실시예 37Example 37 Inv-529Inv-529 6.796.79 516516 39.739.7 실시예 38Example 38 Inv-563Inv-563 6.836.83 517517 39.139.1 실시예 39Example 39 Inv-575Inv-575 6.816.81 517517 39.239.2 실시예 40Example 40 Inv-598Inv-598 6.836.83 518518 38.838.8 실시예 41Example 41 Inv-604Inv-604 6.836.83 517517 39.139.1 실시예 42Example 42 Inv-615Inv-615 6.816.81 517517 40.740.7 실시예 43Example 43 Inv-633Inv-633 6.766.76 516516 40.540.5 실시예 44Example 44 Inv-646Inv-646 6.796.79 516516 39.739.7 실시예 45Example 45 Inv-660Inv-660 6.836.83 517517 39.139.1 실시예 46Example 46 Inv-681Inv-681 6.816.81 517517 39.239.2 실시예 47Example 47 Inv-691Inv-691 6.836.83 518518 38.838.8 실시예 48Example 48 Inv-713Inv-713 6.836.83 517517 39.139.1 실시예 49Example 49 Inv-728Inv-728 6.816.81 517517 39.239.2 실시예 50Example 50 Inv-742Inv-742 6.836.83 518518 38.838.8 비교예 1Comparative Example 1 CBPCBP 6.93 6.93 516516 38.2 38.2

상기 표1에 나타낸 바와 같이, 본 발명에 따른 화합물을 발광층으로 사용한 실시예 1 내지 50의 녹색 유기 EL 소자의 경우, 종래 CBP를 사용한 비교예 1의 녹색 유기 EL 소자에 비해, 효율 및 구동전압 면에서 우수한 성능을 나타내는 것을 알 수 있다.As shown in Table 1, in the case of the green organic EL devices of Examples 1 to 50 using the compound according to the present invention as a light emitting layer, in comparison with the green organic EL device of Comparative Example 1 using conventional CBP, Which shows excellent performance.

Claims (10)

하기 화학식 1로 표시되는 화합물:
[화학식 1]
Figure 112015084142212-pat00199

상기 화학식 1에서,
Y1과 Y2, Y2와 Y3, 및 Y3와 Y4 중 하나는 모두 C(R1)이되, 각각의 C(R1)은 R1이 서로 축합하여 하기 화학식 2로 표시되는 축합 고리를 형성하고,
Y1 내지 Y4 중에서 하기 화학식 2의 축합 고리를 형성하지 않은 나머지는 각각 독립적으로 N 또는 C(R1)이며,
이때, R1이 복수인 경우, 이들은 서로 동일하거나 상이하고;
[화학식 2]
Figure 112015084142212-pat00200

상기 화학식 2에서,
점선은 화학식 1에 축합되는 부위를 의미하고,
Y5와 Y6, Y6과 Y7 및 Y7과 Y8 중 하나는 모두 C(R2)이되, 각각의 C(R2)은 R2가 서로 축합하여 하기 화학식 3으로 표시되는 축합 고리를 형성하고,
Y5 내지 Y8 중에서 하기 화학식 3의 축합 고리를 형성하지 않은 나머지는 각각 독립적으로 N 또는 C(R2)이며,
이때, R2이 복수인 경우, 이들은 서로 동일하거나 상이하며;
[화학식 3]
Figure 112015084142212-pat00201

상기 화학식 3에서,
점선은 화학식 2에 축합되는 부위를 의미하고,
Y9 내지 Y12는 각각 독립적으로 N 또는 C(R3)이고, 이때 R3이 복수인 경우, 이들은 서로 동일하거나 상이하며;
X1, X4 및 X5는 각각 독립적으로 O, S, Se, N(Ar1), C(Ar2)(Ar3) 및 Si(Ar4)(Ar5)로 이루어진 군에서 선택되고, 이때 X1, X4 및 X5 중에서 적어도 하나는 N(Ar1)이며;
X2 및 X3는 각각 독립적으로 N 또는 C(R4)이고, 이때 R4가 복수인 경우, 이들은 서로 동일하거나 상이하며;
R1 내지 R4 및 Ar1 내지 Ar5는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), 할로겐, 시아노기, 아미노기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, C1~C40의 알킬보론기, C6~C40의 아릴보론기, C1~C40의 포스핀기, C1~C40의 포스핀옥사이드기 및 C6~C40의 아릴실릴기로 이루어진 군에서 선택되며,
R1 내지 R4 및 Ar1 내지 Ar5의 C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, C1~C40의 알킬보론기, C6~C40의 아릴보론기, C1~C40의 포스핀기, C1~C40의 포스핀옥사이드기 및 C6~C40의 아릴실릴기는 각각 독립적으로 중수소(D), 할로겐, 시아노기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, C1~C40의 알킬보론기, C6~C40의 아릴보론기, C1~C40의 포스핀기, C1~C40의 포스핀옥사이드기 및 C6~C40의 아릴실릴기로 이루어진 군으로부터 선택되는 1종 이상의 치환기로 치환되거나 비치환될 수 있으며, 이때 상기 치환기가 복수인 경우, 이들은 서로 동일하거나 또는 상이할 수 있다.
A compound represented by the following formula (1):
[Chemical Formula 1]
Figure 112015084142212-pat00199

In Formula 1,
Wherein one of Y 1 and Y 2 , Y 2 and Y 3 , and one of Y 3 and Y 4 is C (R 1 ), and each C (R 1 ) is a condensation product of R 1 and R 1 , Forming a ring,
Y 1 to Y 4 are independently N or C (R 1 ), and the remainder not forming the condensed ring of the formula (2)
When plural R &lt; 1 &gt; s are the same or different from each other;
(2)
Figure 112015084142212-pat00200

In Formula 2,
The dotted line means a site condensed in the formula (1)
Wherein one of Y 5 and Y 6 , Y 6 and Y 7, and Y 7 and Y 8 is both C (R 2 ), and each of C (R 2 ) and R 2 is condensed with each other to form a condensed ring Lt; / RTI &gt;
To from Y 5 to Y 8 rest does not form a condensed ring of the general formula (3) are each independently N or C (R 2),
When R 2 is plural, they are the same or different from each other;
(3)
Figure 112015084142212-pat00201

In Formula 3,
The dotted line means a site condensed in the formula (2)
Y 9 to Y 12 are each independently N or C (R 3 ), and when R 3 is plural, they are the same or different from each other;
X 1, X 4 and X 5 is selected from the group consisting of each independently O, S, Se, N ( Ar 1), C (Ar 2) (Ar 3) and Si (Ar 4) (Ar 5 ), Wherein at least one of X 1 , X 4 and X 5 is N (Ar 1 );
X 2 and X 3 are each independently N or C (R 4 ), wherein when R 4 is plural, they are the same or different from each other;
R 1 to R 4 and Ar 1 to Ar 5 are the same or different and each independently represents hydrogen, deuterium (D), halogen, cyano group, amino group, C 1 to C 40 alkyl group, C 2 to C 40 alkene A C 2 to C 40 alkynyl group, a C 6 to C 40 aryl group, a heteroaryl group having 5 to 40 nuclear atoms, a C 6 to C 40 aryloxy group, a C 1 to C 40 alkyloxy group , A C 6 to C 40 arylamine group, a C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C 1 to C 40 alkylsilyl group, a C 1 to C 40 alkylboron group , C 6 ~ C 40 aryl boron group, C 1 ~ C 40 phosphine group, C 1 ~ C 40 phosphine oxide group, and a C 6 ~ is selected from the group consisting of C 40 of arylsilyl of,
R 1 to R 4 and Ar 1 to Ar 5 of C 1 ~ C 40 alkyl group, C 2 ~ C 40 alkenyl group, C 2 ~ C 40 of the alkynyl group, C 6 ~ C 40 aryl group, nuclear atoms of 5 to 40 heteroaryl group, C 6 ~ C 40 of the aryloxy group, C 1 ~ C 40 alkyloxy group of, C 6 ~ C 40 aryl amine group, C 3 ~ C 40 cycloalkyl group, a nuclear atoms of 3 to 40 heterocycloalkyl group, C 1 ~ C 40 alkylsilyl group, C 1 ~ C 40 group of an alkyl boron, C 6 ~ C 40 aryl boron group, C 1 ~ C 40 of the phosphine group, C 1 ~ C 40 of the phosphine oxide group, and a C 6 ~ C 40 aryl silyl groups are each independently a heavy hydrogen (D), a halogen, a cyano group, an alkenyl group of C 1 ~ C 40 alkyl group, C 2 ~ C 40 of, C 2 ~ C 40 alkynyl group, C 6 ~ C 40 aryl group, an aryloxy group of nuclear atoms aryl of from 5 to 40 heteroaryl group, a C 6 ~ C 40, alkyloxy group of C 1 ~ C 40 of, C 6 ~ C 40 of the arylamine group, C 3 ~ C 40 cycloalkyl group, a 3 to 40 nuclear atoms of a heterocycloalkyl group, C 1 ~ C 40 alkyl yarn Group, C 1 ~ C 40 group of an alkyl boron, C 6 ~ C 40 aryl boron group, C 1 ~ C 40 of the phosphine group, C 1 ~ C 40 phosphine oxide group, and a C 6 ~ C 40 aryl silyl And when the substituent is plural, they may be the same or different from each other.
제1항에 있어서,
상기 화합물은 하기 화학식 4 내지 9 중 어느 하나로 표시되는 것이 특징인 화합물:
[화학식 4]
Figure 112013108009545-pat00202

[화학식 5]
Figure 112013108009545-pat00203

[화학식 6]
Figure 112013108009545-pat00204

[화학식 7]
Figure 112013108009545-pat00205

[화학식 8]
Figure 112013108009545-pat00206

[화학식 9]
Figure 112013108009545-pat00207

상기 화학식 4 내지 9에서,
상기 X1 내지 X4, 및 Y1 내지 Y8은 각각 제1항에서 정의한 바와 같다.
The method according to claim 1,
Wherein said compound is represented by any one of the following formulas (4) to (9):
[Chemical Formula 4]
Figure 112013108009545-pat00202

[Chemical Formula 5]
Figure 112013108009545-pat00203

[Chemical Formula 6]
Figure 112013108009545-pat00204

(7)
Figure 112013108009545-pat00205

[Chemical Formula 8]
Figure 112013108009545-pat00206

[Chemical Formula 9]
Figure 112013108009545-pat00207

In the above formulas 4 to 9,
X 1 to X 4 , And Y 1 to Y 8 are as defined in claim 1, respectively.
제1항에 있어서,
상기 화학식 1의 화합물은 하기 화학식 C-1 내지 C-36 중 어느 하나로 표시되는 것이 특징인 화합물:
Figure 112015084142212-pat00221

Figure 112015084142212-pat00209

Figure 112015084142212-pat00210

Figure 112015084142212-pat00211

Figure 112015084142212-pat00212

Figure 112015084142212-pat00213

상기 화학식 C-1 내지 화학식 C-36 에서,
X1 내지 X5, 및 Y1 내지 Y12는 각각 제1항에서 정의한 바와 같다.
The method according to claim 1,
Wherein the compound of Formula 1 is represented by any one of the following Formulas C-1 to C-36:
Figure 112015084142212-pat00221

Figure 112015084142212-pat00209

Figure 112015084142212-pat00210

Figure 112015084142212-pat00211

Figure 112015084142212-pat00212

Figure 112015084142212-pat00213

In the above formulas C-1 to C-36,
X 1 to X 5 , and Y 1 to Y 12 are as defined in claim 1, respectively.
제1항에 있어서,
상기 화학식 1의 화합물은 하기 화학식 10 내지 15 중 어느 하나로 표시되는 것이 특징인 화합물:
[화학식 10]
Figure 112013108009545-pat00214

[화학식 11]
Figure 112013108009545-pat00215

[화학식 12]
Figure 112013108009545-pat00216

[화학식 13]
Figure 112013108009545-pat00217

[화학식 14]
Figure 112013108009545-pat00218

[화학식 15]
Figure 112013108009545-pat00219

상기 화학식 10 내지 15에서,
X2 및 X3, Y1 내지 Y4, 및 Ar1 내지 Ar5는 각각 제1항에서 정의한 바와 같다.
The method according to claim 1,
Wherein the compound of formula (1) is represented by any one of the following formulas (10) to (15):
[Chemical formula 10]
Figure 112013108009545-pat00214

(11)
Figure 112013108009545-pat00215

[Chemical Formula 12]
Figure 112013108009545-pat00216

[Chemical Formula 13]
Figure 112013108009545-pat00217

[Chemical Formula 14]
Figure 112013108009545-pat00218

[Chemical Formula 15]
Figure 112013108009545-pat00219

In the above formulas 10 to 15,
X 2 and X 3 , Y 1 to Y 4 , and Ar 1 to Ar 5 are as defined in claim 1, respectively.
제1항에 있어서,
상기 화학식 1의 화합물은 하기 화학식 A-1 내지 A-24 중 어느 하나로 표시되는 것이 특징인 화합물:
Figure 112013108009545-pat00220

상기 화학식 A-1 내지 A-24에서,
R4, Y1 내지 Y4 및 Ar1 내지 Ar5은 각각 제1항에서 정의한 바와 같다.
The method according to claim 1,
Wherein the compound of Formula 1 is represented by any one of the following Formulas A-1 to A-24:
Figure 112013108009545-pat00220

In the above Formulas A-1 to A-24,
R 4 , Y 1 to Y 4, and Ar 1 to Ar 5 are as defined in claim 1, respectively.
제1항에 있어서,
X4 및 X5는 모두 N(Ar1)이고,
Ar1은 제1항에서 정의한 바와 같은 것이 특징인 화합물.
The method according to claim 1,
X 4 and X 5 are both N (Ar 1 )
Wherein Ar &lt; 1 &gt; is as defined in claim 1 .
제1항에 있어서,
Y1 내지 Y4는 모두 C(R1)이고,
Y5 내지 Y8는 모두 C(R2)이며,
Y9 내지 Y12는 모두 C(R3)이고,
R1 내지 R3는 각각 제1항에서 정의한 바와 같은 것이 특징인 화합물.
The method according to claim 1,
Y 1 to Y 4 are both C (R 1 )
Y 5 to Y 8 are both C (R 2 )
Y 9 to Y 12 are all C (R 3 )
Wherein R &lt; 1 &gt; to R &lt; 3 &gt; are each as defined in claim 1.
제1항에 있어서,
R1 내지 R4 및 Ar1 내지 Ar5는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소(D), C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기 및 C6~C40의 아릴아민기로 이루어진 군에서 선택되는 것이 특징인 화합물.
The method according to claim 1,
R 1 to R 4 and Ar 1 to Ar 5 are the same or different, each independently represent hydrogen, deuterium (D), C 6 ~ C 40 aryl group, the number of nuclear atoms of 5 to 40 heteroaryl group, and C 6 of the - the compound is characterized by being selected from the group consisting of C 40 arylamines.
양극, 음극 및 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하며,
상기 1층 이상의 유기물층 중 적어도 하나는 제1항 내지 제8항 중 어느 한 항에 기재된 화합물을 포함하는 유기 전계 발광 소자.
A cathode, and at least one organic layer interposed between the anode and the cathode,
Wherein at least one of the one or more organic layers includes the compound according to any one of claims 1 to 8.
제9항에 있어서,
상기 화합물을 포함하는 1층 이상의 유기물층 중 적어도 하나는 발광층인 것이 특징인 유기 전계 발광 소자.
10. The method of claim 9,
Wherein at least one of the one or more organic layers including the compound is a light emitting layer.
KR1020130144909A 2013-11-26 2013-11-26 Organic compounds and organic electro luminescence device comprising the same KR101622809B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020130144909A KR101622809B1 (en) 2013-11-26 2013-11-26 Organic compounds and organic electro luminescence device comprising the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020130144909A KR101622809B1 (en) 2013-11-26 2013-11-26 Organic compounds and organic electro luminescence device comprising the same

Publications (2)

Publication Number Publication Date
KR20150061177A KR20150061177A (en) 2015-06-04
KR101622809B1 true KR101622809B1 (en) 2016-05-20

Family

ID=53499217

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020130144909A KR101622809B1 (en) 2013-11-26 2013-11-26 Organic compounds and organic electro luminescence device comprising the same

Country Status (1)

Country Link
KR (1) KR101622809B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170016701A (en) * 2015-08-04 2017-02-14 주식회사 두산 Organic light-emitting compound and organic electroluminescent device using the same
KR20180074062A (en) * 2016-12-23 2018-07-03 주식회사 두산 Organic compounds and organic electro luminescence device comprising the same

Also Published As

Publication number Publication date
KR20150061177A (en) 2015-06-04

Similar Documents

Publication Publication Date Title
KR101612164B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101560674B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR20170065317A (en) Organic compounds and organic electro luminescence device comprising the same
KR101609027B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101571591B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101601356B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR102508486B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101599597B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR20150061174A (en) Organic compounds and organic electro luminescence device comprising the same
KR20180022189A (en) Organic compounds and organic electro luminescence device comprising the same
KR20130076223A (en) Organic light-emitting compound and organic electroluminescent device using the same
KR20170075524A (en) Organic compounds and organic electro luminescence device comprising the same
KR20140145451A (en) Organic compounds and organic electro luminescence device comprising the same
KR101576570B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101634852B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101548040B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101612160B1 (en) Organic compound and organic electroluminescent device comprising the same
KR101556819B1 (en) Organic compounds and organic electro luminescence device using the same
KR101622809B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101634849B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101561332B1 (en) New organic compounds and organic electro luminescence device comprising the same
KR20160079548A (en) Organic light-emitting compound and organic electroluminescent device using the same
KR20160041695A (en) Organic light-emitting compound and organic electroluminescent device using the same
KR20150086107A (en) Organic compounds and organic electro luminescence device comprising the same
KR102339569B1 (en) Organic light-emitting compound and organic electroluminescent device using the same

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
X091 Application refused [patent]
AMND Amendment
X701 Decision to grant (after re-examination)
LAPS Lapse due to unpaid annual fee